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The Ikaros family transcription factors are critical regulators of T cell development and 
leukemogenesis.  Loss of function of all five family members leads to an early block in murine 
lymphocyte development, whereas reduced function results in the development of T cell 
leukemias.  Loss of a single family member has only minimal affects on T cell development, 
suggesting compensating functions of the family members, and emphasizing a need to study 
expression and function of the whole Ikaros family.  We analyzed the expression of all five 
family members in human and murine thymocytes as they progressed from the CD4–CD8– 
double negative (DN) to the CD4+CD8+ double positive (DP) developmental stages, and found 
differences in the expression of Helios and Eos mRNA between the two species.  Further, 
whereas Ikaros and Aiolos mRNA levels increased in both species, protein levels only increased 
in murine thymocytes.  These data suggest that regulation of Ikaros family expression during T 
cell development differed between the two species.   
To further examine expression of Ikaros family members during human T cell 
development, we used multi-parameter flow cytometry to identify subpopulations of human 
thymocytes.  We defined seven populations of CD3– CD4+CD8– immature single positive (ISP) 
and CD3– DP cells to identify when TCRβ is expressed.  We were able to delineate the pre-β-
selection ISP1 and DP1 populations and the TCRβ expressing ISP2 and DP2 populations using 
expression of CD1a, CD28, and CD44.  The ISP2 and DP2 populations had a higher percentage 
of proliferating cells, consistent with these being post-β-selection stages.  Protein levels of 
Ikaros, Helios, and Aiolos all increased with β-selection, however this increase was transient for 
Ikaros and Helios levels.   
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We further identified 22 populations of thymocytes that express CD3 and showed that 
CD4 expression is down-regulated after positive selection to create a CD8+CD4–/lo transitional 
single positive (TSP) developmental stage.  Commitment to the CD8 T cell lineage occurs in 
TSP thymocytes and is marked by expression of CD27.  Among CD4+ cells, expression of CD27 
can first be seen in MSP2 CD4+ thymocytes, suggesting that commitment to the CD4 lineage 
occurs at this stage.  Ikaros levels increased during the DP9 stage, and Helios and Aiolos 
expression increased in TSP thymocytes.  The increase in Helios was transient, and Helios levels 
decreased as cells developed through the MSP CD4+ and MSP CD8+ stages.  Aiolos levels 
increased in cells proceeding from the TSP to the MSP CD8+ stage.  Within MSP CD4+ 
thymocytes, Aiolos levels increased transiently beginning in the MSP2 CD4+ thymocytes 
suggesting that increases in Aiolos protein are associated with CD4/CD8 lineage commitment. 
Pediatric T cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease that 
develops as a result of clonal expansion of thymocyte populations that bypass regulatory 
selection steps.  We analyzed expression of the Ikaros family members in the leukemic cells 
from pediatric T-ALL patients and compared them to normal thymic populations, finding that 
mRNA levels of at least one Ikaros family member were elevated in the cells from every T-ALL 
patient analyzed.  By comparing the ratio of the Ikaros family mRNA levels, we were able to 
classify the T-ALL patients into groups that showed diverse expression of surface markers.  The 
lack of correlation between Ikaros and Aiolos mRNA and protein levels within the T-ALL 
suggest that further studies are needed to determine the significance of both mRNA ratios and 
protein levels in T-ALL patients.  Further, studies are required to identify the roles of the Ikaros 
family members during the key selection steps of normal thymic development in order to 
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Chapter 1. Introduction 
T cells are a major contributor to the functional immune system.  There are two classes of 
T cells, αβ T cells and γδ T cells, which are identified by the T cell receptor (TCR) chain 
heterodimer that they express.  αβ T cells compose 95% of the T cell population in the blood and 
peripheral lymphoid organs and can be separated into two major subpopulations according to 
their expression of the CD4 or CD8 co-receptor.  CD4+ T cells are known as helper T cells and 
produce cytokines necessary for activation and differentiation of other immune cells.  CD8+ T 
cells are cytotoxic cells that function to kill cells that are infected with intracellular pathogens or 
are cancerous. 
Before they can function in the periphery, T cells must go through a highly regulated 
process of development.  In order to add diversity to the TCR repertoire, TCR loci undergo 
V(D)J recombination.  V(D)J recombination is an error filled process, and developmental 
checkpoints ensure that thymocytes produce functional TCR chains before they egress from the 
thymus.  For development of αβ T cells, there are at least six major selection points: T cell 
lineage commitment, αβ/γδ lineage commitment, β-selection, positive selection, negative 
selection, and CD4/CD8 lineage commitment.   
A thorough understanding of human T cell development is important for determining the 
mechanisms by which immunologic diseases develop and identifying potential therapeutics.  The 
selection steps that regulate thymic development are associated with bursts of proliferation and 
increased susceptibility to apoptosis.  Defects in proliferation and apoptosis can lead to the 
development of leukemia.  Further, improper survival or apoptosis during selection can lead to 
autoimmunity or immunodeficiency, respectively.  The Ikaros family transcription factors are 
key regulators of survival, proliferation, and differentiation during T cell development.  The 
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current work focuses on the Ikaros family of transcription factors, their expression during 
selection steps in human thymic development, and their role in the development of T cell acute 
lymphoblastic leukemia (T-ALL). 
 
Ikaros Family of Transcription Factors 
Structure 
This family of five proteins, Ikaros, Helios, Aiolos, Eos, and Pegasus, shares a similar 
structure containing two highly homologous zinc finger domains: a N-terminal DNA binding 
domain and a C-terminal dimerization domain (Fig 1-1A).  Dimerization is required for high 
affinity DNA binding, and the two zinc fingers in the C-terminal domain mediate both 
homodimerization and heterodimerization with any of the other family members (1-5).  The N-
terminal DNA binding domain contains four zinc fingers for all family members except Pegasus, 
which only has 3 (Fig. 1-1B).  The high homology at this domain between Ikaros, Helios, Aiolos, 
and Eos, allows for binding of a similar DNA consensus sequence (GGGAA) (Fig 1-1D), 
whereas Pegasus binds with high affinity to the consensus sequence GXXTGTXG (3, 4, 6).  The 
Ikaros family members are also able to undergo alternative splicing, which can result in the loss 
of one or more zinc fingers from the DNA binding domain.  Further, though the Ikaros family is 
highly conserved in humans and mice (7), alternative splice sites are used in the processing of 
human Ikaros to produce isoforms containing a sixty base pairs intronic sequence following exon 
2 or missing thirty base pairs at the 3’ end of exon 6 (Fig. 1-1C) (8-11).   
 
DNA Binding  
   The DNA binding zinc fingers are encoded in three exons: one in exon 3, two in exon 4,
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Figure 1-1.  Ikaros family protein structure.  A) The protein structure of Ikaros, Helios, 
Aiolos, and Eos.  The four zinc fingers of the DNA binding domain (F1-F4) and the two zinc 
fingers of the dimerization domain (F5-F6) are shown (dark boxes).  B) The three exons and five 
zinc fingers of the Pegasus protein are shown. C)  Alternative splicing of human Ikaros mRNA 
can result in the insertion of 60bp after exon 2 (black box) or 30bp deletion at the 3’ end of exon 
6 (white box).  D)  Alignment of the amino acids flanking the DNA binding zinc fingers of the 
Ikaros family members.  The cysteine and histidine residues that coordinate the zinc ions are 











































and one in exon 5.  The second and third zinc fingers are required for binding to the consensus 
sequence, GGGAA (12, 13).  The first and fourth zinc fingers impart more specific gene 
targeting, and their loss, through alternative splicing of exons 3 and 5, results in more 
promiscuous DNA binding and a more diffuse nuclear localization pattern (1, 6, 14).  These 
different isoforms not only bind DNA sequences with varying affinity, but also are capable of 
differentially activating or repressing transcription (6, 14, 15).  In particular, abnormalities in T 
cell development were more severe in mice expressing an Ikaros isoform missing the fourth zinc 
finger (IkΔF4) than one missing the first zinc finger (IkΔF1), with aggressive T cell lymphomas 
developing in the former (14).  RNA-Seq analysis revealed that expression of IkΔF4 resulted in 
up-regulation of more genes than expression of IkΔF1, particularly those associated with cell 
adhesion, cell communication, and signal transduction.   Loss or mutation of the second and third 
zinc fingers produces a dominant negative isoform that is unable to bind DNA, but can still 
heterodimerize with other family members and prevent their DNA binding (1, 12, 16).   
 
Subcellular Localization 
Subcellular localization can be affected through alternative splicing and loss of 
phosphorylation sites not associated with the zinc finger domains.  Full length Ikaros isoforms 
with the exon 2 insertion have different DNA binding preferences and have a more diffuse 
nuclear localization than full length Ikaros without the insertion (17).  Ikaros family isoforms 
normally show punctate nuclear staining at pericentromeric heterochromatin (PC-HC), however 
some isoforms have cytoplasmic localization and can recruit other isoforms to the cytoplasm (1, 
6, 15).  The isoforms located in the cytoplasm are missing multiple exons, and interestingly, 
while not all cytoplasmic isoforms are missing exon 6, the loss of exon 6 results in a change in 
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localization.  Thus, both expression of different family members and different isoforms can 
affect DNA binding and function of the Ikaros family. 
Ikaros function and DNA binding is also regulated by phosphorylation.  Ikaros can be 
phosphorylated at multiple sites by casein kinase 2 (CK2), at conserved linker sequences 
between the DNA-binding zinc fingers by an as yet unidentified kinase, and at two sites each by 
spleen tyrosine kinase (SYK) and Bruton’s tyrosine kinase (Btk) in B cells (18-24).  
Phosphorylation within the linker sequences is conserved among proteins with C2H2 zinc finger 
proteins similar to Ikaros, and mediates detachment from the DNA during the G2/M phase of the 
cell cycle (18).  Phosphorylation by SYK and Btk are required for nuclear localization of Ikaros 
and increased DNA binding affinity, whereas CK2 mediated phosphorylation at amino acids 13 
or 294 prevents PC-HC localization of Ikaros and decreases binding affinity (19-21).  
Interestingly, activation of thymocytes with phorbol myristate acetate (PMA) and ionomycin 
resulted in dephosphorylation of Ikaros at amino acids 13 and 294, increased binding to the TdT 
regulatory element, and TdT transcriptional repression (20).  CK2 dependent phosphorylation of 
a region in exon 7 of Ikaros is also necessary for progression through the cell cycle (22).  
Retroviral transduction of NIH 3T3 fibroblasts with Ikaros resulted in a cell cycle arrest in the 
late G1 phase.  The block in cell cycle progression was increased when CK2 phosphorylation 
sites were mutated to alanines, and abrogated in cells expressing an Ikaros DNA-binding mutant.  
Dephosphorylation of CK2-specific sites is mediated by PP1, resulting in increased DNA 
binding, PC-HC localization of both Ikaros and PP1, and increased protein stability (25).  
Together, these results point to the importance of posttranslational modifications to control 
Ikaros DNA binding and cellular localization.  Though it has been shown that phosphorylation 
can similarly affect Aiolos localization and gene regulation (26), further studies are needed to 
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determine the mechanisms and affects of posttranslational modifications of Helios, Aiolos, Eos, 
and Pegasus. 
Regulation of Gene Transcription 
The Ikaros family is able to both activate and repress gene transcription.  Ikaros, Aiolos, 
and Helios have all been shown to associate with the nucleosome remodeling and histone 
deacetylase (NuRD) complex (27-30).  The NuRD complex has subunits capable of inducing 
ATP-dependent chromatin remodeling and histone deacetylation (31-33).  The interaction of 
Ikaros with NuRD has been associated with gene repression, as seen in the ability of Ikaros 
family members to silence Notch target genes, as well as the Il2 locus in anergy and tolerance 
(34-38).  However, recent studies have identified both Ikaros and NuRD associated with 
transcriptionally active genes (27, 39, 40).  A role for Ikaros in regulating transcription 
elongation was suggested by its association with cyclin-dependent kinase 9 (CDK9), the catalytic 
subunit of P-TEFb, as well as protein phosphatase 1 (PP1), a positive regulator of P-TEFb 
function and Ikaros DNA binding (25, 40, 41).  Recently it was shown that a small percentage of 
Ikaros co-purified with subunits of P-TEFb, NuRD, and PP1, and this complex was required for 
transcription elongation at the c-Kit locus (40).  This study suggested that higher levels of Ikaros 
were required for the recruitment of an elongation-competent NuRD/P-TEFb complex and PP1 
to genes with stalled RNA polymerase II.  Thus, increases in Ikaros expression in thymocyte 
subsets may serve to transition Ikaros from a transcriptional repressor to a transcriptional 
activator associated with the elongation-competent NuRD/P-TEFb complex. 
Ikaros has also been associated with other chromatin remodeling complexes.  Ikaros is 
able to interact with the polycomb repressive complex 2 (PRC2) and recruit it to repressed genes 
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to induce histone H3 lysine 27 trimethylation (H3K27me3) (42).  Ikaros-PRC2 interactions 
appear to be involved in regulating Notch target genes, as these genes are ectopically expressed 
in Ikaros deficient DP cells and show reduced H3K27me3 marks (27, 43, 44).  Ikaros also 
associates with the chromatin remodeling switching defective/sucrose non-fermenting 
(SWI/SNF) complex in T cells, and this interaction may be required for rearrangement of the 
TCRA locus (28, 45).   
The Role of the Ikaros Family in T Cell Development 
The Ikaros family of transcription factors is necessary for the development of T cells, B 
cells, and NK cells in mice (46).  Homozygous expression of a dominant negative Ikaros isoform 
(IkDN/DN) resulted in a developmental block in the differentiation of common lymphoid 
progenitor cells in the bone marrow.  The dominant negative isoform lacks the DNA binding 
domain zinc fingers of Ikaros but retains the ability to heterodimerize with the other family 
members, also altering their function (1). Thus, IkDN/DN mice lack most, if not all, Ikaros family 
function.  In contrast, IkDN/+ mice produce T cells, but rapidly develop T cell leukemias after loss 
of the single wild-type allele and clonal expansion within the thymus (47).  Further, T cell 
leukemia/lymphoma also developed in HelDN/DN mice, IkΔF4/ΔF4 mice, and IkPlstc/+ mice, which 
have a single base mutation in the third zinc finger that inhibits DNA binding (14, 48, 49).  The 
phenotypes of these mice suggest that the Ikaros family is necessary for differentiation to the T 
cell lineage and proper regulation of proliferation in developing thymocytes in order to prevent 
leukemogenesis. 
While elimination of the function of the whole family causes profound defects, T cell 
development is only minimally affected in mice that are deficient in a single Ikaros family 
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member.  Ikaros null mice (Ik–/–) are able to develop T cells after birth, but lack fetal T cells (50).  
In contrast, neither Hel–/– nor Ai–/– mice show major defects in T cell development (51, 52).  
However, T cells in all of these models have increased proliferation in response to TCR 
signaling.  The differences in severity between the null mice and dominant negative mice suggest 
a redundancy of function between the Ikaros family members, and that reduced functionality of 
multiple Ikaros family members is required for rapid development of T cell leukemias.  Thus, it 
is important that studies examine the expression and function of the entire family of proteins in 
relation to one another. 
Studying the whole Ikaros family is also important because each family member can 
affect transcription differently.  For instance, in chicken B cells, expression of the Src homology 
2-containing-inositol 5-phosphatase (SHIP) was up-regulated in Ikaros deficient cells but down-
regulated in Helios deficient cells (53).  Further, it has been shown that Aiolos is a more potent 
transcriptional activator than Ikaros, which is more potent than Helios (2, 5, 54).  Even small 
changes in expression of one family member can have drastic affects on the cell.  Transgenic 
mice developed B cell lymphomas after Helios was expressed in B cells at a level ten-fold lower 
than Ikaros (55).  Further studies are needed to determine how heterodimerization of different 
family members affects gene targeting and function. 
Regulation of Ikaros family expression and function is important for proper 
lymphopoeisis.  Chromatin immuoprecipitation studies found that Ikaros can bind over 10,000 
genomic sites associated with 6,746 genes (27, 43, 54).  Potential Ikaros binding sites can be 
found in the promoters and enhancers of a number of genes critical for T cell development 
including those for Rag-1, Rag-2, TdT, pTα, TCRα, TCRβ, CD3γδ, CD3ε, Notch, IL-7R, IL-2R, 
IL-2, CD4, and CD8α (6, 44, 54, 56-67).  Further, Ikaros family members can regulate 
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expression of proteins involved in survival, cell cycle progression, and the phosphatidylinositol 
3-kinase (PI3K) signaling pathway, as well as other transcription factors including Ikaros, 
Aiolos, Eos, and Pegasus themselves (26, 44, 54, 59, 60, 68-76).  Finally, the Ikaros family DNA 
binding consensus sequence is the same as that for the Notch co-factor RBP-Jκ, and Ikaros 
members can competitively bind and regulate Notch target genes (14, 43, 44, 60, 77).  Notch 
signaling is required for proliferation and differentiation at multiple selection steps during thymic 
development, and the Ikaros family may be involved in regulation of Notch signaling at these 
steps. 
 
The Role of the Ikaros Family in T Cell Acute Lymphoblastic Leukemia 
T-ALL is a heterogeneous disease, with leukemic cells being derived from different 
stages throughout T cell development (78-80).  T-ALL patients are grouped according to the 
expression of surface markers used to identify normal thymic populations (80) or expression of 
TCR chains by the leukemic cells (78).  There is conflicting data regarding whether these surface 
markers can be used to predict patient outcomes.  While one group determined that patients with 
leukemic cells expressing a pre-TCR had a better four-year disease free survival rate than those 
lacking intracellular TCRβ expression or expressing a mature TCR (79), another group found no 
difference between these groups (81).  Likewise, CD34 expression has been associated with poor 
prognosis by one group, but not by another (82, 83).  The different findings in these studies may 
be due to the heterogeneity of the T-ALL cells.  For example, some CD34+ T-ALL cells do not 
express a TCR, similar to normal DN cells, while other CD34+ T-ALL cells do express a TCR, 
unlike any normal thymic population.  Further studies attempting to associate protein expression 
11 
 
and prognosis thus will either need to include multiple surface markers, or focus on the 
underlying mechanisms within the cell that are regulating surface protein expression. 
A role for the Ikaros family in the development of T-ALL was first suggested by the 
rapid development of leukemia in IkDN/+ mice with one hundred percent penetrance (47).  A role 
for Ikaros family members in pediatric T-ALL has not been established.  While some studies 
reported the expression of dominant negative isoforms of Ikaros in all cases of pediatric T-ALL 
studied (8-10), others were only able to find these isoforms in a few cases (84-92).  Aberrant 
Helios isoforms and loss of Helios have been reported in cases of adult T-ALL (93-96), but are 
as yet to be reported in pediatric T-ALL.  In contrast, aberrant expression of Ikaros family 
members has been reported in B cell and myeloid leukemias (87-92, 97-103).  Further, Aiolos 
expression is up-regulated in cases of B cell chronic lymphocytic leukemia (104-106).  These 
data suggest that aberrant Ikaros family member expression does occur in human hematopoietic 
malignancies, though it is not highly associated with T-ALL as expected from murine models. 
The limited identification of altered Ikaros family expression in T-ALL brings to question 
differences in the function and expression of these proteins in murine and human thymocytes.  
The Ikaros literature focuses on the function of Ikaros itself in murine thymocytes.  Further 
studies are needed that assess expression and function of all family members, particularly in 
human thymocytes.  In order to identify roles for these proteins in human thymocyte 
development and leukemogenesis, a more thorough understanding of the processes of human 
thymocyte development and selection is necessary. 
 
Human αβT Cell Development 
Although there are similarities between murine and human T cell development, there are  
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also significant differences that discourage a complete reliance on murine models to make 
inferences about the mechanisms regulating human thymic development.  In general, both 
murine and human thymocytes progress from a CD4–CD8– (DN) stage to a CD4+CD8+ double 
positive (DP) stage before maturing to either a single positive (SP) CD4+ or SP CD8+ cell prior 
to thymic egress.  However, the surface markers used to identify some subpopulations differ 
between the species.  Whereas murine DN subpopulations are identified according to their 
expression of CD44 and CD25 (107), human DN subpopulations are identified by their 
expression of CD34, CD38, and CD1a (108, 109).  Further, human DN thymocytes up-regulate 
CD4 first to become immature single positive (ISP) CD4+ cells before entering the DP stage 
(110), but murine thymocytes transition through an ISP CD8+ stage (111). The altered expression 
of surface markers between the species is indicative of more substantial differences in signaling 
and transcriptional regulation, and makes direct comparisons between murine and human 
thymocyte populations difficult.   
Thymocytes in both species must rearrange their TCR loci and proceed through similar 
selections steps to complete development. However, there are differences in what stage of 
development the selections steps occur, how cells respond to thymic signals, and the genes that 
are expressed in response.  For instance, strong Notch signals induce αβ T cell development in 
murine thymocytes, but γδ T cell development in human thymocytes (112-114).  Further, TCRβ 
protein is expressed in DN murine thymocytes, but is not found until the ISP or DP stage of 
human T cell development (115-119).  These differences have implications on the signals that 
thymocytes receive for survival, proliferation, and differentiation, and thus may be important for 
species-specific mechanisms of disease development. 
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While the literature describing T cell development in the murine thymus is vast, there is 
limited information on human thymocyte development. In depth studies of human development 
are necessary to identify the mechanistic differences between the species and gain a better 
understanding of human T cell related disease development.  Within this chapter, we review the 
lineage commitment and selections steps for αβT cell development, focusing on what is known 
in human T cell development when possible.   
 
T Cell Lineage Commitment 
T cells are derived from hematopoietic stem cells (HSCs) in the bone marrow, but 
complete their development in the thymus.  As cells differentiate toward the lymphoid lineage, 
they lose their self-renewal capabilities as well as their ability to differentiate along the 
megakaryocyte/erythroid and myeloid pathways.  Early thymic progenitors (ETPs) do not 
express the co-receptors CD4 or CD8 and are thus referred to as DN thymocytes.  The immature 
nature of these cells can be seen by their expression of CD34 and their lack of TCR components 
(120).  DN cells in the human thymus are commonly separated into three populations based on 
their expression of CD38 and CD1a: CD38–CD1a– DN1 cells, CD38+CD1a– DN2 cells, and 
CD38+CD1a+ DN3 cells (109).  Human DN thymocytes first up-regulate CD4 to enter the 
CD4+CD8– ISP stage, then cells enter the DP stage with expression of CD8 (121).  Prior to 
thymic egress, cells down-regulate either CD4 or CD8 to become mature single positive (MSP) 
cells that can function in the periphery. 
ETPs maintain the ability to differentiate into T cells, natural killer (NK) cells, and 
dendritic cells (DCs) (122-126).  As DN thymocytes develop, they become restricted to the T 
cell lineage.  Whereas DN2 thymocytes have potential for DC and NK differentiation, DN3 
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thymocytes differentiate almost exclusively into T cells (127).  Restricted potential to the T cell 
lineage is also associated with down-regulation of CD34 (122).  Thus ETPs are tripotent for the 
T cell, NK cell, and DC fates, but differentiation is restricted to the T cell fate as CD34 
expression is lost and CD1a expression is gained. 
Commitment to the T cell lineage occurs when thymocytes begin to rearrange the TCR 
loci. The TCR chains are composed of a variable and a constant region.  The variable region is 
generated through recombination of variable (V), diversity (D), and joining (J) segments within 
the TCR loci.  The variable regions of TCRα and TCRγ are composed of only V and J segments, 
whereas TCRβ and TCRδ variable regions contain V, D, and J segments.  There are multiple V, 
D, and J segments within in each locus, allowing for many potential V(D)J combinations.    
Recombination is initiated by the introduction of double stranded breaks at the 5’ end of 
the heptamer of the RSS sites by the recombination-activating genes (RAG-1 and RAG-2).  This 
break leaves a hairpin end on the coding sequence for the gene segment.  The RAG protein 
complex makes a single stranded break at a random site close to the hairpin, forming a single 
stranded tail that is made of the original coding sequence and its palindromic sequence, or P-
nucleotides.  Non-encoded N-nucleotides can then be added to the tail by terminal 
deoxynucleotidyltransferase (TdT).  Nucleotides may also be deleted from the tail by 
exonuclease activity.  Finally, the strands adjacent to the two segments are paired and joined by 
the nonhomologous end joining machinery.  Diversity is thus introduced into the TCR 
heterodimer repertoire through the use of different combinations of V(D)J segments, the 
introduction of P- and N-nucleotides at the junction, deletion of nucleotides at the junction by 
exonuclease activity, as well as the random combination of TCRα/β or TCRγ/δ heterodimers. 
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 Recombination events occur sequentially in the TCRδ, TCRγ, TCRβ, and TCRα gene loci 
(109, 115).  DN1 cells are tripotent and have all TCR loci in the germline configuration, with the 
exception of <10% of cells that show Dδ2-Dδ3 recombination (109).  The frequency of Dδ2-Dδ3 
recombination increases with differentiation to the DN2 stage, and Dδ2-Jδ1 recombination 
events can be detected in these cells.  Though complete Vδ1-Jδ1 and Vδ2-Jδ1 transcripts can be 
detected within DN3 cells, approximately 15% of DN3 cells still have the TCRδ locus in the 
germline configuration, consistent with the finding that a limited number of CD1a+ DN cells 
have the ability to differentiate into NK cells (109, 115, 127).  Germline configuration of the 
TCRδ locus was not detected in the ISP population (115).  As conventional NK cells only 
express germline TCRδ transcripts (128, 129), these data suggest that T cell lineage commitment 
begins in the DN2 stage and is mostly complete within DN3 cells.  Consistent with this timing of 
commitment, DN2 thymocytes express low levels of mRNA for the pre-T cell receptor α-chain 
(pTα), but mRNA levels increase significantly within DN3 cells (130). 
Notch signaling has been identified as a key pathway in determining restriction to the T 
cell fate.  There are four Notch receptors (Notch1-4) that can bind either the Delta-like (DL1, 
DL3,and DL4) or Searate-like (Jagged 1 and Jagged2) ligands to produce differential signals 
(131).  Upon ligand binding, the Notch proteins undergo two proteolytic cleavage events, 
releasing the active intracellular Notch domain (ICN).  The ICN moves to the nucleus where it 
regulates activation of a network of genes.  T cell differentiation can be induced in human 
CD34+lin– cord blood progenitors (CBPs) that are cultured on OP9-DL1 cells, a murine bone 
marrow derived stromal cell line expressing the DL1 ligand, but not untransduced OP9 cells 
(132, 133).  Likewise, expression of the Notch1 ICN in CBPs inhibits differentiation of myeloid 
cells and B cells on MS-5 cells, a murine bone marrow derived stromal cell line, while 
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promoting differentiation of pre-T/NK cells (134).  These ICN-transduced CBPs are also capable 
of ectopic differentiation of CD3+ DP T cells in the bone marrow of sublethally irradiated NOD-
SCID mice at the expense of monocyte and B cell differentiation. Conversely, inhibition of 
Notch cleavage via administration of a γ-secretase inhibitor (GSI) in an in vitro human-mouse 
fetal thymic organ culture (FTOC) system hinders T cell development while promoting 
differentiation of DCs, B, and NK cells (135).   
Differences in expression of Notch ligands in the bone marrow and thymus may help to 
restrict T cell development to the thymus.  ETPs enter the thymus at the cortical-medullary 
junction and traverse the cortical zone to the subcapsular region as they differentiate through the 
DN and ISP stages (136).  DL4 and DL1 protein are expressed at low levels on cortical thymic 
epithelial cells (cTECs), and Jagged2 protein is abundantly expressed on both cTECs and 
medullary thymic epithelial cells (mTECs) (137).  DL1, DL4, and Jagged2 are able to promote T 
cell development from CBPs and induce expression of Notch3 (132, 133, 137, 138).  Notch3 is 
expressed on the earliest CD34+CD1a– thymocytes but not CBPs (130, 131).  Notch3 and 
Jagged2 provide the strongest Notch signaling, and their expression in the thymus may help to 
provide the strong Notch signal necessary for initial commitment to the T cell lineage (131, 135).  
Further, commitment to the T cell lineage may be restricted to the thymus by the expression of 
Jagged1 in the bone marrow instead of Jagged2 (138-142).  Retroviral expression of Jagged1 on 
OP9 cells inhibits T cell differentiation of CBPs, and Jagged1 mRNA expression is limited to 
mTECs in the thymus (131, 137).   
Notch activation alone is not sufficient for development of T cells, IL-7 signaling is 
required for T cell lineage differentiation in the thymus.  Although retroviral expression of 
Notch1 ICN in thymic precursors can inhibit non-T lineages, cells are blocked at an early stage 
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of T cell development (134, 143).  These cells up-regulate transcription of RAG-1 and Notch 
target genes, but do not progress to the DN3 stage.  Notch1 signaling also up-regulates and 
maintains IL-7 receptor α (IL-7Rα) expression on the cell surface (143, 144).  IL-7 is required 
for survival of DN thymocytes when cultured with OP9 cells (144).  Retroviral expression of the 
IL-7Rα on CBPs is not able to restrict differentiation to the T cell lineage, but promotes T cell 
differentiation past the DN2 stage (143).  Consistent with a need for IL-7 signaling for 
differentiation, when CBPs from patients with severe combined immunodeficiency (SCID) 
caused by mutations in IL-7Rα were transferred into NOD-Scid-Il2rg–/– mice, T cell 
differentiation was blocked at an early CD1a– stage prior to initiation of Dδ2-Dδ3 
rearrangements (145). 
Together these data suggest that strong Notch signaling upon thymic entry is needed to 
restrict cells to the T cell lineage and increase expression of Notch target genes, including IL-
7Rα.  Il-7R signaling is then necessary for further early T cell differentiation.  IL-7 is also 
required for survival and proliferation of thymocytes prior to expression of a TCR, and survival 
and proliferation are increased with concurrent Notch signaling (144).  
 
γδ/αβ Lineage Commitment 
γδ T cells comprise an average of less than 5% of T cells in peripheral blood, lymphoid 
organs and epithelial layers, with the exception of increased presence in the splenic red pulp and 
intestinal epithelium (146-150). Though small, this population of cells is thought to play 
important rolls in the early defense against pathogens at mucosal membranes and cancer 
surveillance.  The TCRδ and TCRγ chains are the first to complete rearrangement in the thymus 
(78, 109, 115).  The human TCRD locus contains three Dδ segments (Dδ1-3), three Jδ segments 
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(Jδ1-3), and one constant region segment (Cδ) (109, 115).  The location of the TCRD gene 
within the TCRA gene has made it difficult to distinguish Vα and Vδ gene segments, but six 
possible Vδ segments have been identified (Vδ1-6), with Vδ1 and Vδ2 preferentially used in 
human thymocytes and peripheral γδT cells, respectively. Complete Vδ1-Jδ1 and Vδ2-Jδ1 
rearrangements can be seen in a small proportion of DN3 thymocytes and over 50% of ISP 
thymocytes.  The human TCRG has eleven Vγ segments (Vγ1-11) and five Jγ (Jγ1.1-1.3, Jγ2.1, 
and Jγ2.3) segments associated with two constant regions (Cγ1-2).  Vγ-Jγ1.1/2/1 rearrangements 
occur in the DN2 and DN3 stages of thymic development, whereas Vγ-Jγ1.3/2.3 rearrangements 
are not abundantly seen until the DN3 stage and peak in CD3– DP and CD8+ MSP cells.  
Although these Vγ-Jγ1.3/2.3 rearrangements are preferentially used in the thymus in both 
TCRγδ+ and TCRαβ+ thymocytes, Vγ-Jγ1.2 rearrangements are rare in the thymus but 
preferentially seen in peripheral blood γδT cells.   
These data suggest that TCR-dependent selection of γδT cells can occur as early as the 
DN3 stage, but human thymocytes retain γδT cell potential through the DP stage of development 
(116, 151).   DN3, CD4+ ISP, and early DP were all capable of differentiating into γδT cells in a 
human-mouse FTOC (116).  The final CD4 and CD8 phenotype of the resultant γδT cells were 
not reported after FTOC.  Freshly purified immature CD1a+ TCRγδ+ thymocytes express RAG-1 
mRNA and have DN, CD4 SP, and DP phenotypes (151, 152). Mature CD1a– TCRγδ+ 
thymocytes, however, have only a DN or CD8 SP phenotype, consistent with peripheral γδT cell 
phenotypes (148, 152).   
Rearrangement of the TCRB gene for development of αβT cells occurs later in 
development.  The TCRB locus contains two paired D and C segments (Dβ1/Cβ1 and Dβ2/Cβ2) 
separated by six or seven J segments, respectively (Jβ1.1-1.6 and Jβ2.1-2.7), and fifty-two 
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potential V segments (109).  Dβ-Jβ rearrangements can first be seen in a large number of DN3 
cells using mostly Jβ1 segments, and increase in ISP cells with a switch to Jβ2 usage (109, 115).  
A high frequency of in frame V(D)J rearrangements are first seen in ISP cells using Jβ2 
rearrangements, and CD3– DP cells using Jβ1 rearrangements.  When a TCRβ protein is 
expressed, it pairs with the pTα protein to form the pre-TCR.  As pTα mRNA is expressed in 
CD34+ cells prior to thymic entry (118), expression of the pre-TCR can occur upon expression of 
TCRβ after in frame TCRB rearrangements in the ISP and DP stages (115, 117, 119). 
Both γδT cell selection and β-selection can occur during the ISP and DP stages of 
development (116, 117, 119, 151), thus some difference in signaling must help distinguish 
between TCRγδ and TCRαβ lineage.  Three models have been proposed for αβ/γδ lineage 
commitment: the stochastic model, the instructive model, and the signal strength model.  The 
stochastic model presumes that αβ/γδ lineage commitment occurs early in development prior to 
expression of any TCR chains, and only cells that produce functional TCR chains that match 
their predetermined lineage survive.  This model was developed to explain the development of 
DP cells in TCRβ–/– and TCRγδ transgenic mice (153, 154).  As progression to the DP stage was 
considered to signify commitment to the αβ lineage in murine thymocytes and occurred in the 
absence of pre-TCR expression, these results were taken as support that lineage commitment 
occurred independent of TCR signaling. 
The instructive model posits that it is the functional TCRγδ or pre-TCR produced by the 
cell that instructs the cells to enter the respective γδT or αβT cell lineages.  Support for this 
model stems from the lack of in-frame γ and δ rearrangements in murine αβT cells, suggesting 
that cells that produced a functional TCRγδ are diverted from the αβ lineage (154-157).  Recent 
studies using murine thymocytes suggest that the strength of signal received upon TCRγδ or pre-
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TCR stimulation determines lineage fate, further developing the instructive model into the 
strength of signal model.  γδ T cell development is promoted by stronger TCR signals while 
weaker signals promote αβ T cell development (158-160).  Supplementation of a weak TCRγδ 
signal with a pre-TCR signal induces γδT cell development (160), whereas attenuation of TCRγδ 
signal promotes development to the DP stage (158).   
Studies of γ, δ, and β rearrangement in mature human TCRγδ or TCRαβ expressing 
thymocytes, peripheral blood lymphocytes, and T-ALL cells support the instructive model.  
Nearly all TCRαβ+ cells had completely rearranged the TCRD or TCRG locus, but these were 
rarely in frame, particularly at the TCRD locus (116, 161, 162).  Production of in-frame 
rearrangement of both the TCRD and TCRG was estimated to occur in less than 7% of αβ 
thymocytes, and production of a functional TCRγδ would be further limited in these cells due to 
limited functional pairing of γ and δ chains (116).  These data suggest that functional TCRγδ 
production precludes a cell from adopting the αβT cell lineage. In contrast, complete 
rearrangement at the TCRB locus was rare in TCRγδ+ cells, averaging only 8.7% of γδ 
thymocytes as measured by Joachims, et al., but partial rearrangement of TCRB was extensive 
(116, 161-163).  This latter finding is not surprising given that completed γδ rearrangements are 
not seen until the DN3 stage, at which time Dβ-Jβ rearrangements have already begun. The low 
prevalence of complete TCRB rearrangements in γδ thymocytes supports data suggesting that 
γδT cell potential is highest in less mature cells but is retained through the DP stage when 
complete TCRB rearrangements are abundant (116, 151). 
Studies into the signal strength model of human TCRγδ and pre-TCR are limited.  One 
study measured the production of TCRαβ+ and TCRγδ+ thymocytes after transduction of CD34+ 
or ISP thymocytes with a constitutively active form of the tyrosine kinase Lck, which is involved 
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in TCR signaling (115).  Intermediate expression of Lck in CD34+ thymocytes had no effect on 
the production of TCRγδ+ thymocytes, but led to a large decrease in the production of TCRαβ+ 
and a block at the ISP stage of development.  Intermediate expression of Lck in ISP thymocytes 
had a similar negative effect on TCRαβ+ thymocyte development, but increased TCRγδ+ 
thymocyte production.  High expression of Lck in either subset inhibited development of all 
TCR+ thymocytes.  These results suggest that signal strength may have different effects on 
lineage selection at different stages of development, and that TCRγδ strength may be lower in 
human thymocytes, as intermediate Lck levels did not induce negative selection in these cells. 
Notch signaling is important for differential development of γδT and αβT cells.  Whereas 
strong Notch signaling in early thymocytes is required for αβT cell development of murine 
thymocytes (112-114), strong signals are required for γδT cell development of human 
thymocytes (121, 130, 164).  Inhibition of Notch signaling with a GSI increased the ability of 
DN2 or DN3 human thymocytes to develop into DP and express a TCRαβ, while decreasing the 
number of γδT cells produced upon culture with OP9-DL1 or OP9-DL4 cells (130).  Likewise, 
ICN-transduction of CD34hi ETP increased the development of TCRγδ+ cells and reduced the 
development of TCRαβ+ in a human-mouse FTOC (164).  More specifically, development of 
human TCRγδ+ thymocytes is increased via Notch3 interactions with Jagged1 or Jagged2, but 
not DL4 (131), and culture of CD34hi ETP on OP9-DL1 cells in the presence of GSI decreases 
the expression of Notch3 mRNA in a dose dependent manner (130).  These data suggest that the 
differential expression of Notch3 in human thymocytes but not in murine thymocytes may 






Cells differentiating along the αβ lineage must first successfully rearrange the TCRB 
locus.  Following successful TCRB rearrangement, a functional TCRβ protein pairs with the 
invariant pTα chain, as well as CD3-δ, ε, γ, and ζ chains, to form the pre-TCR complex.  The 
pTα has unique features that distinguish it from TCRα and contribute to the localization and 
signaling of the pre-TCR.  The human pTα cytoplasmic tail (CT) is important for pre-TCR 
localization and function.  At 114aa long, the human pTα CT is longer than both the TCRα CT 
(6-8aa) and murine pTα CT (30aa).  Both the murine and human pTα CT contain a 
juxtamembrane cysteine residue that can be palmitated to direct surface localization of the pre-
TCR to lipid rafts where it will be in close proximity to other signaling proteins (165, 166).  The 
pTα CTs in both species also contain short proline-rich motifs, potential protein kinase C (PKC) 
substrate sites, and a CD2-like motif, all of which may participate in signal transduction through 
the pre-TCR (167, 168).  The human pTα CT contains two unique motifs not found in the murine 
protein: an ER retention signal and a tyrosine-based internalization motif, both of which help to 
maintain low surface expression of pTα (168-170). 
Unlike TCRα and TCRβ, which contain two extracellular IgG domains, pTα has only one 
extracellular IgG domain.  The single IgG domain of pTα is able to interact with the constant 
IgG domain of TCRβ (Cβ) similar to the Cα domain of TCRα (171).  The variable IgG domain 
of TCRβ (Vβ) has a hydrophobic patch that normally interacts with a similar hydrophobic region 
in the Vα domain of TCRα.  Crystallographic studies of the human pTα/TCRβ complex revealed 
that pTα has a hydrophobic “top” that is able to interact with the hydrophobic region of Vβ from 
another pTα/TCRβ complex to form a dimer (171).  This dual interaction of pTα with Cβ and Vβ 
suggests that pTα may play a chaperone role to ensure that both the Cβ and Vβ domains properly 
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fold.  Expression of a pTα variant that is missing the extracellular IgG domain (pTαb) or contains 
mutations of key hydrophobic amino acids in the IgG domain reduced surface expression of the 
pre-TCR and resulted in its retention in the endoplasmic reticulum (ER) in human T cell lines 
(171).  This is in contrast to murine pre-TCR complexes composed of a pTα missing the 
extracellular domain, which successfully reach the cell surface and induce DP development (172, 
173).  The murine pTα would not be able to make the same contacts with Vβ due to the presence 
of an extra glycan in the region of interface, and lacks the ER retention signal in the CT to limit 
surface expression (168, 169, 174).  These data suggest that the pTα extracellular domain plays a 
different role in murine and human thymus pre-TCR localization, and may serve a chaperone-
like function that is necessary for surface expression in human thymocytes. 
The pTα and CD3 chains are expressed prior to TCRB rearrangement (Mitchell, et. al., 
unpublished data) (118, 175, 176), thus formation of the pre-TCR complex during development 
can occur after successful TCRβ expression.  Production of a TCRβ protein that folds with pTα 
to form the pre-TCR may release the complex from the ER, allowing for localization to lipid 
rafts on the cell surface and signal transduction (165, 166, 171).  Successful production of TCRβ 
and signaling through the pre-TCR is known as β-selection.  Progress through β-selection is 
associated with cell proliferation, allelic exclusion of the TCRB locus, and opening of the TCRA 
locus for rearrangement (177-181).   
The exact timing of β-selection in human thymocytes is not well understood.  It has been 
suggested that β-selection could occur as early as the DN3 stage based on the identification of 
complete V(D)J rearrangement and one report of intracellular TCRβ (icTCRβ) expression in a 
minimal number of cells at that stage (109, 115, 116).  Initial studies reported that β-selection 
occurred in the DP stage and was accompanied by expression of CD8β on the cell surface (119).  
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However, later studies reported that as many as 85% of early CD4+CD8α+CD8β– DP cells 
expressed icTCRβ (115-117).  Expression of icTCRβ was found in 5-40% of ISP cells in these 
studies (115-118), and was associated with expression of CD28 and CD71 (117). 
Successful production of TCRβ and occurrence of β-selection may also be determined 
indirectly by measuring the resultant increase in proliferation.  Early thymocytes maintain a low 
level of proliferation, with about 10% of cells in the S, G2, or M phase of the cell cycle (116, 
118, 119).  Expression of icTCRβ in ISP and DP thymocytes is associated with an increase in 
proliferation (118).  Studies using Rag–/– mice, in which T cell development is blocked prior to 
β-selection, have shown that proliferation occurs as a result of pre-TCR signaling through similar 
pathways as TCRαβ activation.  Both the PKC and Ras-mitogen activate protein kinase (MAPK) 
pathways are involved in mediating proliferation and differentiation downstream of pre-TCR 
signaling.  Expression of TCRβ or activated forms of the signaling molecules Lck, PKC, Ras, or 
c-Raf-1 in Rag–/– murine DN thymocytes is able to induce proliferation, to restore thymic 
cellularity, and allow differentiation to the DP stage (182-185).  Pre-TCR mediated proliferation 
is also dependent on Notch signaling, as human CD28+ ISP cells did not undergo extensive cell 
division when cultured on OP9 stromal cells, but did when cultured on OP-DL1 cells (117). 
Expression of TCRβ as part of the pre-TCR also results in allelic exclusion of the non-
productive TCRB locus to ensure that only the productively rearranged TCRβ is expressed.  Pre-
TCR signaling leads to a decrease in Rag-1 and Rag-2 expression to prevent further 
rearrangement (117, 130).  The exact mechanisms by which the non-productive TCRB locus is 
epigenetically modified to prevent expression are not well understood, but expression of a TCRβ 
transgene in murine thymocytes prevents rearrangement of the endogenous TCRB loci 
suggesting that pre-TCR signaling leads to allelic exclusion (186).  Studies in murine thymocytes 
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suggest that the PKC pathway is involved in mediating allelic exclusion, as expression of 
activated forms of PKC or its upstream mediator Lck prevents TCRβ gene rearrangement (185, 
187, 188).  Expression of activated Ras or Raf does not inhibit TCRβ rearrangement at the DN 
stage, suggesting that the MAPK pathway is involved in proliferation and differentiation, but not 
initial allelic exclusion (183, 184).  However, further studies found that Raf and the MAPK 
pathway activated transcription factor Ets1 are necessary for maintenance of allelic exclusion in 
the DP population when Rag proteins are re-expressed for TCRA rearrangement (189, 190). 
After successful TCRβ production, the cell must be able to produce a functional TCRα 
protein to replace the pTα.  Cellular activation leads to a decrease in full-length pTαa mRNA 
expression (166), and mRNA levels of both pTαa and pTαb, the variant lacking the extracellular 
IgG domain, decrease after β-selection in icTCRβ+CD28+ ISP and blasting DP cells (117, 166).  
The ratio of pTαb:pTαa mRNA increases as human thymocytes traverse β-selection, presumably 
retaining TCRβ protein in the ER and controlling the pre-TCR signal (166, 169, 191).  
Completion of β-selection also results in the opening of the TCRA locus in preparation for its 
rearrangement, as can be seen by the expression of TCR-Cα in icTCRβ+CD28+ ISP and CD3– 
DP cells but not in CD28– ISP or DN cells (117, 130). 
 
Positive and Negative Selection 
Once thymocytes express both a TCRα and a TCRβ chain, selection steps must ensure 
that the resultant TCRαβ is capable of recognizing antigen presented by MHC molecules.  
Positive selection occurs when developing thymocytes recognize self-MHC and receive a signal 
for survival and further differentiation.  Negative selection occurs when TCR engagement on 
developing thymocytes results in apoptosis as a means of self-tolerance.  The affinity model has 
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been used to explain the difference between positive and negative selection: a low affinity 
interaction between the TCR and peptide/MHC complex (pMHC) leads to a weaker signal and 
positive selection, while a high affinity interaction leads to a stronger signal and negative 
selection.   
This model has been supported in murine models in which presentation of low affinity or 
high affinity ligands are expressed in TCR transgenic animals.  The HY TCR is a MHC-I 
restricted TCR that produces CD8+ T cells in female mice, but results in negative selection of 
cells in males due to the presence of the high avidity Y chromosome-encoded antigen H-Y (192, 
193).  The ovalbumin peptide SIINFEKL induces negative selection in MHC-I restricted OT-I 
TCR transgenic mice, but single amino acid substitutions resulted in positive selection.  These 
altered peptide ligands (APLs) had affinities for the OT-I TCR that were 3.5-8.8 times weaker 
than the original SIINFEKL peptide (194, 195).  Further, the naturally occurring positively 
selecting ligands Catnb and Cappa1 have affinities that are 15.6 and 24.3 times lower than 
SIINFEKL when presented by the H-2Kb MHC-I protein to OT-I TCRs (196).  Though these 
affinities are low, they are still higher than non-selecting APLs (195).  These studies, along with 
others, helped to establish TCR affinity thresholds necessary for positive selection and negative 
selection (197-201).   
 
Cortex specific peptide production 
Within the thymus, differences in pMHC affinities are achieved by distinct peptide 
processing and protein expression in cTECs and mTECs.  Proteolytic pathways active in cTECs 
produce unique peptides for positive selection.  Peptides that are presented by MHC-I molecules 
are derived from proteasomal degradation of proteins present in the cytosol.  The peptides enter 
27 
 
the ER through the transporters associated with antigen processing (TAP) and are loaded into the 
MHC-I protein, completing its folding and allowing for its export to the cell surface.  The 20S 
proteasome has three catalytic subunits β1, β2, and β5, which cleave after acidic, basic, and 
hydrophobic residues, respectively.  An immunoproteasome contains altered catalytic subunits 
(β1i, β2i, and β5i) that can be induced by interferon-γ and are constitutively expressed in the 
spleen and thymus (202-205).  Most MHC-I molecules preferentially bind peptides with a 
hydrophobic C-terminal amino acid, while some bind peptides with basic C-termini.  The 
immunoproteasome preferentially produces peptides with hydrophobic and basic C-termini to 
bind MHC-I (206, 207).  Both the housekeeping proteasome and immunoproteasome are present 
in mTECs.  cTECs also express a third proteasome, the thymoproteasome, which contains a 
unique β5 sub-unit, β5t, along with β1i and β2i (208).   
The thymoproteasome produces a unique set of peptides in cTECs for thymocyte positive 
selection.  β5t is less efficient at cleaving peptides after hydrophobic amino acids than β5i, so the 
thymoproteasome preferentially produces peptides with hydrophilic C-termini, particularly 
cleaving after bases (208-210).  Thymoproteasomes thus produce peptides which have similar 
affinities for OT-I TCR as positively selecting APLs when presented by MHC-I, while the TCR 
binding affinities of pMHC complexes made by immunoproteasomes are similar to the negative 
selecting SIINFEKL peptide (210).  An alternate explanation for the low affinity interactions that 
result from thymoproteasome produced peptides is that the weaker peptide-MHC binding caused 
by the basic C terminal amino acid of the peptide results in partially or fully empty MHC-I 
molecules on the surface of cTECs.  Empty MHC-I molecules have been reported to be 
expressed on the surface of cells, including cTECs, and weaker staining for MHC-I molecules on 
cTECs compared to mTECs may be a result of internalization of less stable, empty complexes 
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(211-214).  The requirement of the thymoproteasome for positive selection of CD8+ T cells has 
been shown in 5βt–/– mice (208).  These mice fail to produce CD8+ T cells even though cTEC 
development is normal, MHC-I expression on cTECs is similar to wild type mice, and CD4+ T 
cell selection is unaffected.  Further replacement of 5βt with 5βi in cTECs was not able to restore 
normal positive selection, suggesting that the altered peptide production of the thymoproteasome 
is necessary for positive selection of a diverse CD8+ T cell pool (215, 216). 
Production of altered peptides for presentation by MHC-II complexes for positive 
selection of CD4+ T cells is also predicted to occur in cTECs.  MHC-II heterodimers formed in 
the ER are stabilized through interactions with the invariant chain (Ii), which targets MHC-II 
complexes to the endocytic pathway.  Once in the endosome, Ii is cleaved by cathepsins, leaving 
only the class II-associated Ii peptide (CLIP) associated with the MHC-II.  Exchange of CLIP for 
peptides processed in the endosome results in release of the pMHC complex for transport to the 
cell surface.  Within professional antigen presenting cells (APCs), exogenous proteins are 
endocytosed and processed into peptides in the endosome.  Neither cTECs nor mTECs are 
efficient at phagocytosis, but are able to present endogenous peptides that are presented in the 
endosome through increased macroautophagy in these cells, particularly cTECs (217). 
cTECs uniquely express two proteases that affect peptide processing and presentation by 
MHC-II complexes.   Human cTECs express cathepsin (Cat) V, while mTECs and APCs 
express Cat S and Cat L (218, 219).  Mice do not encode for a Cat V protein, but murine Cat L 
shares higher homology with human Cat V than human Cat L (220), and is expressed exclusively 
in cTECs while murine Cat S is expressed in mTECs and APCs (221-223).  Cat L knock out 
mice have impaired CD4+ positive selection, even though MHC-II expression is normal and 
CD8+ T cell production is not affected (221, 224).   The role for Cat L in positive selection may 
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be two-fold.  Cat L is involved in cleavage of Ii, and loss of Cat L in murine cTECs leads to an 
increase in the expression of CLIP-MHC complexes on the surface of the cells (221).  The 
effects of altered Ii degradation are MHC-II haplotype dependent (224, 225), but defective CD4+ 
T cell positive selection did not show the same haplotype dependence, indicating that Cat L plays 
a role in MHC-II peptide presentation that is independent of its function in Ii cleavage (224).  
Expression of Cat L in a fibroblast cell line altered a subset of peptides presented by MHC-II 
molecules, either through generation of new peptides or degradation of other peptides (226).  
Further, Cat L knock out mice show increased negative selection of CD4+ SP cells, suggesting 
that a different repertoire of cells is positively selected in the presence or absence of Cat L (224). 
The thymus-specific serine protease (TSSP) is only expressed in the endosomes of cTECs 
and thymic DCs, and also plays a role in CD4+ T cell positive selection.  Initial analysis of the 
role of TSSP in mice showed no significant changes in CD4+ T cell selection, but further studies 
have shown that impairment of positive selection by loss of TSSP is peptide/TCR specific (227-
230).  As with Cat L knock out mice, when TSSP knock out mice show impaired selection, it is 
accompanied by increased negative selection, suggesting that TSSP may play a role in 
processing of specific peptides (229, 230).  Further, the TSSP gene, PRSS16, is found in a 
diabetes susceptibility locus in humans, and loss of TSSP was found to be protective in NOD 
mice due to altered positive and negative selection of islet reactive T cells (229). 
 
Presentation of tissue specific antigens in the medulla 
Whereas protease expression in cTECs produces unique low affinity peptides for positive 
selection, the mTECs and thymic DCs are equipped to present self-peptides for negative 
selection of strongly self-reactive T cells, known as central tolerance.  Single cell analysis of 
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murine mTECs has revealed that they can express almost 20,000 protein-coding genes, the most 
reported in any cell type (231).  Gene expression is higher in mTECs than cTECs in both murine 
and human thymocytes, and includes expression of tissue-specific antigens (TSAs) (231-234).  
This promiscuous gene expression is caused, in part, by the expression of two proteins: 
autoimmune regulator (AIRE) and Fezf2.  AIRE was first identified as the gene responsible for 
autoimmune polyglandular syndrome type 1 (APS-1), an autosomal recessive multi-organ 
autoimmune disease (235, 236).  AIRE-deficient mice show decreased expression of TSAs in 
mTECs and also develop a multi-organ autoimmune disease, though the target organs are 
different (232, 237-239).  Single cell transcriptome analysis of AIRE+/+ and AIRE–/– murine 
mTECs identified almost 4000 tissue-specific genes that are up-regulated in the presence of 
AIRE, including 594 genes whose expression was fully dependent on AIRE expression (231).   
AIRE induces expression of TSAs from chromosomal clusters normally associated with 
areas of repressed transcription, and different gene clusters are expressed in individual mTECs 
(231, 233).  A DNA-binding domain has not been identified in the AIRE protein, but the first 
plant homeodomain finger (PHD1) is able to bind unmethylated histone H3 at lysine-4 
(H3K4m0) (240, 241).  Further, the SAND (Sp100, AIRE-1, NucP41/75, and DEAF-1) domain 
can bind the to a complex of activating transcription factor 7 interacting protein (ATF7ip) and 
methyl CpG binding protein 1 (MBD1), which target AIRE to transcriptionally repressed areas 
with methylated CpG islands (242).  Together these features appear to target AIRE specifically 
to areas of repressed transcription, rather than specific genes, which would explain the broad 
expression profile of AIRE.  AIRE also interacts with proteins involved in transcription, such as 
cyclic AMP response element-binding protein, positive transcription elongation factor b (P-
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TEFb), and DNA-dependent protein kinase (DNA-PK), and pre-mRNA processing to affect 
expression of TSA transcripts (243-249). 
AIRE is only expressed in a subset of mature CD80hi mTECs, but not all TSAs in AIRE+ 
mTECs are AIRE-dependent, and some TSAs are expressed in AIRE– mTECs, suggesting the 
possibility of other proteins that regulate TSA expression in mTECs (231-233, 250-253).  Only 
recently was it reported that Fezf2 also regulates TSA expression in thymocytes (251).  Fezf2 is 
expressed in murine and human mTECs, with low expression levels in a subset of CD80lo 
mTECs and higher expression in all mature CD80hi mTECs.  Nude mice engrafted with Fezf2-
deficient thymi had splenomegaly and infiltration of inflammatory cells in multiple organs.  
Further, expression of some TSAs, including some known to be associated with autoimmune 
disease, was decreased in Fezf2-deficient mTECs in an AIRE-independent manner.  While these 
findings help to explain some of the discrepancies in TSA expression in AIRE– mTECs and of 
AIRE-independent genes, microarray analysis of mTEC gene expression suggests that 
expression of only 60% of TSAs are AIRE- or Fezf2-dependent, and other unknown mechanisms 
of TSA regulation must exist. 
mTECs are not the only source of peripheral antigens in the thymus.  AIRE expression 
has recently been identified in murine thymic B cells, which can mediate negative selection of 
CD4+ thymocytes (254).  DCs are also able to pick up antigen in the periphery, migrate to the 
thymus, and present it to developing T cells (255, 256).  Further it has been shown that antigen 
circulating in the blood can enter the thymus and be presented by SIRPα+ thymic DCs, which can 
be found near small vessels in the thymus (257-259).  Thymic DCs are also able to present TSAs 
that have been produced by mTECs and transferred to the DCs, possibly via exosome release by 
the mTECs (260-263).  The presentation of TSAs by DCs and B cells allows for professional 
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antigen presentation on MHC-II molecules, which may be necessary for proper CD4+ T cell 
negative selection.  Whereas CD8+ T cells can be negatively selected by antigen presentation on 
either mTECs or DCS, CD4+ T cells appear to require thymic APCs for proper negative 
selection (260).  Thymic DCs are also required for induction of negative selection in the murine 
cortex (264, 265). 
 
Signaling differences in positive and negative selection 
While both positively and negatively selecting ligands interact with the TCR, they induce 
qualitatively different signals within the cell.  Impairment of extracellular signal-related kinase 
(ERK) activation in murine thymocytes results in a deficiency in positive selection but does not 
affect negative selection unless ERK signaling is completely blocked (266-274).  ERK has a 
lower activation threshold than other TCR signaling kinases, and low affinity ligands have been 
shown to induce weak but sustained ERK signals associated with localization to the Golgi, while 
high affinity ligands induce strong, transient ERK signals at the plasma membrane (201, 271, 
274, 275).  Positive selection has been shown to require that the cell maintain sustained 
interactions with a pMHC complex, which may be necessary to maintain the low ERK signaling 
(276, 277).  In contrast, attenuation of Jun amino-terminal kinase (JNK) or p38 signaling 
specifically inhibits negative selection but not positive selection (275, 278, 279).  JNK and p38 
have higher activation thresholds than ERK, and thus may require a stronger TCR signal strength 
for activation and mediation of negative selection (275).  Further studies are required to identify 
how qualitatively different TCR signaling by negatively selecting ligands leads to apoptosis 
through the activation of the pro-apoptotic Bim, Bax, and Bak proteins (280, 281). 
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High affinity TCR:pMHC interactions do not always result in negative selection within 
the thymus, they can also induce regulatory T cell (Treg) development (259, 282, 283).  Treg cell 
development is impaired in patients with mutations in the AIRE gene or other mutations that 
result in decreased AIRE expression, suggesting a role for mTEC derived TSAs for Treg 
development (284-287).  Treg commitment requires CD28 co-stimulation, which is provided by 
thymic dendritic cells that have been activated by thymic stromal lymphopoietin (TSLP) 
produced by Hassall’s corpuscles in the human thymus (288-291).  Further stimulation with IL-
2, produced by TECs or mature CD4+ SP cells, or IL-15, produced by B cells and macrophages, 
is also necessary for Treg development (292, 293).  The exact mechanism by which cells 
differentiate between Treg and negative selection signals is yet unknown. 
 
CD4/CD8 Lineage Commitment 
Prior to egress from the thymus, DP thymocytes must down-regulate one of their co-
receptors and commit to either the CD4+ or CD8+ T cell lineage.  The CD4 and CD8 co-receptors 
bind to MHC-II and MHC-I molecules, respectively.  CD4 or CD8 binding to the MHC serves to 
stabilize the MHC:TCR interaction and bring the Src family tyrosine kinase Lck in proximity to 
the TCR to participate in TCR signaling.  As positive selection signals are received by cortical 
DP thymocytes expressing both co-receptors, the cells must have a way of differentiating what 
the MHC specificity of the TCR is.  As expected, murine thymocytes transgenically expressing 
the MHC-II-specific AND TCR are efficiently selected into the CD4+ lineage, but when the 
MHC-II molecule is mutated so as not to recognize CD4, cells are selected into the CD8+ lineage 
(294).  This study suggested that while MHC:TCR interactions alone are sufficient for positive 
selection, proper interaction between the MHC and CD4 or CD8 is necessary for lineage 
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commitment.  Three models of lineage commitment have been proposed based on experiments in 
murine thymocytes: the stochastic model, the instructive model, and the signal duration/kinetic 
signaling model. 
The stochastic model proposes that CD4 or CD8 expression is terminated independent of 
TCR specificity, so that one of the two co-receptors is randomly down-regulated.  Thymocytes 
will only survive positive selection if the MHC specificity of the TCR matches that of the 
expressed co-receptor.  Thus, according to this model, thymocytes expressing a MHC-I restricted 
TCR that down-regulated CD8 to commit to the CD4 lineage would not survive but could be 
rescued by forced expression of CD8.  The model was supported by studies that found the 
production CD4+ SP cells when a CD8 transgene was expressed in MHC-I restricted TCR 
transgenic mice, and similarly CD8+ SP cells developed when CD4 was constitutively expressed 
in MHC-II restricted TCR transgenic or β2-microglobulin deficient mice (295-297).  Contrary to 
these findings, CD4+ SP cells were not produced when CD8 was constitutively expressed with a 
different MHC-I restricted TCR (298-300).  In another study, it was determined that expression 
of transgenic TCRs led to highly efficient selection of SP cells expressing the coordinated co-
receptor, suggesting an instructive model of development (301).  
The instructive model suggests that lineage is determined based on the difference in 
signal received by thymocytes depending on whether CD4 or CD8 is engaged by the MHC.  This 
model was prompted by the finding that CD4 binds Lck with a higher affinity than CD8, and 
thus CD4:MHC-II binding recruits more Lck to the TCR complex (302-304).  Expression of a 
hybrid protein containing the extracellular and transmembrane CD8 domains fused to the CD4 
cytoplasmic domain in a MHC-I restricted transgenic mouse resulted in the production of MHC-
I-restricted CD4+ T cells (298, 305).  Further, by altering Lck activity lineage commitment could 
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be altered in transgenic mice: constitutively active Lck induced CD4+ T cell development with a 
MHC-I-restricted TCR, and catalytically inactive Lck induced CD8+ T cell development with a 
MHC-II-restricted TCR (306, 307).  However, another study showed that a CD4 protein that was 
unable to interact with Lck was still able to induce production of CD4+ SP cells, suggesting that 
recruitment of Lck to the signaling complex by CD4 is not essential for CD4+ T cell commitment 
(308). 
The signal duration/kinetic signaling model suggests that lineage commitment is 
determined by the duration of signal received through MHC-I-restricted and MHC-II-restricted 
TCRs due to differential kinetics of CD8 and CD4 expression.  In a seminal study, MHC-I-
restricted TCR transgenic thymocytes incubated for a short period of time with a high affinity 
ligand developed into SP CD8+ cells, as expected, but if the incubation period was extended the 
cells developed into SP CD4+ cells (309).  These results suggested that lineage commitment is 
determined by the duration of the TCR signal received, rather than the strength of signal.  
Further, lineage commitment can occur independent of MHC specificity if the TCR signal is 
either terminated (SP CD8+ cells) or elongated (SP CD4+ cells) (309-311).   
Murine thymocytes transition through a CD4+CD8lo transitional single positive (TSP) 
stage after receiving a positive selection signal (312-315).  These TSP cells retain the ability to 
differentiate into both CD4+ and CD8+ SP cells in culture, putting into question both the 
stochastic and instructive models (313-316).  Further studies have shown that CD8 transcription 
is terminated after positive selection of DP thymocytes regardless of whether the TCR 
recognizes antigen in MHC-I or MHC-II molecules (317-320).  Thus, down-regulation of CD8 
on a positively selected thymocyte would lead to an interruption in the TCR signal on MHC-I-
restricted thymocytes, but have no affect on MHC-II-restricted thymocytes.  To further confirm 
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that co-receptor down-regulation affects lineage commitment, studies were performed in which 
CD4 was expressed under the control of the CD8α enhancer and promoter, either as a transgene 
or as a knock-in at the CD8α locus (311, 318).  In these mice, MHC-II-restricted thymocytes 
developed into cytotoxic T cells that expressed granzyme B and the CD8+ T cell specific 
transcription factor Runx3.   
Commitment to the CD4 or CD8 lineage is dependent on expression of the transcription 
factors ThPOK and Runx3, respectively.  The requirement of ThPOK in CD4 lineage 
commitment was first identified through gene mapping of a spontaneous recessive mutation in 
mice that resulted in a loss of CD4+ T cell development due to positively selected MHC-II-
restricted cells being diverted to the CD8 lineage (321-324).   Loss of ThPOK function through 
mutation or deletion leads to a decrease in SP CD4+ cell development in a dose dependent 
manner (325, 326).  Decreases in ThPOK expression were associated with increased expression 
of Runx3, perforin, and IFN-γ in murine TSP CD4+ and SP CD4+ cells, suggesting that ThPOK 
expression represses CD8 lineage gene expression (325).  Conversely, retroviral expression of 
ThPOK is capable of diverting MHC-I-restricted cells to the CD4 lineage (323).  ThPOK is 
expressed in mature CD4 SP but not CD8 SP (323, 324).  However, analysis of TSP cells 
expressing GFP from the ThPOK locus revealed three levels of GFP expression (325, 326).  As 
expected GFPhi TSP cells were committed to the CD4 lineage and GFP– TSP cells were 
committed to the CD8 lineage, but the GFPint TSP population retained the ability to differentiate 
into both CD4 SP and CD8 SP cells (326).  This study further showed that the ThPOK proximal 
enhancer is required for expression of ThPOK at high enough levels sufficient for commitment 
to the CD4 lineage, and that ThPOK may solidify commitment to the CD4 lineage through 
antagonism of silencers in both the CD4 and ThPOK loci. 
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Runx3 appears to play a similar role in CD8 lineage commitment as ThPOK does in CD4 
commitment.  Runx3 protein is exclusively expressed in CD8+ SP thymocytes, whereas Runx1 
expression is higher in DN but present throughout development (325, 327, 328).  Loss of Runx3 
expression results in a decrease in CD8 SP production and an accumulation of DP cells with a 
mature TCRβhiHSAlo phenotype, suggesting that repression of the CD4 locus does not occur in 
these cells (327, 329-331).  Further studies found that increased Runx binding at the CD4 
silencer occurred in CD8 SP cells and that Runx binding sites are required for CD4 repression 
(328-330).  Enhancers within the CD8 gene locus also contain Runx binding sites, and Runx 
binding at the post-selection CD8 gene enhancer E8I is restricted to CD8 SP cells, suggesting a 
role for Runx3 regulation of CD8 re-expression (328).  ThPOK expression is increased in TSP or 
CD8 SP cells when binding of both Runx1 and Runx3 are inhibited, either through knockdown 
of these genes specifically or of their binding partner Cbfβ (332).  This study also showed that 
Runx proteins bind silencer elements in the ThPOK locus, but did not differentiate between 
Runx1 and Runx3 binding.  These data suggest a role for Runx proteins in regulating CD4, CD8, 
and ThPOK expression in CD8 SP thymocytes.   
A final aspect of the kinetic signaling model over the signal duration model is the role of 
cytokines in determining lineage commitment.  Specifically, the kinetic signaling model poses 
that cytokine signaling, particularly IL-7 receptor (IL-7R) signaling, is responsible for final 
commitment to the CD8 lineage (317).  DP thymocytes are not responsive to IL-7R signaling due 
to high expression of suppressor of cytokine signaling-1 (SOCS1), a negative regulator of Jak3-
kinase phosphorylation downstream of cytokine signaling, which is down-regulated upon 
positive selection (333, 334).  Mice deficient in SOCS1 have increased numbers of CD8 SP 
thymocytes, whereas SOCS1 transgenic mice were deficient in CD8 SP thymocytes, suggesting a 
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role for cytokine signaling in the development of CD8 lineage commitment (334-336).  Further, 
SOCS1 deficiency in MHC-II restricted thymocytes leads to the development of CD8 SP cells 
with effector function (336).  IL-7 is needed in culture for CD8 SP development (317), and IL-7 
signaling increases expression of CD8α transcription through targeting of the E8I enhancer 
(337).  Importantly, IL-7 signaling is capable of inducing Runx3 expression from the distal 
promoter (335).  Together these studies show that IL-7R signaling can induce CD8α and Runx3 
expression in a TCR independent manner, and is necessary for CD8 lineage commitment. 
 
Analysis of Ikaros Family Expression in Human T Cell Development and T-ALL 
To begin to elucidate the differences in Ikaros family function in murine and human T 
cell development, we investigated the expression of Ikaros family members in human 
thymocytes and compared this to expression in pediatric T-ALL patients.  We began by 
determining the mRNA and protein expression levels in populations of murine and human 
thymocytes from the DN2 to DP stages of development.  Differences in expression patterns of 
Helios and Aiolos between the species prompted a more thorough analysis of human thymocytes.  
To be able to identify changes in Ikaros family expression in small populations of cells, we used 
multi-parameter flow cytometry to identify subpopulations of human thymocytes and determine 
stages in which β-selection, positive selection, and CD4/CD8 lineage commitment likely occur.  
Finally, we analyzed mRNA expression of the entire Ikaros family, as well as protein expression 
of Ikaros and Aiolos, in cases of pediatric T-ALL compared to normal thymic populations to 
identify changes in Ikaros family expression.  Our data represent the most thorough investigation 
into the subpopulations of human thymic development, and expression of the Ikaros family in 
human T cell development and leukemogenesis. 
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Chapter 2. Expression and splicing of Ikaros family members 
in murine and human thymocytes 
 
Abstract 
The Ikaros family of transcription factors includes five highly homologous members that 
can homodimerize or heterodimerize in any combination.  Dimerization is essential for their 
ability to bind DNA and function as transcription factors.  Previous studies showed that 
eliminating the function of the entire family blocks lymphocyte development while deletion of 
individual family members has relatively minor defects.  These data indicate that multiple family 
members function during T cell development, so we examined the changes in expression of each 
family member as thymocytes progressed from the CD4–CD8– double negative (DN) to the 
CD4+CD8+ double positive (DP) developmental stage.  Further, we compared the expression of 
each family member in murine and human thymocytes.  In both species, Ikaros and Aiolos 
mRNA levels increased as thymocytes progressed through the DN to DP transition, but the 
corresponding increases in protein levels were only observed in mice.  Further, Ikaros and Aiolos 
underwent extensive alternative splicing in mice, whereas only Ikaros was extensively spliced in 
humans.  Helios mRNA and protein levels decreased during murine T cell development, but 
increased during human T cell development.  These differences in the expression and splicing of 
Ikaros family members between human and murine thymocytes indicate that the Ikaros family of 




T cell development in the thymus is a highly ordered process that includes intermittent 
periods of proliferation and selection with the purpose of producing a diverse repertoire of T 
cells.  Early T cell progenitors entering the thymus lack CD4 and CD8 expression and are called 
CD4–CD8– double negative (DN) thymocytes.  In mice, DN thymocytes can be subdivided into 
at least four major populations (DN1-4) based on their expression of CD44 and CD25 (107).  
After the DN stage, murine thymocytes express CD8 to become immature single positive (ISP) 
CD8+ thymocytes before expressing CD4 to become CD4+CD8+ double positive (DP) 
thymocytes (111).  In humans, DN thymocytes are commonly divided into three subsets (DN1-3) 
based on their expression of CD34, CD38, and CD1a (109, 338, 339).  After the DN3 stage, 
human thymocytes express CD4 to become ISP CD4+ thymocytes and then CD8 to become DP 
thymocytes (110). 
During early T cell development, thymocytes progress through a series of checkpoints.  
The first major checkpoints involve restricting the lineage potential of the cells to the T cell 
lineage and then to the αβ T cell lineage.  Once committed to the αβ T cell lineage, thymocytes 
progress through the next major checkpoint, which occurs when TCRβ is expressed for the first 
time.  TCRβ protein can be first detected in murine DN3 thymocytes (180) and human ISP 
thymocytes (117).  The next major checkpoint occurs following expression of TCRα protein, 
which happens for the first time in DP thymocytes in mice and humans. 
The Ikaros family of transcription factors is required for T cell development (16, 340).  
The members of this family of five proteins (Ikaros, Helios, Aiolos, Eos, and Pegasus) share two 
zinc finger domains that are highly homologous across the family members.  The N-terminal 
domain includes the DNA-binding domain, and the C-terminal domain mediates dimerization.  
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Each family member can homodimerize or heterodimerize with any other family member, and 
dimerization is required for high affinity DNA binding and transcriptional activity (1-5).  
Because of the extensive dimerization that can occur among family members, it is important to 
consider the entire Ikaros family as a whole.  A change in the expression of one family member 
has the potential to alter the functionality of the entire family. 
Adding complexity to the study of the Ikaros family, each family member can undergo 
extensive alternative splicing that results in the deletion of zinc fingers in the DNA binding 
domain.  Deletion of one or two zinc fingers can change the DNA sequences recognized by the 
Ikaros dimer (1, 6, 341).  Deletion of three or more zinc fingers in the DNA binding motif results 
in a dominant-negative variant that can dimerize with other family members, but is unable to 
bind DNA (1). 
The importance of the Ikaros family in hematopoiesis was demonstrated in mice 
expressing the dominant-negative isoform of Ikaros; these mice lacked T, B, and NK cells as 
well as their precursors (46).  In contrast, mice lacking the Ikaros dimerization domain, which 
preserves the function of the other family members, had impaired B cell and fetal T cell 
development, but only mild deficits in postnatal T cell development (50).  The differences in the 
phenotypes observed in these two mouse lines demonstrate that multiple Ikaros family members 
are critical for T cell development.  To determine which family members might be required for T 
cell development, we analyzed how mRNA levels, protein levels, and alternative splicing of 
Ikaros family members change during early T cell development.  In addition, we provide the first 




Materials and Methods 
Antibodies 
The anti-mouse antibodies, anti-TER119-FITC, anti-CD4 FITC, anti-CD24-PE, anti-
CD44-PE-Cy7, and anti-CD25-APCCy7, were purchased from eBioscience (San Diego, CA, 
USA).  Anti-CD8-FITC, anti-CD8-AF647, and anti-CD4-Pacific Blue were purchased from BD 
Biosciences (San Jose, CA, USA).  The anti-human antibodies, anti-CD1a-PerCP-Cy5.5, anti-
CD1a-PECy5, anti-CD3-APCCy7, anti-CD4-Pacific Blue, anti-CD7-FITC, anti-CD8-BV785, 
anti-CD8-FITC, anti-CD34-PE, anti-CD34-PECy7, and anti-CD38-AF700 were purchased from 
Biolegend (San Diego, CA).  Anti-Aiolos-PE was purchased from e-Biosciences, and anti-Mouse 
IgG1κ-PE and anti-Ikaros-PE were purchased from BD Biosciences.  The anti-human/mouse 
antibody, anti-Helios-AF647, was purchased from eBioscience.  The anti-Armenian Hamster 
IgG-AF647 control was purchased from Biolegend. 
 
FACS-purification of murine thymocytes 
Wild-type C57BL/6 mice were housed under specific pathogen-free conditions and used 
between the ages of 3-5 weeks.  All experiments were performed in compliance with the 
University of Kansas Medical Center Institutional Animal Care and Use Committee.  To obtain 
DN thymocytes, single cell suspensions of murine thymocytes were immunodepleted using 
magnetic beads conjugated to anti-CD4 and anti-CD8 (BD Biosciences).  The remaining DN 
cells were labeled with anti-TER119, anti-CD4, anti-CD8, anti-CD25, and anti-CD44.  Using a 
BD FACSAria IIIu (BD Biosciences), cells were gated on TER119–CD4–CD8– thymocytes and 




To collect ISP thymocytes, total thymocytes were depleted using magnetic beads 
conjugated to anti-CD4.  Remaining cells were labeled with anti-CD4, anti-CD8, and anti-CD24, 
and CD8+CD24+ ISP cells were FACS-purified.  To obtain DP thymocytes, single cell 
suspensions of total murine thymocytes were labeled with anti-CD4 and anti-CD8, and were 
FACS-purified. 
 
FACS-purification of human thymocytes 
After obtaining consent from the parent or guardian, human thymus samples were 
obtained from children (0 – 18 years) that underwent corrective surgery at Children’s Mercy 
Hospital (Kansas City, MO) for congenital cardiac defects.  Tissue samples were obtained in 
compliance with the Institutional Review Boards at Children’s Mercy Hospital and the 
University of Kansas Medical Center. 
To obtain DN and ISP thymocytes, single cell suspensions of total thymocytes were 
immunodepleted using magnetic beads conjugated to anti-CD8 and anti-CD3 (BD Biosciences).  
The remaining cells were labeled with anti-CD1a, anti-CD3, anti-CD4, anti-CD8, anti-CD34, 
and anti-CD38.  CD4–CD8– DN cells were gated on CD3–CD34+ thymocytes.  DN2 and DN3 
populations were FACS-purified using a FACSAria IIIu (BD Biosciences) according to their 
expression of CD1a and CD38.  For the ISP population, cells were gated on CD4+CD8– 
thymocytes and CD3– ISP cells were FACS-purified.  For DP thymocytes, single cell 
suspensions of human thymocytes were labeled with anti-CD4 and anti-CD8 and CD4+CD8+ 





Quantitative RT-PCR (qRT-PCR) 
Total mRNA was isolated from FACS-purified thymocytes using the RNeasy Mini Kit or 
RNeasy Micro Kit (Qiagen, Valencia, CA), depending on total cell count.  Isolated mRNA was 
converted to cDNA using the TaqMan® High Capacity RNA-to-cDNA™ kit (Applied 
Biosystems, Foster City, CA).  For qRT-PCR, 2µL of cDNA was amplified using TaqMan® 
Gene Expression Assays for the Ikaros family members or GAPDH housekeeping gene (Ikaros: 
Mm01187878_m1, Hs00958473_m1; Helios: Mm00496108_m1; Aiolos: mM01306721_m1, 
Hs00232635_m1; Eos: Mm00496114_m1, Hs00223842_m1; Pegasus: Mm00731061_s1, 
Hs00223846_m1; GAPDH: Mm99999915_g1, Hs03929097_g1; Applied Biosystems), and was 
performed using a 7500 Fast Real-Time PCR System (Applied Biosystems).  Relative expression 
levels of Ikaros family members were calculated relative to GAPDH using a relative 
quantification study in the 7500 Fast System Software.  At least five independent experiments 
were performed for each subset, and in each experiment the samples were run in triplicate and 
averaged.  Statistical significance was determined using the Log2(Fold Change), or –ΔΔCt. 
 
Western blot analysis 
Cell lysates prepared from 2-3×105 cells of each murine thymocyte population or 4-5×105 
cells of each human thymocyte population were separated by SDS-PAGE, transferred to 
nitrocellulose and probed with antibodies against murine Ikaros, murine Aiolos, murine p38 
MAPK, human Ikaros, human Aiolos, or human p38 MAPK (all purchased from Santa Cruz 
Biotechnology, Inc., Dallas, TX).  Bands were visualized using horseradish peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology, Inc.) and Pierce™ ECL Western 
Blotting Substrate (Life Technologies, Grand Island, NY), and detected using an ImageQuant 
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LAS-4000 gel imager (GE Healthcare Systems, Pittsburgh, PA).  Protein levels of Ikaros and 
Aiolos were measured relative to p38 MAPK levels using the total densitometry for all protein 
isoforms as measured with MultiGauge Software (FujiFilm).    
 
Intracellular staining 
Intracellular staining was performed using the FoxP3/Transcription Factor Staining 
Buffer Set (eBioscience) according to the manufacturer’s instructions.  Single cell suspensions of 
murine thymocytes were labeled on their surface using anti-CD3, anti-CD4, anti-CD8, anti-
CD24, anti-CD25, anti-CD44, and anti-TCRβ.  Cells were washed three times with PBS before 
addition of the Fixation/Permeabilization working solution.  Cells were washed twice with 1X 
Permeabilization Buffer before labeling with anti-Helios or isotype control.  Single cell 
suspensions of human thymocytes were first labeled on their surface with anti-CD1a, anti-CD3, 
anti-CD4, anti-CD8, anti-CD34, and anti-CD38.  After washing and fixation/permeabilization as 
described, cells were intracellularly labeled with either anti-Ikaros or anti-Aiolos and anti-Helios, 
or isotype control antibodies.  Cells were analyzed using a BD LSR II (BD Biosciences), and 
data were analyzed with BD FACSDiva software (BD Biosciences) and FlowJo (TreeStar, Inc., 
Ashland, OR).  Fold change was measured as the ratio of geometric fluorescence intensity 
between Ikaros family member and isotype control labeled cells.  
 
Nested PCR 
Isolated total mRNA was reverse transcribed to cDNA with AMV RT (Promega, 
Madison, WI) before amplification with Taq DNA Polymerase (Fisher Scientific, Pittsburgh, 
PA).  Primary PCR reactions were performed using cloning primers specific to the 5´ UTR and 
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3´ UTR, and nested PCR reactions were then performed with primers that spanned all possible 
exon pairs (Tables 2-1 and 2-2).  PCR products were run on a 2% agarose gel that was then 
stained with ethidium bromide and washed with water before visualization using an ImageQuant 
LAS-4000 gel imager (GE Healthcare Systems). 
 
Helios variant cloning 
Isolated total human mRNA was reverse transcribed and amplified with the AccuScript 
PFUUltra II RT-PCR Kit (Agilent Technologies, Inc., Santa Clara, CA) using the cloning 
primers listed for Helios in Table 2-1.  PCR products were cut with EcoRI and XhoI (Promega), 
and purified from an agarose gel using the QIAquick Gel Extraction Kit (Qiagen), and cloned 
into the MIGR1 vector.  cDNA was collected from positively transformed colonies using the IBI 
High Speed Plasmid Mini Kit (Midwest Scientific, Valley Park, MO) and sequenced by 
GENEWIZ, Inc. (South Plainfield, NJ). 
 
Statistics 
For most figures, statistics were performed using the one-way ANOVA with a Tukey 
posthoc test, and significance was defined as p < 0.05.  For statistical analysis of the mRNA 
levels of Ikaros family members relative to Ikaros, the two-way ANOVA was used with a 
Bonferroni posthoc test, and significance was defined as p < 0.05.
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Table 2-1.  Nested PCR primers for murine Ikaros and Aiolos 
Murine Ikaros Aiolos 
5’ Cloning CGCCCGAATTCACATAACCTGAAGAC GCCGGAATTCGGCGACATGGAAGATATAC 
Exon 2 Forward TCAGTGACACTCCAGATGAAGG ACGCTCTGAATGACTACAGCTTGCC 
Exon 3 Forward TCAGGAGTTGGAGGCATTCG TGAACTGCGACGTGTGCGGG 
Exon 4 Forward TACCCAGAAAGGCAACCTCC AGATGCGCTCACGGGACACCT 
Exon 5 Forward TGGATATTGTGGCCGGAGC GCCGTACAAGTGTGAGTTCTGCG 
Exon 4 Reverse GCAGGCATAGTTGCAAAGATGG CCCGTGAGCGCATCTCTCCTTTG 
Exon 5 Reverse CCAAGTAGTTGTGGCATCGC TCGGCAGCGTTCCTTGTGCT 
Exon 6 Reverse CTCTTACGTTTGGCGACATTGC TCGGCTTTGATGTGTCTTGCCTCC 
Exon 7 Reverse CTCCGATGACACAGACTTGG GGACAGACCTCGTTCAGAAGGCAAG 




Table 2-2.  Nested PCR primers for human Ikaros, Aiolos, and Helios 
Human Ikaros Aiolos Helios 
5’ Cloning CGACGCACAAATCCACATAACCTGAG GGCAGCGACATGGAAGATATAC TGCACTTTGACTATGGAAACAGAGGC 
Exon 1 Forward CATGGATGCTGATGAGGGTC CACTCAGGAGCAGTCTGTG  
Exon 2 Forward TAAGCGATACTCCAGATGAGGG AATGTGGACAGTGGAGAAGGC TTGACCTCACCTCAAGCACACC 
Exon 3 Forward TCGGGAGTTGGAGGCATTCG GTCTCATTCGATAGTAGCAGGC ATTGAGAGCAGCGAGGTGGC 
Exon 4 Forward GGCACATCAAGCTGCATTCC AGAAGAGATGCGCTCACGG CTTCCACTGTAACCAGTGTGGAGC 
Exon 5 Forward TGGATATTGTGGCCGAAGC GAGAAGTTCCCTTGAGGAGC ACTGGAGGAACACAAGGAACGC 
Exon 3 Reverse CCATTCATTTCACAGGCACGC TCATCTTTCCACTGGTTGGC GGCCCAATGCAAACCATGCC 
Exon 4 Reverse AGGCGTAGTTGCAGAGGTGG GTGAGCGCATCTCTTCTTTGG GCGTCCCTTCTTCTACAGGC 
Exon 5 Reverse CCAAGTAGTTGTGGCAGCG CCTCAAGGGAACTTCTCTGC CTGCGCTGCTTGTAGCTTCG 
Exon 6 Reverse GACGTTACTTGCTAGTCTGTCC GCTAATCTGTCCAGTACGAGAGC GAGCTTCTCTATGACAGCAGGTCTC 
Exon 7 Reverse TTGTGCAGCTGGTACATCG ACCGTTTGACATCTCAGCC CCACTTCAGCGATTGTGCTTGG 








mRNA levels of Ikaros family members during early murine T cell development 
We FACS-purified murine DN2, DN3, DN4, ISP, and DP thymocytes and analyzed the 
relative mRNA levels of each Ikaros family member in each cell population using qRT-PCR 
(Fig. 2-1A).  Of the five family members, Aiolos mRNA levels increased most dramatically as 
thymocytes progressed from the DN2 to the DP stage; Aiolos mRNA levels in DP thymocytes 
were 27-fold higher than in DN3 thymocytes.  Ikaros mRNA levels also increased during early T 
cell development and were 3.0-fold higher in DP thymocytes than in DN3 thymocytes.  Pegasus 
mRNA levels were 1.6-fold higher in DN2 thymocytes than DN3 thymocytes, but increased to 
4.1-fold higher in DP thymocytes than DN3 cells. 
By contrast, Helios and Eos mRNA levels decreased as thymocytes progressed from the 
DN2 stage to the DP stage.  Helios mRNA levels were 2.6-fold higher in DN2 thymocytes than 
DN3 cells and were similar in the DN3, DN4, ISP, and DP populations.  Eos mRNA levels were 
comparable in DN2 and DN3 thymocytes, but were 10-fold higher in DN3 thymocytes than DP 
cells.   
For the calculations in Fig. 2-1A, the mRNA levels of each Ikaros family member were 
first normalized to that of GAPDH before comparing cell populations.  GAPDH can be induced 
in mature T cells (342), so it is unclear whether this is an appropriate control gene for these 
assays.  In addition, because Ikaros family members dimerize with each, the ratio of family 
members is an important parameter.  Hence, we directly compared the mRNA levels of each 
Ikaros family member to that of Ikaros itself (Fig. 2-1B).  Ikaros was the predominant mRNA 
species in DN2 thymocytes; Ikaros mRNA levels were 7.3-
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Figure 2-1.  Ikaros, Aiolos, and Pegasus mRNA levels increase during early murine T cell 
development.  mRNA isolated from murine DN2 (CD4–CD8–CD44+CD25hi), DN3 (CD4–CD8–
CD44–CD25hi), DN4 (CD4–CD8–CD44–CD25–), ISP (CD4–CD8+CD24+), and DP (CD4+CD8+) 
thymocyte populations was subjected to qRT-PCR.  A) For each thymocyte population, the 
relative expression of each Ikaros family member was normalized to that of DN3 thymocytes and 
the log2 (Fold Change) is shown.   (n = 7 independent samples; *p < 0.05, **p < 0.01, ***p < 
0.001 as compared to DN3)  B) For each population, relative mRNA levels of the Ikaros family 








































































































































































fold higher than Helios, 14-fold higher than Pegasus, 15-fold higher than Eos, and 30-fold higher 
than Aiolos (p < 0.01 for all family members compared to Ikaros).  As thymocytes progressed 
through development, their Aiolos mRNA levels increased to such an extent that Ikaros and 
Aiolos mRNA levels were comparable in DN4, ISP, and DP thymocytes.  Pegasus, Helios, and 
Eos mRNA levels remained significantly lower than Ikaros in all murine thymocyte populations 
tested (p < 0.001).  Relative to Ikaros mRNA levels, Eos mRNA levels decreased throughout 
early T cell development; Eos mRNA levels at the DP stage were 380-fold lower than those of 
Ikaros (p < 0.001 for DP compared to DN2).  Helios and Pegasus mRNA levels did not change 
significantly relative to Ikaros.  These data suggest that the mRNA levels of some Ikaros family 
member are regulated independently.  In addition, Ikaros and Aiolos are the predominant family 
members expressed in murine thymocytes, but the other family members are also present, 
particularly in early stages of T cell development. 
 
Protein levels of Ikaros family members during murine T cell development 
To determine whether the Ikaros family protein levels correlated with their mRNA levels, 
we analyzed Ikaros, Aiolos, and Helios protein levels (Fig. 2-2).  According to the western blot 
analysis and consistent with previous reports (2), Ikaros and Aiolos protein levels were 2.5-fold 
and 11-fold higher in DP thymocytes than DN3 thymocytes, respectively (Fig. 2-2A).  Helios 
protein levels were assessed by intracellular staining and flow cytometry (Fig. 2-2B) and found 
to be 2.3-fold higher in DN2 thymocytes than in DN3 thymocytes.  Helios protein levels 
transiently increased in DN4 thymocytes before decreasing to levels just above the isotype 
control in DP thymocytes. 
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Figure 2-2.  Ikaros and Aiolos protein levels increase and Helios protein levels decrease 
during early murine T cell development.  A) Cell lysates prepared from FACS-purified murine 
DN2, DN3, DN4, ISP, and DP thymocytes were probed with antibodies against Ikaros, Aiolos, 
or p38 MAPK.  Using densitometry, the sums of the splice variants were normalized to the 
quantity of p38 MAPK.  The fold change in protein level relative to DN3 is shown.  Data are 
representative of at least five independent experiments.  B) Murine thymocytes were surface 
labeled with antibodies against CD4, CD8, CD24, CD25, CD44 and TCRβ before fixing, 
permeabilizing, and intracellular staining with either anti-Helios (dark line) or isotype control 
(shaded histogram).  DN thymocytes were gated on surface CD24+TCRβ– cells before being 
gated based on CD25 and CD44 expression.  For each population shown, the geometric mean 
fluorescence intensity (GMFI) of the anti-Helios staining was divided by the GMFI of the 
isotype control.  Data are representative of six mice and three independent experiments. (*p < 








































































































In summary, Ikaros and Aiolos mRNA and protein levels increased as murine thymocytes 
progressed from the DN2 to the DP developmental stage.  By contrast, Helios mRNA and 
protein levels decreased, except for a transient increase in protein levels at the DN4 stage. 
 
Splice variants of Ikaros and Aiolos in murine thymocytes 
When cell lysates were probed with anti-Ikaros, three bands were detected (Fig. 2-2A), 
suggesting the presence of alternative splice variants.  To identify the bands, we performed 
nested RT-PCR using mRNA isolated from FACS-purified murine DN3, DN4, ISP, and DP 
thymocytes (Fig. 2-3).  Using the nested PCR primers to amplify exons 2 through 7, bands 
corresponding to the molecular weights of full-length Ikaros (Ik-Full), Ikaros lacking exon 3 (Ik-
Δ3), Ikaros lacking exons 5 and 6 (Ik-Δ5/6), and Ikaros lacking exons 3 and 5 (Ik-Δ3/5) were 
detected.  To verify the identity of these splice variants, we performed nested PCR using primers 
that amplified each possible pair of exons; an example of the data generated by this approach is 
shown in Fig. 2-3C.  Based on the nested PCR and the predicted molecular weights, Ik-Full, Ik-
Δ5/6, and Ik-Δ3 are the most likely splice variants detected by western blot (Fig. 2-2A).  These 
data are consistent with previous reports showing that Ik-Δ3 is a prominent splice variant in 
murine thymocytes (6, 343) 
The splice variants detected for Ikaros at the protein and mRNA levels were similar in all 
thymocyte populations tested.  In addition, the proportion of total Ikaros represented by each 
splice variant was comparable in each population.  Ik-Δ3/5 was readily detected by nested PCR, 
but the protein product was not observed.  The polyclonal anti-Ikaros antibodies used were raised 
against an unknown C-terminal epitope and the antibodies could recognize Ik-Δ3 and Ik-Δ5/6, so 
it is unlikely that the lack of Ik-Δ3/5 detection is due to lack of antibody recognition.
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Figure 2-3.  Ikaros and Aiolos mRNA undergo extensive splicing during early T cell 
development.  A) The exon structure of Ikaros and Aiolos is shown along with the location of 
the four N-terminal DNA binding zinc fingers and the two C-terminal zinc fingers that mediate 
dimerization.  The outer and inner primer pairs for the nested PCR are shown.  B and D) Total 
mRNA isolated from DN3, DN4, ISP, and DP thymocytes was amplified using the outer primers 
shown in (A).  The PCR product was reamplified using the inner primers shown in (A).  The 
identity of the splice variants for Ikaros (B) and Aiolos (D) are shown.  Data shown represent 
two independently derived sets of thymocytes, out of four independent experiments.  C) To 
confirm splice variants, total mRNA isolated from DN3, DN4, ISP, and DP thymocytes was 
amplified using the outer primers shown in (A), and the PCR product was reamplified using all 
possible pairs of inner primers described in Table 2-1.  A representative gel is shown for Ikaros 
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For Aiolos, two bands were detected by western blot.  The ratio of the two bands changed 
from being nearly equivalent in DN4 thymocytes to being predominantly full-length in DP 
thymocytes.  To identify the two bands, we performed nested PCR, using the same strategy as 
for Ikaros (Fig. 2-3D).  While the splice variants detected at the protein level were consistent 
across thymocyte populations, the mRNA species detected were highly variable between 
thymocyte populations and between mice.  Based on the molecular weights of the protein bands 
and the splice variants most consistently detected at the mRNA level, the most likely Aiolos 
isoforms observed at the protein level are full-length Aiolos and Ai-Δ5/6.  In each mouse 
analyzed, Ai-Δ5/6 mRNA was detected in DN thymocytes and the band decreased in intensity in 
ISP and DP thymocytes.  This observation is consistent with the protein data showing that, as a 
percentage of total Aiolos, Ai-Δ5/6 is more prevalent in DN4 thymocytes than DP thymocytes.   
To summarize, Ikaros and Aiolos expression increased at the protein and mRNA levels as 
murine thymocytes progressed from the DN2 to the DP developmental stage.  Three Ikaros and 
two Aiolos splice variants were detected at the protein level for each thymocyte population 
analyzed, although the ratio of the two Aiolos isoforms shifted as thymocytes progressed through 
development.  For both Ikaros and Aiolos, multiple splice variants, including dominant negative 
splice variants, were detected at the mRNA level, but not the protein level, indicating that the 
mRNA was not translated, the antibodies could not detect the splice variant, or the splice variants 
were expressed at levels below the limits of detection. 
 
mRNA levels of Ikaros family members during early human T cell development 
mRNA was isolated from FACS-purified human DN2, DN3, ISP, and DP thymocytes 
and subjected to qRT-PCR.  Ikaros, Aiolos, Helios, and Pegasus mRNA levels increased as 
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thymocytes progressed from the DN2 developmental stage to the DP stage, while Eos mRNA 
levels remained constant (Fig. 2-4A).  As in mice, the most dramatic change detected was in 
Aiolos mRNA levels, which were 18-fold higher in DP thymocytes than DN2 thymocytes.  
Ikaros and Pegasus mRNA levels in DP thymocytes were 4.4-fold and 2.5-fold than in DN2 
thymocytes, respectively.  In contrast to murine thymocytes, in which Helios mRNA levels 
decreased during early T cell development, Helios mRNA levels increased in human thymocytes.  
Helios mRNA levels in DN3 thymocytes were 2.3-fold higher than in DN2 thymocytes and 10-
fold higher in DP thymocytes than DN2 thymocytes. 
We also compared the mRNA levels of each Ikaros family member to that of Ikaros (Fig. 
2-4B).  Ikaros mRNA was the most abundant family member expressed in all populations except 
the DP population.  As thymocytes matured into the DP stage, the relative quantity of Helios 
increased from 9.0-fold less than Ikaros (p < 0.05) to 3.9-fold less than Ikaros and the difference 
between Ikaros and Helios mRNA levels at the DP stage was not statistically significant.  
Similarly, Aiolos mRNA levels increased from 20-fold lower than Ikaros to 5.2-fold lower than 
Ikaros and the change in the Ikaros to Aiolos ratio was statistically significant (p < 0.05).  
Conversely, Eos mRNA levels decreased from 14-fold less than Ikaros to 52-fold less than 
Ikaros, and Pegasus mRNA decreased from 3,500-fold less than Ikaros to more than 10,000-fold 
less than Ikaros.  These data indicate that Ikaros, Aiolos, and Helios are significant contributors 
to the total quantity of Ikaros family mRNA, but Eos may also function in human thymocytes, 
particularly in DN cells. 
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Figure 2-4.  Ikaros, Helios, Aiolos, and Pegasus mRNA levels increase during early human 
T cell development.  mRNA isolated from human DN2 (CD4–CD8–CD3–CD34+CD38+CD1a–
), DN3 (CD4–CD8–CD3–CD34+CD38+CD1a+), ISP (CD4+CD8–CD3–), and DP 
(CD4+CD8+) thymocytes was subjected to qRT-PCR.  A) For each thymocyte population, the 
relative expression of each Ikaros family member was normalized to that of DN2 thymocytes and 
the log2 (Fold Change) is shown.   (n = 5 independent samples; * p < 0.05, ** p < 0.01, *** p < 
0.001 as compared to DN3)  (B) For each population, relative mRNA levels of the Ikaros family 







































































































































































Protein levels of Ikaros family members during human T cell development 
Despite statistically significant increases in Ikaros and Aiolos mRNA levels, western blot 
analysis showed that Ikaros and Aiolos protein levels remained similar across the thymocyte 
populations (Fig. 2-5A).  However, subtle changes in protein levels were noted using 
intracellular staining and flow cytometry (Fig. 2-5B).  For example, Aiolos protein levels were 
1.9-fold higher in DP thymocytes than in DN2 cells.  In DP thymocytes, a distinct subpopulation 
of cells with slightly higher Ikaros protein could be detected.  Helios protein levels increased to a 
greater extent than Ikaros and Aiolos as thymocytes matured; Helios protein levels were 4.9-fold 
higher in DP thymocytes than the earlier developmental stages.  These data suggest that post-
transcriptional regulation of Ikaros and Aiolos is a critical factor in regulating protein levels, 
while Helios protein levels are more tightly linked to transcriptional control. 
 
Splice variants of Ikaros and Aiolos in human thymocytes 
Using western blot analysis, we detected three bands when cell lysates derived from 
DN2, DN3, ISP, and DP thymocytes were probed with anti-Ikaros (Fig. 2-5A), suggesting that 
multiple splice variants of Ikaros are expressed in human thymocytes.  To identify the Ikaros 
splice variants, we used nested PCR (Fig. 2-6A).  The pattern of Ikaros splicing was complex 
and varied across thymocyte populations and between individuals.  In addition to the loss of 
intact exons, Ikaros splice variants can include the addition of sixty intronic base pairs following 
exon 2 and the deletion of thirty base pairs at the 3ʹ end of exon 6 (8-10).  These additions and 
deletions resulted in the complex pattern seen in the nested PCR.  The identity of each mRNA 
species in Fig. 2-6A was determined by calculating its molecular weight and verified using 
nested PCR primers that include each possible pair of exons, as shown in Fig. 2-6B.  Because of 
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Figure 2-5. Helios protein levels, but not Ikaros and Aiolos protein levels, increase during 
early human T cell development. A) Cell lysates prepared from FACS-purified human DN2, 
DN3, ISP, and DP thymocytes were probed with antibodies against Ikaros, Aiolos, or p38 
MAPK and quantified as described in the legend to Figure 2-2.  Data are representative of three 
independent experiments.  B) Human thymocytes were labeled with antibodies against CD4, 
CD8, CD34, CD38, and CD1a before fixing, permeabilizing, and staining with anti-Helios and 
either anti-Ikaros or anti-Aiolos (dark lines) or the appropriate isotype controls (shaded 
histogram).  For each population shown, the geometric mean fluorescence intensity (GMFI) of 
the anti-Ikaros, anti-Aiolos, or anti-Helios staining was divided by the GMFI of the 


































































































































Figure 2-6.  Ikaros and Helios, but not Aiolos, mRNA undergoes extensive alternative 
splicing in human thymocytes.  Nested RT-PCR was performed on FACS-purified DN2, DN3, 
ISP, and DP human thymocytes to examine Ikaros (A), Aiolos (C), and Helios (D) alternative 
splicing, as described in the legend to Figure 2-3A. Two representative sample sets are shown 
from three independent experiments.  B) A representative gel showing the results of nested RT-

























































































































































the complexity of Ikaros splicing and the fact that not all mRNA splice variants are translated at 
detectable levels, we are unable to definitively identify the two minor splice variants of Ikaros 
detected on the western blot.  Possible splice variants represented by the band at 55 kD are Ik-Δ3 
or Ik-Δ5/6.  The band at 39 kD might be Ik-Δ3/4/5/6. 
Unlike Ikaros, only one Aiolos band could be detected by western blot and this band was 
full-length Aiolos (Fig. 2-5A).  Using nested RT-PCR, we detected one sample in which Aiolos 
lacked exon 5 (Ai-Δ5), but all the other samples only contained full-length Aiolos (Fig. 2-6C).  
Helios was also subjected to alternate mRNA splicing, as determined by nested RT-PCR (Fig. 2-
6D).  The splicing pattern varied between patients and between thymocyte populations, but 
samples containing full-length Helios (Helios-Full), Helios lacking the terminal seventy-eight 
bases of exon 3 (Hel-Δ3b), Helios lacking exon 6 (Hel-Δ6), and Helios lacking part of exon 3 
and all of exon 6 (Hel-Δ3b/6) were detected.  Hel-Δ3b is missing the first DNA-binding zinc 
finger, as previously reported (3).  Hel-Δ6 and Hel-Δ3b/6 have not been previously reported, but 
we used high fidelity RT-PCR to amplify the mRNA from total human thymocytes and 




We report the first comprehensive characterization of the expression and splicing patterns 
of the entire Ikaros family of transcription factors during the DN, ISP, and DP stages of murine 
and human T cell development.  In both mice and humans, Ikaros and Aiolos mRNA levels 
increased as thymocytes differentiated from the DN2 to DP stages (Figs 2-1 and 2-4), but the 
corresponding increase in protein levels was only observed in mice (Fig. 2-2), suggesting that 
human Ikaros and Aiolos mRNA might be stored for rapid translation following a stimulus.  
Further, multiple Ikaros and Aiolos mRNA splice variants were detected in mice (Fig. 2-3), but 
only Ikaros underwent extensive alternative splicing in humans (Fig. 2-6).  Another remarkable 
difference between mice and humans was that Helios mRNA and protein levels decreased during 
murine T cell development (Figs. 2-1 and 2-2), but increased during human T cell development 
(Figs. 2-4 and 2-5).  Helios mRNA underwent alternative splicing in humans and we identified 
two novel splice variants (Hel-Δ6 and Hel-Δ3b/6).  These differences in the expression and 
splicing of Ikaros family members between human and murine thymocytes indicate that the 
Ikaros family of transcription factors regulates murine and human T cell development 
differently. 
The importance of small changes in expression levels among Ikaros family members was 
highlighted in a study by Dovat, et. al. (55), who transgenically expressed Helios in murine B 
cells, which express very low levels of endogenous Helios (5).  Even though the transgenic 
expression resulted in a level of Helios that was approximately ten-fold lower than Ikaros, the 




The significance of changing the protein levels of any family member during T cell 
development is that the ratio of each family member to each other family member changes, 
thereby altering the composition of the Ikaros family dimers.  In mice, DN2 thymocytes 
expressed Ikaros and Helios protein, suggesting that the predominant dimers in murine DN2 
thymocytes are likely Ikaros-Ikaros homodimers and Ikaros-Helios heterodimers, the latter of 
which have been demonstrated to form in a murine thymocyte cell line (5, 30).  As murine 
thymocytes progress toward the DP developmental stage, the dimer species likely switch to 
predominantly Ikaros- and Aiolos-containing homodimers and heterodimers, which are also 
known to occur in murine thymocyte cell lines (27).  In humans, the only family member whose 
protein levels changed significantly during T cell development is Helios (Fig. 2-5).  Our data 
would predict that dimers containing Ikaros and Helios are common in human DP thymocytes, 
whereas DN2 thymocytes would express primarily Ikaros- and Aiolos- containing dimers. 
The Ikaros family members are derived from duplication events originating with a 
common gene (344).  Consistent with this shared origin, the family members share a high degree 
of homology, particularly within the DNA binding sites, which are nearly perfectly conserved 
across family members and between humans and mice (2, 3).  This homology means that Ikaros, 
Aiolos, and Helios can bind identical DNA sequences with comparable affinity, but the ability of 
each family member to drive transcription varies; Aiolos activity is greater than that of Ikaros, 
which is greater than Helios (2, 5).  The observations that different Ikaros family members vary 
in their transcriptional potency despite comparable DNA binding suggests that the activity of 
each family member is determined by their ability to bind co-transcription factors. 
A protein complex that has been linked to Ikaros function is the nucleosome remodeling 
and histone deacetylase (NuRD) complex.  Ikaros, Aiolos, and Helios are all capable of 
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associating with the NuRD complex, but the nature of the Ikaros dimers present in the cells can 
regulate which genes are bound by the NuRD complex (27-30).  Mi-2β, the catalytic core protein 
of the NuRD complex, primarily associates with genes that promote differentiation in the 
presence of Ikaros and genes associated with proliferation in the absence of Ikaros (27).  The 
mechanism for this differential gene association is unknown, but may be related to the nature of 
the Ikaros dimers present in the cell. 
An example of where differences in the expression of Ikaros family members may 
influence gene transcription is in the expression of CD4 and CD8α.  In mice, Ikaros and Mi-2β 
bind the CD8α and CD4 genetic loci.  Mi-2β binds the CD8α locus during early T cell 
development and is removed from the DNA when CD8 is expressed later in development (65).  
During the DP stage, Mi-2β associates with the CD4 locus and disruption of Mi-2β expression 
results in the inability to optimally express CD4 (66, 345).  The role of Ikaros family members in 
Mi-2β-mediated regulation of CD4 and CD8 transcription is unclear, but Ikaros associates with 
the CD8α and CD4 loci in murine DN and DP thymocytes (65, 66, 346).  This constitutive 
association of Ikaros with these loci suggests that other Ikaros family members may regulate Mi-
2β recruitment or release.  The increase in Aiolos expression we observed in murine thymocytes 
(Fig. 2-2) may affect Mi-2β binding to these loci.  In support of this model, Ikaros+/–Aiolos –/– 
mice have an increase in the number of CD4+CD8–/lo cells with an immature phenotype (346).  
This population resembles the CD4+ ISP stage of human development.  Thus, the opposing 
expression of CD4 and CD8 observed in human and murine ISP thymocytes may be related to 
the fact that Aiolos protein levels increase in murine thymocytes and Helios protein levels 
increase in human thymocytes. 
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Another mechanism by which Ikaros dimer composition might regulate T cell 
development is through control of Notch-dependent transcription.  Ikaros, Aiolos, and Helios 
bind the same DNA consensus sequence (GGGAA) as the Notch-dependent transcriptional 
regulator RBP-Jκ (14, 43, 44, 60, 77).  Based on this observation, it has been proposed that 
Ikaros might act as a competitive inhibitor of Notch-dependent transcription.  In support of this 
model, murine thymocytes lacking Ikaros have elevated expression of Notch-dependent genes 
(44, 60).  In addition, the increase in Aiolos protein levels in murine thymocytes correlates with 
the developmental stage at which cells reduce their ability to respond to Notch ligation (347). 
In addition to the protein levels of Aiolos and Helios being markedly different between 
human and murine thymocytes, the splicing patterns of Ikaros and Aiolos were also different.  In 
mice, three prominent variants of Ikaros were found: Ik-FL, Ik-Δ5/6, and Ik-Δ3 (Fig. 2-2).  These 
variants were detected at the mRNA and protein levels and the relative quantity of each variant 
was comparable in each thymocyte population tested.  By contrast, mRNA splicing of Ikaros in 
human thymocytes varied dramatically across the thymocyte populations and between patients 
(Fig. 2-6), but the major Ikaros isoform detected at the protein level was full-length.  Some splice 
variants detected at the mRNA level in normal thymocytes had been previously reported to be 
aberrant splice variants in patients with acute lymphoblastic leukemia (8-10, 85, 90, 91, 100, 
105).  Our data suggest that these unusual splice variants occur naturally, although their relative 
abundance may be elevated in leukemia and they may be translated into protein in leukemia.  For 
Aiolos, the opposite splicing pattern was noted; there was minimal splicing in human thymocytes 
(Fig. 2-6), but highly variable splicing in murine thymocytes (Fig. 2-3).  This variability in 




During human T cell development, there were marked changes in the mRNA levels of 
Ikaros and Aiolos that were not detected at the protein level (Figs. 2-4 and 2-5).  This 
discrepancy between mRNA and protein levels was not observed in murine thymocytes nor was 
it observed for human Helios.  These data indicate that the rates of synthesis or degradation of 
Ikaros and Aiolos proteins change during human T cell development.  Recent studies have 
shown that the thalidomide derivatives lenalidomide and pomalidomide induce the degradation 
of Ikaros and Aiolos through activation of the CRBN-CRL4 E3 ubiquitin ligase (348-351).  
Importantly, Helios is resistant to CRBN-CRL4-mediated degradation (351), suggesting a 
possible mechanism for the selective increase in Helios protein levels. 
In summary, we report the first comprehensive characterization of the expression and 
splicing of Ikaros family members during murine and human T cell development.  In both 
species, members of the Ikaros family change their expression at the mRNA and protein levels in 
manners that are expected to profoundly alter the functionality of the family.  In addition, there 
were notable differences in the expression and splicing patterns of Ikaros family members that 
clearly indicate that murine and human T cell development are regulated differently. 
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Chapter 3. Ikaros, Helios, and Aiolos protein levels increase in 
human thymocytes after β selection 
 
Abstract 
In human T cell development, the mechanisms that regulate cell fate decisions after 
TCRβ expression remain unclear.  We defined the stages of T cell development that flank TCRβ 
expression and found distinct patterns of human T cell development.  In half the subjects, T cell 
development progressed from the CD4–CD8– double negative (DN) stage to the CD4+CD8+ 
double positive (DP) stage through an immature single positive (ISP) CD4+ intermediate.  
However, in some patients, CD4 and CD8 were expressed simultaneously and the ISP population 
was small.  In each group of patients, CD3– ISP and DP thymocytes were subdivided into ISP1, 
ISP2, DP1, DP2, DP3, DP4, and DP5 developmental stages according to their expression of 
CD28, CD44, CD1a, CD7, CD45RO, and CD38.  The ISP2, DP2, and DP3 thymocyte 
populations proliferated more robustly than ISP1 and DP1 and expressed markers consistent with 
TCRβ expression.  After the DP3 stage, proliferation returned to baseline levels.  We then 
analyzed protein levels of Ikaros, Helios, and Aiolos, the three Ikaros family members most 
abundantly expressed in human thymocytes.  Ikaros and Helios expression increased transiently 
at the ISP2, DP2, and DP3 populations.  Aiolos expression also increased at the ISP2, DP2, and 
DP3 stages, but its expression remained elevated throughout the DP4 and DP5 stages.  In 
summary, we propose a model of human T cell development that reflects the asynchronous 
nature of TCRβ expression and we define the subpopulations of thymocytes that are highly 




Human T cell precursors enter the thymus at a developmental stage in which the cells 
lack CD4 and CD8 expression and are called CD4–CD8– double negative (DN) thymocytes.  The 
DN thymocyte population can be subdivided into three subsets: DN1 (CD34+CD38–CD1a–), 
DN2 (CD34+CD38+CD1a–), and DN3 (CD34+CD38+CD1a+).  After the DN3 stage, the cells 
express CD4 and CD8 to become CD4+CD8+ double positive (DP) thymocytes.  Finally, the cells 
mature into single positive (SP) CD4+ or SP CD8+ thymocytes and exit the thymus. 
Rearrangement of the TCRD and TCRG genes occurs during the DN stages of human 
development, while TCRA rearrangement occurs in the DP stage (109).  Between the 
rearrangement of TCRG and TCRA genomic loci, V(D)J recombination at the TCRB locus occurs 
and T cell receptor β chain (TCRβ) protein is expressed.  Rearrangement of the TCRB genomic 
locus has been reported to begin as early as the DN3 stage, but TCRβ protein has not been 
detected until the immature single positive (ISP) developmental stage, the stage between the DN 
and DP populations (109, 115-117, 119).  However, there are TCRβ– DP thymocytes (116, 117, 
119), indicating that the exact timing of β selection remains unclear. 
In mice, successful expression of TCRβ leads to proliferation, survival, and 
differentiation (177-179), processes that must be tightly regulated to balance the expansion of 
TCRβ+ thymocytes with the prevention of leukemia.  A family of transcription factors that is 
likely to regulate β selection is the Ikaros family.  The Ikaros family consists of five family 
members (Ikaros, Helios, Aiolos, Eos, and Pegasus) that share a common structure with two zinc 
finger domains, an N-terminal DNA binding domain and a C-terminal dimerization domain.  
Protein dimerization is required for high affinity DNA binding.  The dimerization domain allows 
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for the binding of any family member to any other family member, creating the potential for a 
mixture of homodimers and heterodimers within the same cell (1-5).  Though the different 
family members have similar DNA recognition sites (2, 3), some family members are more 
potent transcriptional activators than others (2, 5). 
Ikaros family functionality is critical for lymphocyte development as expression of 
dominant-negative Ikaros can block murine B and T cell development (16).  Further, during 
murine B cell development, signals from the pre-B cell receptor drive Ikaros and Aiolos 
expression, resulting in loss of expression of the surrogate light chain and withdrawal from the 
cell cycle (2, 352, 353).  
Based on these results, we postulated that the expression of Ikaros family members may 
correlate with TCRβ expression during human T cell development.  Ikaros, Helios, and Aiolos 
mRNA levels increase as human thymocytes progress from the DN to the DP developmental 
stage (354).  However, despite large increases in mRNA levels, only subtle changes in protein 
levels were observed.  To investigate this observation in more detail, we first defined the human 
thymocyte subsets in which TCRβ is expressed and in which cell proliferation occurs.  We then 
correlated these observations with changes in Ikaros, Helios, and Aiolos protein levels. 
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Materials and Methods 
Antibodies 
The anti-human antibodies, anti-CD1a-PerCP-Cy5.5, anti-CD1a-PE-Cy5, anti-CD3- 
Allophycocyanin (APC)-Cy7, anti-CD4-Pacific Blue, anti-CD4-PE-CF594, anti-CD7-FITC, 
anti-CD7-APC, anti-CD8-Brilliant Violet (BV) 785, anti-CD28-Pacific Blue, anti-CD34-BV605, 
anti-CD34-PE, anti-CD38-Alexa Fluor (AF) 700, anti-CD44-PE-Cy7, and anti-TCRγδ-FITC 
were purchased from Biolegend (San Diego, CA).  Anti-Helios-AF647 was purchased from e-
Biosciences (San Diego, CA), and Mouse IgG1κ-PE control, anti-Ikaros-PE, and anti-Aiolos-PE 
were purchased from BD Biosciences (San Jose, CA).  The Armenian Hamster IgG-AF647 
control was purchased from Biolegend. 
 
Human thymocyte labeling 
After obtaining consent from the parent or guardian, human thymus samples were 
obtained from children (0 – 18 years) that underwent corrective surgery at Children’s Mercy 
Hospital (Kansas City, MO) for congenital cardiac defects.  Deidentified tissue samples void of 
any clinical data were obtained in compliance with the Institutional Review Boards at our 
institutions. 
Single cell suspensions of human thymocytes were labeled on their surface with anti-
CD1a, anti-CD3, anti-CD4, anti-CD7, anti-CD8, anti-CD28, anti-CD34, anti-CD38, anti-CD44, 
anti-CD45RO, and anti-TCRγδ, as previously described (355).  Cells were analyzed using a BD 




For labeling with 4',6ʹ-diamidino-2-phenylindole (DAPI) staining, cells were surface 
labeled as indicated.  After washing, cells were fixed in PBS with 2% paraformaldehyde and 
incubated over night at 4°C.  Cells were washed and resuspended in PBS with 0.2% Tween and 1 
µg/ml DAPI and analyzed, as previously described (356).   
For intracellular staining, cells were first surface stained as indicated, washed, and 
incubated in Foxp3/Transcription Factor Staining Buffer Set (Affymetrix/eBioscience, San 
Diego, CA), according to the manufacturer’s instructions.   Permeabilized cells were labeled with 
anti-Helios and either anti-Ikaros or anti-Aiolos, or isotype control antibodies before analyzing 
using the BD LSR II.  Data were analyzed using FlowJo (TreeStar, Inc., Ashland, OR).  Relative 
expression of Ikaros, Helios, and Aiolos in each cell population was defined as the ratio of 
geometric mean fluorescence intensity of each Ikaros family member and the corresponding 
isotype control.  
 
Statistical analysis 
The Student t test was performed for experiments in which two groups were compared.  
For comparisons across groups, the repeated measure ANOVA (Fig. 3-4) or one-way ANOVA 
(Fig. 3-5) analyses with Tukey posthoc tests were performed using GraphPad Prism (GraphPad 




The DN to DP transition in human thymocytes occurs in two patterns 
Before we can analyze the expression patterns of Ikaros, Helios, and Aiolos at β 
selection, we must first define the CD3– thymocyte subsets that express TCRβ.  Because TCRβ 
protein can be first detected in the ISP CD4+ population (109, 115-117, 119), we determined the 
percentage of SP CD4+ thymocytes that lacked surface CD3 expression (Fig. 3-1A).  Based on 
the analysis of 27 patients, we identified two groups of patients.  The percentage of CD4+ cells 
that were CD3– was 22% ± 2.0% in Group 1 (n = 14) and 3.6% ± 0.53% in Group 2 (n = 13). 
To further explore the differences in T cell development between the groups, we gated on 
CD3– thymocytes and re-analyzed CD4 and CD8 expression (Fig. 3-1B).  In group 1 samples, 
DN, ISP CD4+, and DP thymocytes were readily detected.  However, few ISP CD4+ thymocytes 
were observed in group 2 patients.  In two patients, there appeared to be an ISP CD8+ population 
(called Group 3 in Fig. 3-1B).  Because only two of the 27 patients were in group 3, the data 
from these individuals were excluded from further analysis.  To quantify the difference in the 
developmental patterns between groups 1 and 2, we calculated the ratio of CD3– DN cells to 
CD3– ISP CD4+ cells.  This ratio was 0.88 ± 0.13 in Group 1 patients and 6.4 ± 1.7 in Group 2 
patients (p < 0.01). 
In summary, the up-regulation of CD4 and CD8 expression observed during the transition 
from the DN to DP developmental stage can occur in different sequences in different individuals.  
In some cases, CD4 is expressed first, resulting in an ISP CD4+ population.  In other cases, CD4 
and CD8 expression occurs simultaneously.  In rare cases, CD8 is expressed before CD4, 
resulting in an ISP CD8+ population. 
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Figure 3-1. Up-regulation of CD4 and CD8 occurs in two patterns.  A) TCRγδ– thymocytes 
were analyzed for CD4 and CD8 expression (upper panels).  Thymocytes were gated on SP 
CD4+ cells and analyzed for CD3 and CD4 expression.  The percentages of SP CD4+ thymocytes 
that were CD3– were calculated.  Representative dot plots are shown for a thymus with a high 
ISP percentage (Group 1) and low ISP percentage (Group 2).  The scattergram shows the 
percentages of SP CD4+ thymocytes that were CD3– along with the line dividing patients in 
group 1 and group 2.  B) Total thymocytes were gated on CD3– cells and expression of CD4 and 
CD8 expression is shown from a representative thymus from each group.  The ratio of the 
percentages of DN to CD4+ SP thymocytes within the CD3– population was calculated for 

























































ISP thymocytes can be subdivided based on CD44, CD1a, and CD28 expression 
Next, we used CD44, CD1a, and CD28 to subdivide the ISP CD4+ cells thymocytes.  In 
both patient groups, CD28 expression correlated with the expression of CD44 and CD1a, so the 
ISP population could be subdivided into CD44+CD1a+CD28– cells (called ISP1 cells) and 
CD44++CD1a++CD28+ cells (ISP2 cells) (Fig. 3-2A).  Because CD28 has been shown to correlate 
with TCRβ expression (117), we propose that ISP1 thymocytes lack TCRβ protein and ISP2 
thymocytes express TCRβ.  The percentages of ISP CD4+ cells that were ISP1 were 71% ± 4.2% 
in Group 1 patients and 47% ± 6.8% in Group 2 patients (p < 0.01) (Fig. 3-2B). 
To further characterize the ISP1 and ISP2 populations, we analyzed CD7 and CD45RO 
expression (Fig. 3-2C).  CD45RO expression increases as thymocytes progress toward the DP 
developmental stage (357).  In group 1 patients, 93% ± 1.0% of ISP1 cells and 72% ± 4.8% of 
ISP2 cells were CD7++CD45RO–.  The remaining ISP thymocytes were CD7+CD45RO+.  In 
group 2 patients, nearly all ISP1 and ISP2 thymocytes were CD7++CD45RO–. 
These data suggest that ISP thymocytes progress from CD7++CD45RO– to 
CD7+CD45RO+ as they progress through development.  To further test the developmental 
sequence of ISP1 and ISP2 thymocytes, we analyzed the expression of CD28, CD44, CD1a, 
CD28, CD7, and CD45RO on DN3 thymocytes, the stage immediately preceding the ISP stage 
(Fig. 3-2D).  DN3 thymocytes from both groups of patients are uniformly CD44+CD1a+CD28–
CD7++CD45RO–, similar to ISP1 CD7++CD45RO- thymocytes. 
 
CD3– DP thymocytes can be divided into five subsets 
Our analysis of CD7 and CD45RO expression on the ISP population suggested that the 
CD7+CD45RO+ ISP population is the final stage before the DP population.  To test this 
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Figure 3-2. CD1a and CD44 expression correlate with CD28 in ISP cells.  A) ISP CD4+ 
thymocytes were analyzed for CD28, CD44, and CD1a expression and divided into ISP1 and 
ISP2 subpopulations. B) The percentages of ISP thymocytes from each subject in groups 1 and 2 
are shown.  The line indicates the mean ± SE for each group.  C) ISP1 and ISP2 thymocytes 
from group 1 and group 2 patients were analyzed for CD7 and CD45RO expression.  D) DN3 
thymocytes from group 1 (left panels) and group 2 (right panels) patients were analyzed for 
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hypothesis, we analyzed CD7 and CD45RO expression on CD3– and CD3lo DP thymocytes from 
patients in group 1 and group 2 (Fig. 3-3A).  In both groups, 85% ± 1.9% of CD3– DP 
thymocytes were CD7+CD45RO+.  Among CD3lo DP thymocytes, which represent the 
developmental stage after CD3– DP thymocytes, 95% ± 1.3% of the cells were CD7+CD45RO+. 
Because a small percentage of DP thymocytes lack TCRβ expression (119), we further 
divided the CD3– DP subpopulations to define the subsets that express or lack TCRβ.  As with 
the ISP1 and ISP2 thymocytes, we used CD44, CD1a, and CD28 to label CD7++CD45RO– CD3– 
DP thymocytes (Fig. 3-3B).  We called CD44+CD1a+CD28–CD7++CD45RO– DP thymocytes 
DP1 thymocytes and CD44++CD1a++CD28+CD7++CD45RO- DP thymocytes DP2 thymocytes, as 
shown in Fig. 3-3B.  
Next, we used CD38 and CD45RO to subdivide the CD7+CD45RO+CD3– DP 
populations from each group (Fig. 3-3C, plot iii).  As a comparison, we performed parallel 
analysis on DP1 and DP2 thymocytes (Fig. 3-3C, plot i).  DP1 and DP2 thymocytes were 
uniformly CD38+, but DP2 thymocytes expressed slightly higher CD45RO levels than DP1.  
Two populations of CD7+CD45RO+ thymocytes (plot iii) could be detected, one that is similar to 
DP2 thymocytes (CD38+CD45ROlo) and one with increased expression of CD38 and CD45RO 
(CD38hiCD45ROhi).  We propose that the DP2 thymocytes mature into CD38+CD45ROlo 
thymocytes.  To determine whether this is a uniform population, we analyzed CD7 and CD44 
expression.  DP1 and DP2 had similar and high levels of CD7 and DP2 thymocytes expressed 
higher levels of CD44 than DP1 cells (Fig. 3-3C, plot ii).  CD38+CD45ROloCD3– DP thymocytes 
could be divided into CD44hiCD7hi and CD44loCD7lo thymocytes (Fig. 3-3B, plot iv).  The 
CD44hiCD7hi thymocytes resembled DP2 thymocytes, so we called this subset DP3.  We called 
the CD44loCD7lo cells DP4.  In support of the conclusion that DP3 precedes DP4, the 
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Figure 3-3. CD3– DP cells can be divided into five subpopulations.  A) CD3– and CD3lo DP 
thymocytes were analyzed for CD7 and CD45RO expression.  B) CD3–CD7++CD45RO– 
thymocytes were analyzed for CD44, CD1a, and CD28 expression and divided into DP1 (lightly 
shaded cells) and DP2 (darkly shaded cells) subsets.  C) CD3–CD7++CD45RO– thymocytes 
(plots i and ii) and CD3–CD7+CD45RO+ thymocytes (plots iii, iv, and v) were analyzed for 
expression of CD38, CD45RO, CD44, and CD7, as shown.  Lightly shaded cells in plots i and ii 
reflect the shading in panel B. D) DP1, DP2, DP3, DP4, and DP5 thymocytes (as defined in 
panel C) were analyzed for CD28 and CD1a expression.  A-D) Representative dot blots from a 
patient in group 1 (upper panels) and a patient from group 2 (lower panels) are shown in each 













































































































CD38hiCD45ROhi thymocytes from Fig. 3-3B, plot iii were mostly CD44loCD7lo and are called 
DP5. 
 For each subpopulation of CD3– DP thymocytes, we analyzed CD28 and CD1a 
expression (Fig. 3-3D).  As thymocytes progressed from DP1 to DP5, CD1a expression 
increased and remained elevated.  However, CD28 expression was transient and followed a 
similar pattern as CD44; surface protein levels were higher at the DP2 and DP3 stages than the 
other populations. 
In summary, we defined five subsets of CD3– DP thymocytes and placed them into 
developmental sequence by comparing the expression of a set of surface markers with that of the 
developmental stages immediately preceding and following.  We then calculated the percentage 
of CD3– DP thymocytes represented by each subset (Fig. 3-3E).  Unlike ISP thymocytes in 
which there was a difference in the percentage of ISP1 and ISP2 subsets between the two groups 
of patients, there were no statistically significant differences between patient groups observed in 
the percentages of CD3– DP thymocytes within each of the five subsets (data not shown).  Of the 
CD45RO+CD3– DP thymocytes, the cells were equally distributed among the DP3, DP4, and 
DP5 developmental stages. 
 
The rate of proliferation peaks during the ISP2 and DP2 stages 
Expression of TCRβ triggers robust proliferation in murine thymocytes (177, 358).  We 
used cell cycle analysis to determine which human DN, ISP, and DP thymocyte subsets were 
actively proliferating (Fig. 3-4).  On average, fewer than 9% of DN2, DN3, and ISP1 thymocytes 
were in the S, G2, or M phase of the cell cycle.  Likewise, 10% ± 3.4% of the DP1 thymocytes 
were in the S, G2, or M phase of the cell cycle.  By contrast, 25% ± 4.5% of the ISP2 thymocytes
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Figure 3-4. ISP2, DP2, and DP3 cells have increased proliferation.  A) Thymocytes from the 
indicated cell populations were analyzed for DNA content using DAPI.  The percentages of cells 
in the S, G2, or M phase of the cell cycle are shown.  Representative data are shown as 
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were in the S, G2, or M phase of the cell cycle (p < 0.001, compared to ISP1).  Further, 37% ± 
6.6% and 38% ± 7.3% of the DP2 and DP3 thymocytes, respectively, were in the S, G2, or M 
phase of the cell cycle (p < 0.01, DP2 and DP3 thymocytes compared to DN, ISP1, and DP1 
thymocytes).   
Compared to the DP2 and DP3 populations, the percentages of thymocytes in the S, G2, 
or M phase were lower in the DP4 and DP5 stages; 15% ± 5.1% of DP4 thymocytes and 8.5% ± 
1.5% of DP5 thymocytes were in the S, G2, or M phase of the cell cycle (p < 0.01, DP2 and DP3 
thymocytes compared to DP4 and DP5 thymocytes).  These data support the model in which 
TCRβ expression is an asynchronous process with some cells expressing TCRβ and entering the 
cell cycle during the ISP stage and some cells expressing TCRβ and entering the cell cycle 
during the DP stage.  Further, these data suggest that proliferation is reduced in the populations 
immediately prior to surface CD3 expression.  The stepwise reduction in the rate of proliferation 
seen in the DP3, DP4, and DP5 populations further supports our model that these stages 
represent sequential developmental stages. 
 
TCRβ  expression correlates with an increase in Ikaros, Helios, and Aiolos protein levels 
Next, we used intracellular staining and flow cytometry to monitor the protein levels of 
Ikaros, Helios, and Aiolos in the CD3– thymocyte populations (Fig. 3-5).  The protein levels of 
Ikaros, Helios, and Aiolos were higher in the ISP2 population, as compared to the ISP1 
population.  Helios protein levels increased 2.8-fold at this stage (p < 0.05), Aiolos increased 2.0-
fold (p < 0.05), and Ikaros increased 1.9-fold (p < 0.01).  Similarly, Ikaros protein levels in DP2 
thymocytes were 1.9-fold higher than in DP1 cells (p < 0.05) and Aiolos protein levels were 1.8-
fold higher in DP2 cells than DP1 cells (p < 0.05).  Helios protein levels also trended higher in
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Figure 3-4. Ikaros, Helios, and Aiolos protein levels increase with TCRβ expression.  A) The 
indicated populations of thymocytes were intracellularly stained with anti-Helios, anti-Ikaros, or 
anti-Aiolos (dark lines), or the appropriate isotype controls (shaded histogram).  The geometric 
mean fluorescence intensity (GMFI) of the anti-Ikaros, anti-Helios, or anti-Aiolos was 
normalized to the GMFI of the isotype control for each population, and the mean ± SE fold 
change relative to ISP1 is shown for four independent experiments.  
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DP2 thymocytes than DP1, although this difference did not reach statistical significance until the 
DP3 stage (p < 0.001, DP3 vs. DP1).  As thymocytes continued to mature, only Aiolos protein 
levels remained elevated.  By contrast, Helios levels were 3.1-fold higher in DP3 thymocytes 
than DP5 cells (p < 0.001) and Ikaros levels were 1.8-fold higher in DP3 thymocytes than DP5 
cells (p < 0.05), indicating that Ikaros and Helios undergo a transient increase in protein levels 




The data presented here highlight the asynchronous manner by which human thymocytes 
express TCRβ protein.  Using CD28 as a marker of TCRβ expression (117), we show that 
expression of TCRβ correlates with increases in the expression of CD1a, CD44, Ikaros, Helios, 
and Aiolos, but does not strictly correlate with CD4 and CD8 expression.  Importantly, we 
identified CD1a and CD44 as markers that delineated populations of TCRβ– and TCRβ+ cells in 
both the ISP and DP stages within the same thymus (Fig. 3-2A and 3-3B).  Greater percentages 
of CD1a++CD44++CD28+ ISP2 and DP2 cells were in the S, G2, or M phase of the cell cycle than 
CD1a+CD44+CD28– ISP1 and DP1 cells (Fig. 3-4), supporting the model that ISP2 and DP2 
thymocytes express TCRβ.  ISP2 and DP2 thymocytes also had higher expression of Ikaros, 
Helios, and Aiolos protein levels, as compared to ISP1 and DP1 cells.   
Based on our analysis, we propose the model of human T cell development shown in Fig. 
3-6.  Because we are focusing on cells that lack surface TCRαβ or TCRγδ expression, we gated 
on CD3– live events before analyzing the remaining markers.  In developing the model, several 
assumptions were made.  Firstly, as thymocytes progress through the developmental stages, it is 
more likely that protein levels of surface markers change subtly than drastically.  Secondly, once 
TCRβ is expressed, it is highly unlikely that it is lost.  Lastly, TCRβ+ thymocytes proliferate at a 
greater rate than TCRβ– cells, at least until rearrangement of the TCRA locus commences.  
Based on these assumptions, we found three patterns of CD4 and CD8 expression in 
CD3– thymocytes (Fig. 3-1B): the canonical pattern in which CD4 is expressed prior to CD8, 
creating an ISP CD4+ population (Group 1); a pattern in which CD4 and CD8 are expressed 
simultaneously (Group 2); and a third pattern that appeared in two patients in which CD8 is 
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 DN3 ISP1 ISP2 DP1 DP2 DP3 DP4 DP5 
CD4 − + + + + + + + 
CD8 − − − + + + + + 
CD1a + + ++ + ++ ++ ++ ++ 
CD44 + + ++ + ++ ++ + + 
CD28 − − + − + −/+ − − 
CD45RO − − + − + ++ ++ +++ 
CD7 ++ ++ ++/+ ++ ++ ++/+ + + 
CD38 + + + + + + + ++ 











expressed prior to CD4 (Group 3).  While it might be expected that individual cells would take 
random paths from the DN to the DP stage, it was unexpected that most cells in an individual 
followed one of the three patterns.  Because the tissue samples were collected without clinical 
data, we are unable to determine whether the age of the patient, comorbidities, or pre-surgery 
medications might influence the developmental pattern (359-361).  The implications of these 
developmental patterns on physiology or pathophysiology are unknown; however, these 
observations imply that DN3 thymocytes could differentiate directly into ISP1 or DP1 
thymocytes, as shown in Fig. 3-6, or an ISP CD8+ population that is not shown in the figure. 
Regardless of the pathway that thymocytes follow during the DN to DP transition, TCRβ– 
and TCRβ+ subsets of ISP and DP thymocytes could be detected in each individual.  ISP1 and 
DP1 cells appear to be pre-β selection cells based on their lack of CD28 expression (Figs. 3-2A 
and 3-3B) and low proliferation rate (Fig. 3-4).  The presence of TCRβ– DP thymocytes suggests 
that remodeling of the CD8 locus is not dependent on pre-TCR signals, as it is in murine 
thymocytes (65).  Further, these data suggest that ISP1 cells could express TCRβ protein and 
differentiate into ISP2 cells.  The newly formed ISP2 thymocytes likely differentiate into either 
DP2 or DP3 cells, depending on whether the cells up-regulate CD45RO before or after CD8. 
If TCRβ expression fails to occur during the ISP CD4+ stage, the cells likely differentiate 
into DP1 thymocytes.  DP1 cells may retain the potential to successfully rearrange their TCRB 
locus, express TCRβ protein, and differentiate into DP2 thymocytes.  However, if DP1 
thymocytes fail to express TCRβ, the cells likely undergo apoptosis. 
As in murine T cell development, TCRβ expression in human thymocytes triggers robust 
proliferation, as seen by a greater percentage of CD3– DP thymocytes in the S, G2, or M phase of 
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the cell cycle than DN thymocytes (115, 116, 118).  We extend these observations by showing 
which subpopulations of ISP and DP thymocytes are the most rapidly dividing (Fig. 3-4).  
Specifically, more than 20% of ISP2, DP2, and DP3 thymocytes were in the S, G2, or M phase 
of the cell cycle, as compared to less than 10% of ISP1 and DP1 thymocytes.  Proliferation was 
most robust in the DP2 and DP3 stages and then declined in the DP4 and DP5 stages, the final 
stages prior to the expression of TCRα and surface TCR.  This is analogous to the proliferation 
that occurs after TCRβ expression in murine thymocytes.  The first murine thymocytes that 
express TCRβ proliferate more robustly than TCRβ+ thymocytes at later stages (356, 362, 363).  
At the DP5 stage, thymocytes decrease their expression of CD44 and increase their expression of 
CD38 (Fig. 3-3C).  CD38 is first expressed at the DN2 stage, the stage in which rearrangement 
of the TCRD and TCRG loci occurs (109).  This suggests that CD38 transcription may be 
regulated via similar mechanisms as RAG-1 or RAG-2.  In chronic lymphocytic leukemia, CD38 
expression is regulated by the E-box factor, E2A (364).  E2A binds the RAG enhancer regulatory 
element in developing murine B cells (365) and human cancer cell lines (366).  Thus, the 
increase in CD38 expression on DP5 cells may correlate with the onset of TCRA rearrangement. 
With this detailed image of the developmental stages that surround TCRβ expression, we 
are now able to examine changes in the protein levels of Ikaros, Helios, and Aiolos at this critical 
point in human T cell development.  It was previously shown that the mRNA levels of each of 
these molecules increased dramatically as human thymocytes progressed from the DN to the DP 
stages (354).  However, previous data also showed that protein levels in total DP thymocytes 
were only slightly elevated, as compared to DN thymocytes.  Using flow cytometry, we are now 
able to subdivide the ISP and DP populations and detect transient changes in protein expression 
that occur as thymocytes mature. 
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Protein levels of Ikaros, Helios, and Aiolos increased when thymocytes expressed TCRβ 
and proliferated (Fig. 3-5).  The relative increase in Helios expression was greater than that of 
Ikaros and Aiolos, suggesting that the composition of Ikaros family dimers changes when 
thymocytes express TCRβ.  More Ikaros family dimers likely contain Helios in ISP2, DP2, and 
DP3 thymocytes than ISP1 and DP1 cells.  The other significant difference among family 
members is that the increase in Ikaros and Helios protein levels was transient; protein levels of 
these two family members were lower in DP4 and DP5 thymocytes than DP2 and DP3 
thymocytes.  By contrast, Aiolos protein remained elevated in DP4 and DP5 thymocytes.  This 
observation indicates that more Ikaros family dimers contain Aiolos in DP4 and DP5 thymocytes 
than previous developmental stages. 
The importance of small changes in the expression of Ikaros family members was 
demonstrated in a study in which transgenic mice were generated that express low levels of 
Helios (55).  Expressing ten-fold lower levels of Helios than Ikaros resulted in B cell lymphoma.  
The mechanism by which changes in Ikaros family dimers influence gene transcription is 
unknown.  Because of the high degree of homology within the DNA binding motifs of each 
family member, it is likely that all family members can bind the same DNA sequences with 
similar affinities.  However, the relative potency of each family member is different.  For 
example, Aiolos is a more potent transcriptional activator than Ikaros (2). 
Helios expression is different in murine and human thymocytes (354).  Specifically, 
Helios mRNA levels decrease as murine thymocytes progress from the DN to the DP stage while 
Helios mRNA levels increase in human thymocytes.  Thus, it is difficult to draw conclusions 
regarding the function of Ikaros family members using data from the opposite species.  However, 
loss of Ikaros in murine thymocytes obviates the need for TCRβ expression for differentiation 
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into DP thymocytes, even though Ikaros could not drive proliferation after TCRβ expression 
(367).  In human thymocytes, Ikaros, Helios, and Aiolos were most abundantly expressed in the 
thymocyte populations that were most proliferative (Figs. 3-4 and 3-5), suggesting that the Ikaros 
family might promote proliferation in human TCRβ+ thymocytes.  The decrease in Ikaros and 
Helios coupled with sustained Aiolos expression seen in DP4 and DP5 thymocytes might lead to 
the slowing of cell cycle progression and rearranging of the TCRA locus.  More experiments are 
necessary to determine the function of Ikaros in human thymocytes. 
Consistent with a role for Ikaros family members in pre-TCR-mediated proliferation and 
differentiation is the observation that pre-BCR-mediated Ikaros and Aiolos expression during 
murine B cell development induces exit from the cell cycle (352, 353, 368, 369).  Further, 
exogenous expression of Ikaros in a pre-B cell line could halt cell division (369).  In addition, 
expression of Ikaros in an Ikaros-deficient DN3-like murine thymoma cell line can induce 
differentiation and expression of TCRα (45, 370).  This differentiation is independent of TCRβ 
expression as loss of Ikaros expression on a RAG-1–/– background induced differentiation to the 
DP stage and expression of TCRα germline transcripts (367). 
In summary, we defined the stages of human T cell development flanking the expression 
of TCRβ to a greater level of detail than has been previously reported.  Further, we show that 
Ikaros, Helios, and Aiolos protein levels fluctuate during this critical time in T cell development. 
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Chapter 4. Positive selection and lineage commitment of human thymocytes 
occur during the transitional single positive developmental stage 
 
Abstract 
Subdividing human thymocytes into fine populations enables us to define the 
developmental stages at which critical checkpoints occur.  T cell precursors enter the thymus as 
CD4–CD8– double negative (DN) thymocytes and then express both CD4 and CD8 to become 
CD4+CD8+ double positive (DP) thymocytes before maturing into either single positive (SP) 
CD4+ or SP CD8+ thymocytes.  We used multi-parameter flow cytometry to define the 
populations in which positive selection and lineage commitment are most likely to occur and to 
analyze expression of Ikaros, Helios, and Aiolos, key transcription factors required for T cell 
development.  After human thymocytes express CD3 and receive positive selection signals, the 
cells down-regulate expression of CD4 to become transitional single positive (TSP) CD8+ 
thymocytes.  At this stage, there was a transient increase in the Ikaros, Helios, and Aiolos protein 
levels.  After the TSP CD8+ developmental stage, some thymocytes re-express CD4 and become 
CD3hi DP thymocytes before down-regulating CD8 to become mature SP CD4+ thymocytes.  
During CD4+ T cell maturation, Helios expression declined and Aiolos expression transiently 
increased.  For commitment to the CD8+ T cell lineage, TSP CD8+ thymocytes increase their 
expression of CD3 and maintain high levels of Aiolos protein as the cells complete their 
maturation.  In summary, we defined the TSP CD8+ developmental stage in human T cell 




Human T cell development is a multi-step process of selection, proliferation, and 
maturation that produces functional T cells able to participate in an immune response.  Immature 
T cells enter the thymus as CD4–CD8– double negative (DN) thymocytes and, during the DN 
developmental stage, begin rearranging the genomic loci encoding the T cell receptor (TCR) 
chains (109, 116).  After the DN stage, thymocytes express CD4 to become immature single 
positive (ISP) CD4+ thymocytes and then express CD8 to become double positive (DP) 
thymocytes.  Rearrangement of the genomic locus encoding TCRβ is completed during the ISP 
or DP developmental stages and expression of TCRα can be detected within the DP stage (115-
119, 354). 
After expression of TCRα and TCRβ, thymocytes are subjected to positive and negative 
selection, ensuring the production of T cells that express a functional TCR with limited 
autoreactivity.  Selection requires engagement of the TCR and leads to expression of activation 
markers, such as CD69 and CD5, and increased expression of CD3 (276, 371-374).  Positive 
selection induces continued thymocyte maturation, including commitment to the single positive 
(SP) CD4+ or SP CD8+ lineages.  
The lack of clarity regarding the cell populations in which developmental milestones 
occur have led to competing models of thymic selection and lineage commitment.  Positive 
selection is proposed to occur at the DP developmental stage, when CD4 and CD8 are both 
available to bind major histocompatibility complex (MHC).  A possible model of lineage 
commitment is that positive selection stochastically induces down-regulation of either CD4 or 
CD8.  In this model, T cell maturation is dependent on the random chance that the remaining co-
receptor has the same MHC specificity as the TCR.  Alternatively, CD4 and CD8 may induce 
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distinct signals that drive lineage commitment and the down-regulation of the opposing co-
receptor. 
A third model of CD4/CD8 lineage commitment emerged from studies in murine models 
where a transitional single positive (TSP) CD4+CD8lo thymocyte population has been described 
(312-315).  According to this model, positive selection induces decreased CD8 expression (317-
320).  This model posits that down-regulation of CD8 interrupts the MHC/TCR interaction in 
MHC I-restricted thymocytes, while signaling is maintained in MHC II-restricted thymocytes, 
thereby differentiating between the two lineages.  This model is supported by data showing that 
prolonged signaling after positive selection results in the preferential development of SP CD4+ 
thymocytes whereas short-lived signals lead to the production of SP CD8+ thymocytes (309, 
311).   
A family of proteins proposed to regulate positive selection and lineage commitment is 
the Ikaros family of transcription factors.  This family regulates numerous steps of T cell 
development, including regulation of CD4 and CD8 expression, survival, and proliferation (2-4, 
22, 46-48, 66, 340, 346, 367).  Disrupting the function of the Ikaros family in murine thymocytes 
results in the accumulation of TSP CD4+ thymocytes and increased proliferation and apoptosis 
(375).  These data suggest that one or more Ikaros family members are critical for positive 
selection or lineage commitment.   
In this chapter, we will provide the most detailed map of the developmental stages 
surrounding positive selection and lineage commitment yet reported in the human thymus.  In 
addition, we will define how expression of Ikaros, Helios, and Aiolos changes during this time. 
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Materials and Methods 
Human thymocytes 
After obtaining consent from the parent or guardian, human thymus samples were 
obtained from children (0 – 18 years) who underwent corrective surgery at Children’s Mercy 
Hospital (Kansas City, MO) for congenital cardiac defects.  De-identified tissue samples void of 
any clinical data were obtained in compliance with the Institutional Review Boards at our 
institutions. 
 
Antibodies, cell labeling, and flow cytometry 
The anti-human antibodies, anti-CD1a-PerCP-Cy5.5, anti-CD3-APC-Cy7, anti-CD4-
Pacific Blue, anti-CD7-APC, anti-CD7-FITC, anti-CD7-PE, anti-CD8α-BV785, anti-CD25-
PerCPCy5.5, anti-CD28-Pacific Blue, anti-CD38-AF700, anti-CD44-PE-Cy7, anti-CD45RO-
PECy5, anti-CD69-BV650, anti-FoxP3-PE, anti-FoxP3-AF647, anti-Helios-AF647, anti-TCRγδ-
FITC, Armenian hamster IgG-AF647 control, and mouse IgG1κ-PE control were purchased from 
Biolegend (San Diego, CA).  Anti-CD4-PE-eFlour 610, anti-CD8β-PECy7, and anti-CD44-PE 
were purchased from e-Biosciences (San Diego, CA), and anti-CD27-Horizon V500, anti-Ikaros-
PE, anti-Aiolos-PE, and mouse IgG1κ-PE control were purchased from BD Biosciences (San 
Jose, CA).  Armenian hamster IgG-AF647 was purchased from Biolegend. 
Single cell suspensions of human thymocytes were labeled on their surface as previously 
described (355).  For intracellular staining, surface-labeled cells were fixed and permeabilized 
using the Foxp3/Transcription Factor Staining Buffer Set (Affymetrix/eBioscience, San Diego, 
CA), according to the manufacturer’s instructions.  Cells were analyzed using a BD LSR II (BD 
Biosciences) and data were analyzed using BD FACSDiva software (BD Biosciences) or FlowJo 
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(TreeStar, Inc., Ashland, OR).  Relative expression of Ikaros, Helios, and Aiolos in each cell 
population was defined as the ratio of the geometric mean fluorescence intensity of each Ikaros 
family member to the corresponding isotype control.  Representative dot plots are shown from 
one thymus out of eleven analyzed for all surface markers except CD28.  Representative dot 
plots of CD28 expression are shown for one thymus out of four analyzed. 
 
Statistical analysis 
For comparisons across groups, the paired t-test analysis or the repeated measure 
ANOVA analysis with Tukey posthoc test were performed using GraphPad Prism (GraphPad 





DP thymocytes can be divided into twelve subsets 
We previously showed that thymocytes enter the CD3– DP developmental stage as 
CD7++CD45RO– thymocytes and mature into CD7+CD45RO+ thymocytes (376).  In addition, we 
showed that CD3– DP thymocytes progress from CD38loCD45ROlo to CD38hiCD45ROhi.  To 
define the stages of human T cell development through the CD3+ stages, we divided TCRγδ– DP 
thymocytes into CD3–, CD3lo, and CD3hi populations (Fig. 4-1A) and analyzed CD7, CD38, and 
CD45RO expression on each population (Fig. 4-1B).  Consistent with our prior observations, the 
CD3– DP population included a small percentage of CD7++CD45RO– thymocytes while all of the 
CD3+ DP cells were CD7+CD45RO+.  Further, the percentage of cells that were 
CD38hiCD45ROhi increased as DP thymocytes increased their expression of CD3; 27 ± 4.6 % of 
CD3– DP thymocytes, 67 ± 4.5% of CD3lo DP thymocytes, and 78 ± 3.4% of CD3hi DP 
thymocytes were CD38hiCD45ROhi.  These data support a model in which DP thymocytes 
progress from CD7++CD45RO– to CD7+CD45RO+ and from CD38loCD45ROlo to 
CD38hiCD45ROhi. 
We also previously showed that CD3–CD7++CD45RO– DP thymocytes could be divided 
into CD44lo DP1 and CD44med DP2 subsets and that CD3–CD7+CD45RO+ DP thymocytes could 
be divided into DP3, DP4, and DP5 subsets (376) (Fig. 4-1C).  Within the CD3lo DP thymocyte 
population, subsets of cells were identified with similar expression levels of CD38, CD45RO, 
CD44, and CD7 as DP3, DP4, and DP5 thymocytes, and so we labeled the CD3lo subsets DP6, 
DP7, and DP8, as shown in Fig. 4-1C.  In addition, a population of cells (called DP9) was 
observed within the CD38hiCD45ROhi subpopulation that expressed comparable levels of CD7 
as DP8 thymocytes, but higher levels of CD44.
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Figure 4-1. DP thymocytes can be divided into twelve populations.  A) TCRγδ– thymocytes 
were gated on CD4+CD8+ DP cells and analyzed for CD3 expression.  B) CD3–, CD3lo, and 
CD3hi DP thymocytes were analyzed for expression of CD7, CD45RO, and CD38.  C) 
CD38loCD45ROlo and CD38hiCD45ROhi cells from (B) were analyzed for CD44 and CD7 
expression.  The DP3 through DP12 subsets are indicated.  D) Expression of CD44, CD38, and 













































































These data suggest that CD44 expression declines as cells progress from the DP3 to the 
DP8 stage, but then increases at later stages.  Consistent with this model, the lowest expression 
of CD44 among CD3hi DP thymocytes was found on a CD38hiCD45ROhi subset that resembled 
the DP9 stage, and are thus called DP10 thymocytes (Fig. 4-1C).  Further, subpopulations of 
CD38hiCD45ROhi and CD38loCD45ROlo thymocytes were identified with higher CD44 
expression than DP10 thymocytes and we labeled these cells DP11 and DP12, respectively. 
An implication of our analysis of T cell development through the DP stages is that CD44 
expression is high early in T cell development, declines transiently, and then returns to a high 
level.  To test this model, we analyzed CD3 and CD44 expression on total thymocytes (Fig. 4-
1D).  Indeed, CD44 expression was higher on CD3– and CD3hi thymocytes than CD3lo 
thymocytes. 
Another implication of our analysis is that CD38 and CD45RO expression increase as 
thymocytes progress through the CD3– and CD3lo stages and declines as cells reach maturity, as 
previously reported for CD45RO (357).  Indeed, dot plots of total thymocytes analyzed for CD38 
versus CD3 expression and CD45RO versus CD3 expression showed similar patterns (Fig. 4-
1D); CD38 and CD45RO expression was highest among thymocytes with intermediate levels of 
CD3 and lowest among CD3– and CD3hi thymocytes.   Consistent with this model is that DP12 
thymocytes express high levels of CD44, but lower levels of CD38 and CD45RO than other DP 
thymocytes (Fig. 4-1B and C). 
In summary, human DP thymocytes can be divided into at least twelve subpopulations 
based on their expression of CD3, CD7, CD38, CD44, and CD45RO.  Five populations (DP1-5) 
do not express CD3 and were previously identified (376).  There are four populations of CD3lo 
DP thymocytes (DP6-9) and three populations of CD3hi DP thymocytes (DP10-12). 
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Human thymocytes progress through a CD8+CD4lo transitional single positive stage 
In mice, thymocytes progress from the CD3lo DP developmental stage to the CD4+CD8lo 
transitional single positive (TSP) stage (312-315).  To determine whether a comparable 
developmental stage might exist in humans, we examined CD3 and CD7 expression within the 
SP CD4+ and SP CD8+ populations (Fig. 4-2).  SP CD4+ thymocytes could be divided into CD3–
CD7hi, CD3hiCD7lo, and CD3hiCD7hi subsets (Fig. 4-2A).  The CD3–CD7hi subset corresponds to 
the previously described immature single positive (ISP) developmental stage (377).  Few, if any, 
CD3lo SP CD4+ thymocytes were detected, making it unlikely that a TSP subpopulation exists 
within the SP CD4+ population. 
In contrast to the SP CD4+ population, a CD3loCD7lo subset of SP CD8+ thymocytes was 
detected (Fig. 4-2B), which is consistent with the phenotype expected for a TSP developmental 
stage.  Cells within the putative TSP population had CD7, CD38, CD45RO, and CD44 
expression levels that were similar to DP8 and DP9 thymocytes, and we refer to the TSP 
counterparts as TSP1 and TSP2 (Fig. 4-2C).  The phenotypic similarities between DP8, DP9, 
TSP1, and TSP2 thymocytes suggest that these populations represent sequential stages of T cell 
development. 
 
Positive selection is initiated prior to the down-regulation of CD4 
To place the DP8, DP9, TSP1, and TSP2 in developmental sequence, we analyzed CD69 
and CD27 expression on each subset of CD3lo thymocytes (Fig. 4-3A).  At least 80% of DP6, 
DP7, and DP8 thymocytes lacked CD69 or CD27 expression, indicating that few of these cells 
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Figure 4-2. SP CD8+ thymocytes include a CD3lo subset.  SP CD4+ (A) and SP CD8+ (B) 
thymocytes, as defined in Fig. 4-1A, were analyzed for CD3 and CD7 expression.  C) 
CD3loCD7lo SP CD8+ thymocytes from (B) were analyzed for expression of CD38, CD45RO, 




























Figure 4-3.  TSP CD8+ cells are the most mature CD3lo thymocytes. A) CD69 and CD27 
expression were analyzed on the CD3lo DP and TSP CD8+ populations defined in Figs. 4-1 and 
4-2.  The bar graph shows the percentages (mean ± SE) of cells in each population that were 
CD69–CD27–, CD69+CD27–, CD69+CD27+, and CD69–CD27+ (n = 11).  B and C) CD3lo 
thymocyte populations were analyzed for CD69 and CD28 (B) and CD27 and CD28 (C) 
expression.  D) CD69 and CD27 expression were analyzed on CD3lo thymocytes and the CD69–
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had received signals leading to positive selection.  By contrast, 43 ± 4.9% of DP9 thymocytes 
were CD69+CD27– and 6.8 ± 1.2% of DP9 thymocytes were CD69+CD27+.  The percentage of 
thymocytes that expressed CD69 and CD27 trended higher in TSP1 thymocytes than DP 
thymocytes, although the difference did not reach statistical significance.  In TSP2 thymocytes, 
CD69 and CD27 expression was higher than DP9 thymocytes (p < 0.001) and TSP1 thymocytes 
(p < 0.05).  These data indicate that more TSP thymocytes had received positive selection signals 
than DP9 thymocytes, suggesting a developmental progression from the DP9 developmental 
stage to the TSP1 and TSP2 stages.  To test this developmental progression, we analyzed CD28 
expression on each CD3lo thymocyte population (Fig. 4-3B).  Only 47 ± 5.8% of CD69+ DP9 and 
41 ± 5.4% of CD69+ TSP1 thymocytes expressed CD28, but 65 ± 3.7% of CD69+ TSP2 
thymocytes expressed CD28 (p < 0.05 for TSP2 compared to DP9 or TSP1).  Nearly all CD27+ 
DP9, TSP1, and TSP2 thymocytes expressed CD28 (Fig. 4-3C).  In summary, analysis of the 
markers of thymic selection (such as CD69, CD28, and CD27) suggests that TSP2 thymocytes 
represent the final developmental stage prior to up-regulation of CD3. 
To further support our model that thymocytes undergoing selection down-regulate CD4, 
total CD3lo thymocytes were analyzed for CD69 and CD27 expression (Fig. 4-3D).   Among 
CD69–CD27– CD3lo thymocytes, 83 ± 5.3% were DP thymocytes.  The percentage of CD3lo 
thymocytes that were DP cells decreased to 45 ± 6.5% among CD69+CD27– thymocytes and 23 
± 5.3% among CD69+CD27+ cells.  The progressive decrease in the percentage of DP 
thymocytes was associated with a concomitant increase in the percentage of SP CD8+ 
thymocytes. 
In summary, these data indicate that up-regulation of CD69, CD27, and CD28 occur 
before CD3 expression reaches high levels.  Further, as human thymocytes progress through the 
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stages of positive selection, the cells down-regulate surface expression of CD4 to become TSP 
CD8+ thymocytes. 
 
Commitment to the CD4+ T cell lineage  
DP9, TSP1, and TSP2 thymocytes were CD3loCD7lo and represent the final stages of T 
cell development prior to up-regulation of CD3.  Among CD3hi DP thymocytes, DP10 
thymocytes are CD7+ and CD7 increases in the DP11 and DP12 subsets.  As described above, 
CD3hi CD4+ thymocytes can be divided into CD7lo and CD7hi subsets, suggesting that 
CD3hiCD7lo SP CD4+ thymocytes include the earliest stages of the CD3hi SP CD4+ population.  
Because CD38 and CD45RO expression decrease as thymocytes mature (Fig. 4-1D), we 
compared the expression of these markers on CD3hiCD7lo SP CD4+ thymocytes and CD3hi DP 
thymocytes.  A lower percentage of CD3hiCD7lo SP CD4+ thymocytes (51 ± 6.1%) were 
CD38hiCD45ROhi than CD3hi DP thymocytes (78 ± 3.4%) (p < 0.001) (Fig. 4-4A), suggesting 
that the DP10 developmental stage precedes the CD3hiCD7lo SP CD4+ stage.  Among 
CD3hiCD7lo SP CD4+ thymocytes, the CD38hiCD45ROhi and CD38loCD45ROlo populations both 
contained a subset of cells that expressed comparable levels of CD44 as DP10 thymocytes and a 
subset that expressed higher levels of CD44 (data not shown).  We labeled the CD44med and 
CD44hi subsets of CD3hiCD7lo CD4+ thymocytes MSP1 and MSP2, respectively, as shown in 
Fig. 4-4B. 
Because CD38 and CD45RO expression decrease as thymocytes reach maturity (Fig. 4-
1D), we analyzed these markers on the MSP1 and MSP2 populations.  Among MSP1 
thymocytes, 66 ± 6.7% of the cells were CD38hiCD45ROhi, but only 46 ± 6.2% of the MSP2 
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Figure 4-4. CD3hi DP thymocytes represent a transition from TSP CD8+ cells to MSP CD4+ 
cells. A) SP CD4+ thymocytes were gated on CD3hiCD7lo and CD3hiCD7hi populations as 
indicated in Fig. 4-2A, and analyzed for CD38 and CD45RO expression.  B) CD7 and CD44 
expression were analyzed on total CD3hiCD7lo SP CD4+ cells and each CD7hi subset.  MSP1-5 
subpopulations are defined as indicated.  C and D) CD69, CD27, CD28, and CD1a expression 
were analyzed on the CD3hiCD7lo (C) and CD3hiCD7hi (D) subpopulations of DP and SP CD4+ 
thymocytes. E) The percentages (mean ± SE) of cells in each subpopulation that were CD69–
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population were CD38hiCD45ROhi (p < 0.001), supporting the hypothesis that the MSP1 CD4+ 
developmental stage precedes the MSP2 CD4+ stage.  Consistent with a model in which DP10 
thymocytes mature into MSP1 CD4+ thymocytes and then MSP2 CD4+ thymocytes, 10 ± 1.4% 
of DP10 thymocytes, 18 ± 2.7% of MSP1 CD4+ thymocytes, and 42 ± 3.8% of MSP2 CD4+ 
thymocytes expressed CD27 (Fig. 4-4C).  To further test this model, we analyzed CD1a 
expression on DP10, MSP1 CD4+, and MSP2 CD4+ thymocytes because decreased CD1a 
expression is a marker of thymocyte maturation (378).  The percentage of thymocytes that 
expressed CD1a was highest among DP10 thymocytes and lower in the MSP1 CD4+ and MSP2 
CD4+ subsets.  Whereas CD28 was only expressed in DP9 and TSP thymocytes that also 
expressed CD27 (Fig. 4-3C), all DP10, MSP1 CD4+, and MSP2 CD4+ expressed CD28, 
regardless of CD27 expression (Fig. 4-4C). 
Next, we analyzed CD3hiCD7hi DP and SP CD4+ thymocytes.  CD3hiCD7hi DP 
thymocytes include the DP11 and DP12 subsets, which are distinguished based on expression of 
CD38 and CD45RO (Fig. 4-1).  CD3hiCD7hi SP CD4+ thymocytes include cells that are 
CD38hiCD45ROhi (MSP3), CD38loCD45ROlo (MSP4), and CD38–CD45RO– (MSP5) (Fig. 4-
4A).  DP11, DP12, MSP3 CD4+, MSP4 CD4+, and MSP5 CD4+ thymocytes express comparable 
and high levels of CD7 and CD44 (Fig. 4-4B), suggesting that these populations are among the 
final stages prior to thymic egress.  To test this model, we analyzed CD69, CD27, CD1a, and 
CD28 expression on each population.  Consistent with a model in which DP11 thymocytes are 
the least mature CD3hiCD7hi cells, only 31 ± 4.1% of DP11 cells were CD27+, while 56 ± 5.1% 
of DP12 cells and over 75% of each of the CD3hiCD7hi SP CD4+ populations were CD27+. (p < 
0.001 for DP11 or DP12 compared to each of the CD3hiCD7hi SP CD4+ populations) (Fig. 4-4D 
and E).  Further, CD1a expression was high on DP11 cells and decreased as cells matured 
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through the MSP CD4+ stages.  In agreement with MSP5 CD4+ being the most mature 
population of CD4+ thymocytes, these cells had all down-regulated CD1a expression and 48 ± 
3.8% of cells were CD69–. 
In summary, we propose that CD3hi DP thymocytes represent the developmental stages 
between the TSP CD8+ population and the MSP CD4+ thymocytes.  Further, these data suggest 
that DP10 thymocytes can differentiate into either MSP1 CD4+ thymocytes or DP11 thymocytes, 
implying that down-regulation of CD8, CD38, and CD45RO and up-regulation of CD44 are 
asynchronous processes that occur between the TSP CD8+ developmental stage and the MSP 
CD4+ stages.  In addition, the data shown here suggest that MSP5 CD4+ thymocytes represent 
the final developmental stage before cells exit the thymus. 
 
Commitment to the CD8+ T cell lineage 
Besides DP and SP CD4+ thymocytes, the other population that included CD3hiCD7hi 
thymocytes was the SP CD8+ population (Fig. 4-2B).  Like CD3hi CD4+ thymocytes, CD3hiCD7hi 
SP CD8+ thymocytes could be divided into three populations, based on CD38 and CD45RO 
expression: CD38hiCD45ROhi (MSP1 CD8+), CD38loCD45ROlo (MSP2 CD8+), and CD38–
CD45RO– (MSP3 CD8+) (Fig. 4-5A).  Each subset expressed high levels of CD44 (Fig. 4-5B).  
To determine the developmental sequence of the MSP1 CD8+, MSP2 CD8+, and MSP3 CD8+ 
populations, we analyzed CD69 and CD27 expression (Figs. 4-5C and 4-5D).  Nearly all cells in 
these subsets expressed CD69, CD27, or both markers, but the percentage of cells that were 
CD69–CD27+ increased as thymocytes progressed through the MSP1, MSP2, and MSP3 stages.  
In addition, CD1a expression declined as thymocytes matured through the MSP CD8+ subsets.  
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Figure 4-5. CD3hi SP CD8+ cells can be subdivided into three populations. A) SP CD8+ 
thymocytes were gated on the CD3hiCD7hi population as shown in Fig. 4-2B and analyzed for 
CD38 and CD45RO expression.  The MSP1, MSP2, and MSP3 CD8+ subsets are defined as 
shown.  B) Each subset of MSP CD8+ thymocytes was analyzed for CD44 and CD7 expression.  
C) CD8+ MSP1, MSP2, and MSP3 thymocytes were analyzed for their expression of CD69, 
CD27, CD28, and CD1a. D) The percentages (mean ± SE) of MSP CD8+ thymocytes that were 
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CD28 expression was comparable among MSP1, MSP2, and MSP3 CD8+ thymocytes.   These 
data suggest that CD3hi CD8+ thymocytes progress from the MSP1 CD8+ developmental stage 
through the MSP2 CD8+ and MSP3 CD8+ stages.  
 
Differences in the protein levels of Ikaros, Helios and Aiolos across CD3+ thymocyte subsets 
Ikaros, Helios, and Aiolos protein levels increase when TCRβ is first expressed (376).  
For Ikaros and Helios, the increase in expression was transient whereas the increase in Aiolos 
was sustained throughout the CD3– DP populations.  Consistent with this pattern, Ikaros and 
Helios protein levels were 1.6-fold (p<0.001) and 2.0-fold (p<0.001) higher, respectively, in DP6 
thymocytes than in DP8 thymocytes, while Aiolos levels were comparable among the DP6, DP7, 
and DP8 subsets (Fig. 4-6). 
As thymocytes progressed from the DP8 developmental stage to the TSP2 stage, Ikaros, 
Helios, and Aiolos protein levels increased by 2.3-fold, 2.5-fold, and 2.0-fold (p < 0.001 for each 
protein, comparing DP8 and TSP2 thymocytes).  Then, levels of all three proteins were lower in 
DP10 and MSP1 CD4+ thymocytes than TSP2 cells.  The most dramatic difference between the 
TSP2 and MSP1 CD4+ populations occurred with Helios, whose protein levels were 11-fold 
lower in MSP1 CD4+ cells than TSP2 cells.  Helios expression continued to decline as CD4+ and 
CD8+ thymocytes matured, except for subpopulations of MSP3 and MSP5 CD4+ thymocytes.  
Because Helios is highly expressed in regulatory T cells (74, 379), we tested whether Helioshi 
MSP CD4+ thymocytes co-expressed FoxP3 and CD25 (Fig. 4-7).  Indeed, a subset of Helioshi 
MSP3 and MSP5 CD4+ thymocytes expressed FoxP3 and CD25. 
Among MSP CD4+ thymocytes, Aiolos protein levels were 2.5-fold lower in MSP1 CD4+ 
thymocytes than TSP2 cells, increased transiently during the MSP3 and MSP4 CD4+ stages, and 
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Figure 4-6. Ikaros, Helios, and Aiolos expression patterns differ in developing CD3+ 
thymocytes.  CD3lo (A) and CD3hi (B) thymocyte populations were intracellularly stained with 
anti-Ikaros, anti-Helios, anti-Aiolos (dark lines), or an appropriate isotype control (shaded 
histogram).  C) For each population in A and B, the geometric mean fluorescence intensity 
(GMFI) of anti-Ikaros, anti-Helios, or anti-Aiolos was normalized to the GMFI of the isotype 






















































































































































































































































































































































































































































































































































































































































Figure 4-7. Helioshi MSP CD4+ thymocytes are regulatory T cells.  DP11, DP12, and MSP 
CD4+ thymocytes were analyzed for A) Helios and FoxP3 expression, and B) Helios and CD25 








































































































































decreased again at the MSP5 CD4+ stage.  By contrast, Aiolos protein levels were higher in the 
MSP1 CD8+ and MSP2 CD8+ subsets than TSP2 thymocytes. (p < 0.05).  In addition, Aiolos 
levels were 2.3-fold higher in the mature MSP3 CD8+ cells than in the mature MSP5 CD4+ cells 
(p < 0.01).  Unlike Helios and Aiolos, Ikaros protein levels remained steady after the transient 
increase seen in the TSP subsets. 
These data indicate that Ikaros, Helios, and Aiolos undergo a transient increase in protein 
levels during the TSP developmental stage.  However, expression of Helios and Aiolos in 
populations varies: Ikaros expression remains steady, Helios expression declines, except for a 
subpopulation of MSP CD4+ thymocytes, and Aiolos expression increases, particularly among 




The data presented here represent the highest resolution image to date of human T cell 
development beginning with detectable surface CD3 expression.  The multi-parameter flow 
cytometry data revealed twelve subpopulations of DP thymocytes, five subpopulations of SP 
CD8+ thymocytes, and five subpopulations of SP CD4+ thymocytes.  Each of these 
subpopulations can be further divided using additional markers.  Our analysis focused on the 
stages of T cell development surrounding positive selection and lineage commitment and 
resulted in the model shown in Fig. 4-8. 
Based on CD7, CD45RO, CD38, and CD44 expression, we found three pairs of DP 
subsets in which one half of each pair was CD3– and the other subset was CD3lo.  The CD3– 
fractions (DP3, DP4, and DP5) represent the final developmental stages that lack surface CD3 
expression.  We previously showed that these populations express TCRβ and DP3 thymocytes 
are the most highly proliferative population of CD3– thymocytes (376).  Proliferation slows as 
thymocytes progress through the DP4 and DP5 thymocytes, suggesting that these populations are 
undergoing genomic rearrangement at the locus encoding TCRα.  When TCRα is expressed, 
CD3 becomes detectable at the cell surface.  Thymocytes expressing levels of CD7 and CD44 
similar to those of the DP3, DP4, and DP5 developmental stages can express surface CD3, 
indicating that CD7 and CD44 down-regulation is independent of TCRα expression.  Thus, DP3 
thymocytes can differentiate into DP4 or DP6 thymocytes.  Likewise, DP4 thymocytes can 
differentiate into DP5 thymocytes unless they express surface CD3, in which case they become 
DP7 thymocytes. 
A small percentage of DP6, DP7, and DP8 thymocytes express CD69 (Fig. 4-3A), 
suggesting that thymocytes have the potential to become positively selected as soon as surface 
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CD3 is expressed.  After positive selection, thymocytes down-regulate CD4 expression to 
become TSP CD8+ thymocytes (Fig. 4-3C).  We propose that the TSP CD8+ population is 
analogous to the TSP CD4+ thymocytes observed in mice (312-315).  During murine T cell 
development, CD8 expression decreases after positive selection, resulting in the TSP CD4+ 
population (317-320).  In humans, maturation into the TSP CD8+ population is associated with a 
transient increase in Ikaros, Helios, and Aiolos expression (Fig. 4-6).  Studying all three proteins 
is important because Ikaros family members can homodimerize or heterodimerize with each 
other family member and dimerization is required for transcriptional activity (1-5).  Because all 
three proteins increase their expression two- to three-fold, it is likely that the composition of the 
dimers does not change at the TSP stage, but the number of dimers increases.   
Despite the likelihood that dimer composition does not change, data from murine models 
of T cell development indicate that Ikaros family members are important at the TSP stage (380).  
Specifically, expression of a dominant negative Ikaros isoform results in accumulation of 
CD4+CD8lo TSP cells (381).  One function of Ikaros at the TSP stage may be to inhibit 
transcription of TdT and pre-Tα (56, 382).  However, it was suggested that higher levels of 
Ikaros resulted in the recruitment of an elongation-competent NuRD/P-TEFb complex to gene 
targets, rather than the repressive NuRD complex (40).  Thus, increased Ikaros family expression 
at the TSP stage may be required for activation of genes for further maturation.  In addition, 
Ikaros family members may affect the signal strength necessary for lineage commitment, as 
Ikaros and Aiolos can regulate the TCR signaling threshold in murine thymocytes and 
splenocytes (26, 51, 367, 383-385).  Ikaros family members can also regulate CD4 and CD8 
expression (65, 66, 346), a necessary step for lineage commitment.  
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The role of Ikaros in regulating signal strength and CD4/CD8 expression in the TSP stage 
implies that the TSP developmental stage might be the site of lineage commitment.  TSP CD8+ 
thymocytes express CD69 and many TSP CD8+ thymocytes express CD27.  Vanhecke, et al. 
previously showed that CD27+ SP CD4+ and SP CD8+ thymocytes are committed to their 
respective lineages while CD27– SP CD4+ cells could still differentiate into SP CD8+ cells (386).  
This observation suggests that CD27 is a marker of thymocytes committed to the CD4+ or CD8+ 
lineage.  Even though most TSP CD8+ thymocytes expressed CD27, most DP10 thymocytes 
lacked CD27 expression.  Although this observation might suggest that DP10 thymocytes are 
less mature than TSP thymocytes, the fact that TSP thymocytes have lower surface CD3 levels 
places the TSP developmental stage earlier than the DP10 stage.  Thus, the TSP CD8+ 
developmental stage most likely represents the decision point between the CD4+ and CD8+ 
lineages.  CD27+ TSP CD8+ thymocytes likely retain their CD8 expression, up-regulate CD3 and 
mature into MSP1 CD8+ thymocytes, while CD27– TSP CD8+ thymocytes likely re-express 
CD4, becoming DP10 thymocytes (Fig. 4-8). 
Because DP10 and MSP1 CD4+ thymocytes express similar levels of CD38, CD45RO, 
CD7, CD44, CD3, CD69, and CD27 (Figs. 4-1 and 4-4), it is likely that DP10 thymocytes can 
differentiate directly into MSP1 CD4+ thymocytes.  Alternatively, DP10 thymocytes could up-
regulate CD44, becoming DP11 thymocytes.  DP11 thymocytes could differentiate into MSP2 
CD4+ thymocytes or DP12 thymocytes, depending on the sequence in which the cells down-
regulate CD8, CD38, and CD45RO, and up-regulate CD27.  DP12 thymocytes are most similar 




As thymocytes continue to mature into naïve CD4+ and CD8+ T cells, their expression of 
Ikaros, Helios, and Aiolos change in manners that would be predicted to influence the 
composition of the dimers (Fig. 4-6).  Specifically, Ikaros expression remains constant 
throughout the MSP subpopulations.  Aiolos is more highly expressed in MSP CD8+ thymocytes 
than most MSP CD4+ thymocyte subsets.  Helios expression declines as thymocyte mature, 
except for a subset of SP CD4+ thymocytes, which are likely to be the regulatory T cell subset 
(Fig. 4-7) (74, 379).  The function of Ikaros family members at these stages is unclear.  
In summary, we used multi-parameter flow cytometry to define the stages of human T 
cell development in which positive selection and lineage commitment are most likely to occur.  
We observed a transient increase in Ikaros, Helios, and Aiolos expression when thymocytes 
undergo positive selection, and Aiolos is more highly expressed in subsets of mature SP CD4+ 




Chapter 5. Classifying pediatric T cell acute lymphoblastic leukemia patients 
according to Ikaros family expression 
 
Abstract 
Pediatric T cell acute lymphoblastic leukemia (T-ALL) is a highly heterogeneous disease 
in which the cells share phenotypic characteristics with normal human thymocytes.  Attempts 
have been made to classify patients according to the stage of thymic development that the T-
ALL cells most closely resemble.  However, there is no consensus regarding the relevance of 
such a classification scheme.  We obtained twenty-four blood or bone marrow samples from 
newly diagnosed pediatric T-ALL patients and used multi-parameter flow cytometry to 
demonstrate the extent of diversity of T-ALL samples, even among samples that appeared 
similar.  To develop an alternate classification strategy, we examined the mRNA and protein 
levels of each member of the Ikaros family of transcription factors.  Ikaros and Helios mRNA 
were the predominant family members expressed in normal human thymocytes and leukemic 
cells.  By calculating the ratio of Ikaros to Helios mRNA, the T-ALL cases could be divided into 
three groups that were independent of the phenotype of the cells.  However, the protein levels of 
Ikaros and Aiolos did not correlate with the mRNA levels and not all splice variants detected at 
the mRNA level were detected at the protein level.  Future studies will be required to determine 





Pediatric T cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease in 
which the leukemic cells often resemble normal thymocyte populations.  The phenotypic 
similarities between leukemic cells and normal thymocytes have led to the conclusion that 
patients might be classified according to the developmental stage that is most similar to the 
leukemic cells (78, 80).  For example, cells from some T-ALL cases lack TCRβ expression and 
are thought to be derived from early T cell precursors.  During normal human T cell 
development, early T cell precursors are CD4–CD8– double negative (DN) thymocytes that 
express CD34.  DN thymocytes can be divided into DN1, DN2, or DN3 cells, depending on their 
expression of CD38 and CD1a (108, 109).  During the DN stages, the cells commit to either the 
αβ or γδ T cell lineage (130, 164).  Cells from some T-ALL patients resemble uncommitted 
early T cell progenitors and likely emerge from the early DN stages.  Cells from other patients 
express TCRγδ and resemble stages of γδ T cell development. 
In other T-ALL cases, the leukemic cells express cytoplasmic TCRβ, but not surface 
CD3.  During normal T cell development, cytoplasmic TCRβ+ cells are either immature single 
positive (ISP) CD4+ thymocytes or a subpopulation of CD4+CD8+ double positive (DP) 
thymocytes (117, 119).  ISP CD4+ thymocytes are a transition between the DN and DP stages 
(110).  During the DP stage, thymocytes express TCRα, undergo positive or negative selection, 
and differentiate into mature single positive cells that can egress from the thymus and function as 
mature naïve T cells. 
There are conflicting data regarding the prognostic value of classifying pediatric T-ALL 
patients according to the phenotype of the leukemic cells.  For example, some studies reported a 
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poor prognosis for patients whose cells express either CD34 or surface TCR (79, 82), while other 
studies found no differences in survival between groups (81, 83).  In this study, we used multi-
parameter flow cytometry to demonstrate the degree of heterogeneity among T-ALL patients, 
perhaps explaining the challenges faced when attempting to correlate the phenotype of the 
leukemic cells with clinical outcomes. 
As an alternative classification strategy, we tested whether patients could be grouped 
according to their expression of Ikaros family members.  The Ikaros family has been linked to T-
ALL in mice (47-49) and humans (8, 10, 84-86, 88-91) and consists of five highly homologous 
transcription factors: Ikaros, Helios, Aiolos, Eos, and Pegasus.  Each family member has two 
zinc finger domains.  The four N-terminal zinc fingers mediate DNA binding, and the two C-
terminal zinc fingers are required for dimerization.  Transcriptional activity requires dimerization 
and each family member is capable of dimerizing with each other family member (1-5).  
Adding complexity to the study of Ikaros is that some family members undergo 
alternative splicing that results in the deletion of one or more DNA binding zinc fingers.  Loss of 
one or two zinc fingers can result in more promiscuous DNA binding, but deletion of three or 
more zinc fingers can create dominant negative isoforms that block the ability of other family 
members to bind DNA (1-4, 6, 341).  Some reports indicate that alternative splicing is common 
in T-ALL while other reports find it to be rare (8, 10, 84-86, 88-92). 
We compared mRNA and protein levels of each Ikaros family member in normal human 
thymocytes and cells from pediatric T-ALL patients.  We identified patterns of Ikaros family 
mRNA levels that transcend surface phenotypes, suggesting that the key elements in 
investigating mechanisms of leukemogenesis lie in the function of Ikaros family proteins or the 




Materials and Methods 
Human tissue samples 
Human thymus samples were obtained from children (0 – 18 years) that underwent 
corrective surgery at Children’s Mercy Hospital (Kansas City, MO) for congenital cardiac 
defects after obtaining parent or guardian consent.  Tissue samples were obtained in compliance 
with the Institutional Review Boards at Children’s Mercy Hospital and the University of Kansas 
Medical Center. 
Twenty-four blood or bone marrow samples were obtained from newly diagnosed 
pediatric T-ALL patients prior to the initiation of anti-cancer therapy.  Samples from patients 
diagnosed at Children’s Mercy Hospital were collected after obtaining parent or guardian 
consent.  Leukemic cells were enriched by labeling the cells with anti-CD7-PE antibody and 
positively selecting with magnetic beads conjugated to anti-PE antibody (BD Biosciences, San 
Jose, CA).  Other samples were obtained as frozen samples through the Children’s Oncology 
Group (NCI Protocol AALL12B11).  Each sample was divided into aliquots for flow cytometric, 
mRNA, and protein analysis. 
 
Phenotypic analysis of T-ALL samples 
The anti-human antibodies anti-CD1a-PerCP-Cy5.5, anti-CD1a-PECy5, anti-CD3-
APCCy7, anti-CD3-APC-Alexa750, anti-CD4-Pacific Blue, anti-CD5-AF647, anti-CD7-PE, 
anti-CD8-BV785, anti-CD8-FITC, anti-CD27-HV500, anti-CD34-BV605, anti-CD34-PE, anti-
CD34-PECy7, and anti-CD38-AF700, anti-CD44-PECy7, anti-CD45RO-PECy5, anti-CD69-
BV650, anti-TCRγδ-FITC were purchased from Biolegend (San Diego, CA).  Samples were 
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labeled with anti-CD1a, anti-CD3, anti-CD4, anti-CD5, anti-CD7, anti-CD8, anti-CD34, anti-
CD38, and anti-TCRγδ antibodies.  Most samples were also labeled with anti-CD27, anti-CD44, 
anti-CD45RO, and anti-CD69.  Data were acquired using a BD LSR II (BD Biosciences) and 
analyzed using BD FACSDiva software (BD Biosciences). 
 
FACS-purification of human thymocytes 
DN2, DN3, and ISP thymocytes were obtained by depleting total thymocytes with 
magnetic beads conjugated to anti-CD8 and anti-CD3 (BD Biosciences).  Remaining cells were 
divided into the DN2 (CD3–CD4–CD8–CD34+CD38+CD1a–), DN3 (CD3–CD4–CD8–
CD34+CD38+CD1a+), and ISP (CD3–CD4+CD8–) populations using a FACSAria IIIu (BD 
Biosciences).  For total DN or DP thymocytes, cells were labeled with anti-CD4 and anti-CD8 
and CD4–CD8– or CD4+CD8+ thymocytes were FACS-purified. 
 
Quantitative RT-PCR (qRT-PCR) 
Total mRNA was isolated using the RNeasy Mini Kit or RNeasy Micro Kit (Qiagen, 
Valencia, CA), converted to cDNA using the TaqMan® High Capacity RNA-to-cDNA™ kit 
(Applied Biosystems, Foster City, CA), and amplified using TaqMan® Gene Expression Assays: 
Ikaros: Hs00958473_m1; Helios: Hs00212361_m1 ; Aiolos: Hs00232635_m1; Eos: 
Hs00223842_m1; Pegasus: Hs00223846_m1; and GAPDH: Hs03929097_g1 (Applied 
Biosystems).  qRT-PCR was performed using a 7500 Fast Real-Time PCR System (Applied 
Biosystems).  Each sample was run in triplicate.  For normal thymocytes, at least five biological 
replicates were performed for each subset and each replicate was performed in triplicate.  mRNA 
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levels of each Ikaros family member were calculated relative to GAPDH and statistical 
significance was determined using the Log2(Fold Change). 
Western blot analysis 
Cell lysates prepared from 4-5×105 cells were separated by SDS-PAGE, transferred to 
nitrocellulose, and probed with antibodies against Ikaros, Aiolos, or p38 MAPK (all purchased 
from Santa Cruz Biotechnology, Inc., Dallas, TX).  Bands were visualized using horseradish 
peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Inc.) and Pierce™ ECL 
Western Blotting Substrate (Life Technologies, Grand Island, NY), and detected using an 
ImageQuant LAS-4000 gel imager (GE Healthcare systems, Pittsburgh, PA).   
 
Nested PCR 
Total mRNA was reverse transcribed with AMV RT (Promega, Madison, WI) before 
amplification with Taq DNA Polymerase (Fisher Scientific, Pittsburgh, PA).  Primary PCR 
reactions were performed using primers specific to the 5’ UTR and 3’ UTR (Table 5-1).  The 
PCR products were re-amplified using primers that spanned all possible exon pairs.  PCR 
products were separated on an agarose gel, visualized with ethidium bromide and analyzed using 
an ImageQuant LAS-4000 gel imager. 
 
Statistics 
For qRT-PCR data, statistics were performed using the one-way ANOVA with a Tukey 
posthoc test, and significance was defined as p < 0.05.  For linear regression, whether the slope 
of the line was different than zero was determined and significance was defined as p < 0.05.  
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Table 5-1.  Primers used for nested PCR. 
Ikaros  
5’ UTR CGACGCACAAATCCACATAACCTGAG 
Exon 1 Forward CATGGATGCTGATGAGGGTC 
Exon 2 Forward TAAGCGATACTCCAGATGAGGG 
Exon 3 Forward TCGGGAGTTGGAGGCATTCG 
Exon 4 Forward GGCACATCAAGCTGCATTCC 
Exon 5 Forward TGGATATTGTGGCCGAAGC 
Exon 3 Reverse CCATTCATTTCACAGGCACGC 
Exon 4 Reverse AGGCGTAGTTGCAGAGGTGG 
Exon 5 Reverse CCAAGTAGTTGTGGCAGCG 
Exon 6 Reverse GACGTTACTTGCTAGTCTGTCC 
Exon 7 Reverse TTGTGCAGCTGGTACATCG 
3’ UTR TTGTCTGGTCCAGTCCAGTCTATGC 
Aiolos  
5’ UTR GGCAGCGACATGGAAGATATAC 
Exon 1 Forward CACTCAGGAGCAGTCTGTG 
Exon 2 Forward AATGTGGACAGTGGAGAAGGC 
Exon 3 Forward GTCTCATTCGATAGTAGCAGGC 
Exon 4 Forward AGAAGAGATGCGCTCACGG 
Exon 5 Forward GAGAAGTTCCCTTGAGGAGC 
Exon 3 Reverse TCATCTTTCCACTGGTTGGC 
Exon 4 Reverse GTGAGCGCATCTCTTCTTTGG 
Exon 5 Reverse CCTCAAGGGAACTTCTCTGC 
Exon 6 Reverse GCTAATCTGTCCAGTACGAGAGC 
Exon 7 Reverse ACCGTTTGACATCTCAGCC 
3’ UTR GAGACCAGATATTCACTTCAGCAGG 
Helios  
5’ UTR TGCACTTTGACTATGGAAACAGAGGC 
Exon 2 Forward TTGACCTCACCTCAAGCACACC 
Exon 3 Forward ATTGAGAGCAGCGAGGTGGC 
Exon 4 Forward CTTCCACTGTAACCAGTGTGGAGC 
Exon 5 Forward ACTGGAGGAACACAAGGAACGC 
Exon 3 Reverse GGCCCAATGCAAACCATGCC 
Exon 4 Reverse GCGTCCCTTCTTCTACAGGC 
Exon 5 Reverse CTGCGCTGCTTGTAGCTTCG 
Exon 6 Reverse GAGCTTCTCTATGACAGCAGGTCTC 
Exon 7 Reverse CCACTTCAGCGATTGTGCTTGG 





Cells from T-ALL patients with a CD3– DN phenotype 
Multi-parameter flow cytometry was used to define the phenotypic characteristics of the 
cells from pediatric T-ALL patients.  Cells from one patient (PATLGK) were mostly CD7– and 
were CD3–CD4–CD8–CD34+CD1a– (Fig. 5-1A), suggesting that they arose from an early 
developmental stage, possibly early thymic progenitors (387).  However, these cells also 
expressed CD38, which is not typically observed until the DN2 developmental stage (108, 109). 
Cells from five T-ALL patients were CD7+ and CD3–CD4–CD8– (Fig. 5-1B).  In each of 
these five patients, the majority of the cells were CD38+CD1a–, but the expression of CD38 and 
CD1a varied slightly among the patients.  For example, cells from patient PASIZR were CD38lo 
and resembled a DN1/DN2 transition state.  By contrast, cells from patients PASIZW and 
PASKMA were CD1alo, consistent with a DN2/DN3 transition.  Most CD3–CD4–CD8– T-ALL 
cells were CD44hiCD27–CD45RO–, but had varying levels of CD5 and CD69 (Fig. 5-2A and 5-
2B).  In normal human thymocytes, CD5 is expressed on almost all cells and CD69 is not 
expressed until after cells express surface CD3 (388-390).   
 
Pediatric T-ALL cells that lacked CD3, but expressed either CD4 or CD8 
Six CD7+CD3– leukemia samples expressed varying levels of CD4 or CD8 (Fig. 5-1C).  
We classified patient PAQAPZ as CD3– because the CD3– cells were CD8lo and were likely the 
leukemic cells while the CD3+ cells resembled normal peripheral T cells.  Cells from three 
patients (PASTCF, PATHXN, and PAQYHW) were predominantly CD4+ and the CD8 levels 
ranged from negative to high, phenotypes consistent with the ISP CD4+ and DP developmental  
144 
 
Figure 5-1.  Phenotypes of CD3– T-ALL cells. The indicated T-ALL samples were labeled for 
flow cytometry as described in Materials and Methods.  A) CD7 and CD3 expression were 
analyzed (Top panel) and CD7–CD3– cells were analyzed as shown in the remaining panels.  B 






















































Figure 5-2.  Phenotypes of CD3– T-ALL cells.  A) CD7–CD3– cells from Fig. 5-1 were 
analyzed as shown in the remaining panels.  B and C) CD7+CD3– cells from Fig. 5-1 were 
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stages.   Three patients (PASZFR, PATBBG, and PAQAPZ) were CD3–CD4– and expressed low 
levels of CD8, a phenotype that is rare among normal thymocytes (354). 
Among the CD7+CD3– leukemia samples, cells from patient PATBBG were unique in that 
they lacked CD44, CD45RO, and CD38 expression on their surface (Fig. 5-2C).  Cells from the 
three patients that expressed ISP CD4+ and DP markers had varying levels of CD45RO with the 
DP-like T-ALL cells expressing the highest levels of CD45RO (Fig. 5-2C); during normal T cell 
development, increased CD45RO expression correlates with progression to the DP 
developmental stage (391-393).  Cells from patient PASZFR, which were CD3–CD4–CD8lo, 
were also CD45RO+ and had low levels of CD69.  CD38 and CD1a expression was highly 
variable across the six samples and did not correlate with CD4 and CD8 expression.  Cells from 
five of the six patients expressed CD27, even though CD27 is not normally expressed until the 
late stages of T cell development (390). 
 
CD3+ Pediatric T-ALL cells 
Cells from the remaining twelve patients expressed CD3 on their surface (Fig. 5-3).  Cells 
from four patients (PATCSS, PARSZP, PASIYP, and PASJNV) were CD4–CD8–, CD4+CD8–/lo, 
or CD4+CD8+ (Fig. 5-3A).  Cells from each of these four samples expressed CD45RO and 
CD38, but variable levels of CD44 and CD1a (Fig. 5-4A).  Three of these samples expressed low 
levels of CD27.  Cells from patients PARSZP and PASJNV also expressed CD34.   
Cells from three patients (PARVLA, PATCHB, and PASUVH) expressed TCRγδ (Fig. 5-
3B).  Cells from patient PATCHB lacked CD4 and CD8 expression, but the other two samples 
expressed CD4 and cells from patient PARVLA also expressed low levels of CD8.  Cells from  
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Figure 5-3. Phenotypes of CD3+ T-ALL cells. The indicated T-ALL samples were labeled and 

















































Figure 5-4. Phenotypes of CD3+ T-ALL cells. T-ALL cells from Fig. 5-3 were analyzed using 










































































each of these three patients were primarily CD38+CD1aloCD69– (Fig. 5-4B).  Expression of 
CD44 and CD27 varied among these patients. 
Cells from five patients were CD3+TCRγδ– and primarily CD8loCD4– (Fig. 5-3C).  Cells 
from two of these patients (PATVMS and PARSJC) could be subdivided into CD34lo and 
CD34hi subsets while cells from patient PAQNDF were uniformly CD34lo.  Cells from patients 
PATUET and PAQAYI were predominantly CD34–.  Most cells from these six patients 
expressed CD44, CD45RO, CD38, and CD1a (Fig. 5-4C).  Cells from two patients expressed 
CD27 and three patients had low levels of CD69 expression. 
In summary, the phenotyping data indicate that correlating the surface phenotype of the 
leukemic cells to normal thymocyte populations is rarely possible.  In many cases, cells 
expressed combinations of markers that were inconsistent with any normal thymocyte 
populations.  Further, none of the samples shared identical phenotypes. 
 
mRNA levels of Ikaros family members vary among T-ALL cells 
For each T-ALL sample, we determined the relative mRNA levels of each of the five Ikaros 
family members (Fig. 5-5A).  Samples were grouped according to their expression of CD4, CD8 
and TCRγδ and, where possible, the mRNA levels were compared to normal thymocytes within 
each phenotype.  Of the seven T-ALL samples with a DN phenotype, Ikaros mRNA levels were 
elevated in five samples, Helios mRNA levels in four samples, Aiolos mRNA levels in five 
samples, and Pegasus mRNA levels in six samples, as compared to normal DN thymocytes.  
Two patients had low Ikaros mRNA levels, one had low Helios mRNA levels, one had low 
Aiolos mRNA levels, and six had low Eos mRNA levels. 
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Figure 5-5. Helios, Aiolos, and Eos mRNA levels correlate with each other but not surface 
phenotype in T-ALL.  A) mRNA was isolated from each T-ALL sample and normal thymocytes 
and subjected to qRT-PCR.  Relative mRNA levels for each Ikaros family member were 
calculated by normalizing each family member to the mRNA levels of GAPDH.  Then, the 
relative mRNA levels were normalized to that of simultaneously run normal thymocytes.  For T-
ALL samples resembling normal DN, ISP, or DP thymocytes, the average of five normal 
thymocyte samples is shown by the solid line and the dashed line indicates the 95% confidence 
interval. B) For each patient, the relative mRNA levels of each Ikaros family member was 
compared pairwise using linear regression.  The correlation coefficient (R) is shown for each 
pair.  Statistical significance signifies whether the slope of the line is different than zero. (* p < 
0.05, ** p < 0.01, *** p < 0.001).  C) The fold change for the three pairs of Ikaros family 
members with the strongest correlations are shown.  The line of best fit and 95% confidence 
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Eos 
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Ikaros 0.34 0.42 *  0.37 0.31 
Helios 0.90*** 0.81*** 0.61** 





















y = 0.93x + 6.63 
R = 0.90 














0.25 y = 0.013x + 0.56 
R = 0.81 







































































































































































































































































































Among the three T-ALL samples with an ISP phenotype, one patient had elevated Ikaros, 
Helios, Aiolos, and Pegasus mRNA levels.  One patient had elevated Ikaros and Helios mRNA 
levels.  The third patient had low Ikaros mRNA levels.  All three patients whose T-ALL cells 
were CD4+CD8+ had low Ikaros mRNA levels, as compared to normal DP thymocytes.  Two of 
these patients had low Helios mRNA levels; one of these also had low Aiolos and Pegasus 
mRNA levels and the other had low Eos mRNA levels. 
For patients whose cells were CD8lo or TCRγδ+, we compared the expression of each Ikaros 
family member across the samples.  Helios and Aiolos mRNA levels varied most dramatically in 
these patients; the samples that expressed the highest Helios and Aiolos mRNA levels had 47-
fold and 38-fold more than samples with the lowest mRNA levels, respectively.  By contrast, 
cells expressing the highest levels of Ikaros, Eos, and Pegasus had 3.5-fold, 12-fold, and 10-fold 
more mRNA, respectively, than cells expressing the lowest levels of these family members. 
Next, we used linear regression to determine whether the mRNA levels of any Ikaros family 
member correlated with that of any other family member (Figs. 5-5B and 5-5C).  There were 
strong correlations between the mRNA levels of Helios and Aiolos, Helios and Eos, and Aiolos 
and Eos.  There were weak but statistically significant correlations between Helios and Pegasus 
and between Aiolos and Pegasus.  Further, there was a very weak, but statistically significant 
correlation between Ikaros and Aiolos. 
In conclusion, the mRNA levels of the Ikaros family members do not correlate with the 
surface phenotype of the T-ALL cells.  However, the mRNA levels of Helios, Aiolos, and Eos 
correlated strongly with each other, suggesting that these genes are regulated similarly or these 




The contribution of each Ikaros family member to the total Ikaros pool varies 
Next, we calculated the percentage of total Ikaros family mRNA represented by each family 
member (Table 5-2 and Fig. 5-6).  The majority (14/24) of T-ALL samples had a lower 
percentage of Ikaros family members represented by Ikaros than normal thymocytes.  By 
contrast, Helios was overrepresented in 16/24 T-ALL samples, as compared to normal cells.  
Aiolos mRNA represented 1% or less of the total Ikaros mRNA in four T-ALL samples, but 
more than 20% of total Ikaros mRNA in three samples.  Eos mRNA was underrepresented, as 
compared to normal thymocytes, in ten T-ALL samples.  Pegasus represented less than 0.03% of 
total Ikaros mRNA in normal thymocytes, but more than 0.5% in four T-ALL samples and 2.1% 
in one case. 
Next, we determined whether the T-ALL patients could be categorized based on the 
distribution of Ikaros mRNA levels.  Because Ikaros and Helios accounted for most of the Ikaros 
family mRNA in nearly all T-ALL samples, we first calculated the ratio of Ikaros mRNA to 
Helios mRNA.  Three groups of patients emerged, as shown in Table 5-2.  Group I included 
samples in which the ratio of Ikaros to Helios mRNA levels was less than 0.5.  Group II samples 
included those with an Ikaros to Helios ratio between 0.5 and 10.  Group III included samples in 
which the Ikaros to Helios ratio exceeded 10.  Group II could be subdivided into three subgroups 
based on the expression of Aiolos and Eos.  Group IIA samples had minimal contribution from 
either Aiolos or Eos.  Aiolos accounted for more than 10% of the total Ikaros mRNA in samples 
from Group IIB and Eos accounted for more than 20% of total Ikaros in samples in Group IIC. 
The categorization of patients based on Ikaros family expression was independent of the 
surface phenotype of the cells.  For example, most T-ALL groups included patients whose cells 
were CD3– and other patients whose cells were CD3+. 
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Table 5-2.  The contribution of each Ikaros family member to the total pool of Ikaros 
family mRNA.* 













CD38+CD1a– 80 9.8 3.5 6.5 0.03 8.2 
DN3 CD3
–CD4–CD8–
CD38+CD1a+ 71 18 4.3 6.6 0.02 4 
ISP CD3–CD4+CD8– 72 17 7 3.8 0.02 4.2 




 I PATCHB TCRγδ+ CD4–CD8– 12 65 14 8 N.D. 0.19 
PATBBG CD3–CD4–CD8+ 13 69 13 4.4 0.39 0.18 







PATHXN CD3–CD4+CD8+ 51 44 2.2 2.1 0.33 1.2 
PASIZW CD3–CD4–CD8– 52 44 2.6 0.95 0.33 1.2 
PASKMA CD3–CD4–CD8– 58 40 1 0.81 0.05 1.4 
PASZFR CD3–CD4–CD8+ 64 24 4.4 6.1 2.1 2.7 
PATIMP CD3–CD4–CD8– 73 21 4.7 0.55 0.34 3.5 
PARSZP CD3+CD4+CD8+ 74 20 3.4 2 0.21 3.6 
PATVMS CD3+CD4–CD8+ 74 21 3.3 1.3 0.17 3.5 
PAQXHO CD3–CD4–CD8– 75 19 0.3 5 0.07 3.9 
PATCSS CD3+CD4–CD8– 77 20 1.8 1.4 0.28 3.8 









CD4+CD8+ 40 26 23 11 0.23 1.6 
PAQYHW CD3–CD4+CD8+ 44 20 34 2.3 N.D. 2.2 
PAQAPZ CD3–CD4–CD8+ 56 12 24 6.6 1.2 4.7 
PASJNV CD3+CD4+CD8+ 58 28 12 2.4 0.2 2.1 
PAQAYI CD3+CD4–CD8+ 63 24 11 1.3 0.33 2.6 
PATLGK CD7
–CD3–        
CD4–CD8– 71 13 15 1.1 0.58 5.5 
PAQNDF CD3+CD4–/+CD8+ 71 15 12 2.8 0.01 4.8 
Group 
IIC 
PASTCF CD3–CD4+CD8+ 39 21 9.6 30 0.35 1.9 
PASUVH TCRγδ+ CD4+CD8– 54 18 4.4 23 0.86 3.1 
Group 
III 
PASIZR CD3–CD4–CD8– 80 6 12 1.1 0.23 12 
PARSJC CD3+CD4–CD8+ 91 7.3 0.95 0.58 0.19 13 
*The 2–ΔCT for each family member was calculated based on the difference in the CT values for 
each Ikaros family member and GAPDH.  The sum of the 2–ΔCT of the family was normalized to 
100% for each sample. 
**Ik/Hel is the relative mRNA levels of Ikaros divided by that of Helios. 
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Figure 5-6. A graphical representation of the proportion of Ikaros family mRNA 
represented by each family member.  The percentage of total Ikaros family mRNA was 
calculated as described in Table 5-2.  Each bar indicates 100% of the Ikaros family mRNA in 
each normal and T-ALL sample.  Each segment within each bar indicates the portion of the total 






















































































































































































Protein levels and alternative splicing of Ikaros, Aiolos, and Helios in T-ALL 
We used western blot analysis to examine Ikaros and Aiolos protein levels and splicing in 
cells from each T-ALL patient and in normal DN thymocytes (Fig. 5-7).  Ikaros protein levels in 
one patient were similar to that of normal DN thymocytes, but the Ikaros levels were less than 
half of normal in the remaining samples.  The patient with the highest Ikaros protein levels, 
PAQNDF, had lower Ikaros mRNA levels than 18 of the other 23 samples.  Similarly, most T-
ALL samples expressed less full-length Aiolos protein than normal DN thymocytes. 
Low molecular weight bands were detected when membranes were probed with anti-Ikaros 
and anti-Aiolos, suggestive of the presence of alternative splice variants.  We performed nested 
PCR using the primer pairs illustrated in Fig. 5-8A to determine whether Ikaros, Helios, and 
Aiolos might undergo alternative splicing in normal thymocytes and T-ALL cells.  A complex 
pattern of Ikaros splice variants was detected in normal and leukemic cells, consistent with our 
previous observations (354) and that different isoforms can lack exons, lack portions of exons, or 
include intronic sequences (8-10).  In contrast to Ikaros, few T-ALL samples expressed multiple 
splice variants of Aiolos and Helios.   
To verify the identity of the splice variants, nested RT-PCR was performed using primers 
that span each combination of exons (a sample of which is shown in Fig. 5-8E).  For Ikaros, the 
most abundant proteins detected by western blot are most likely full-length Ikaros and Ikaros 
lacking exon 3 (Ik-Δ3).  In addition, numerous other splice variants were detected at the mRNA 
level; the most prevalent of which are shown in Fig. 5-8B. 
 For Aiolos, full-length mRNA was detected in most samples (Fig. 5-8C).  Other splice 
variants detected lacked exon 2 (Ai-Δ2), exon 3 (Ai-Δ3), or exon 4 (Ai-Δ4) or a combination of 
two or more exon deletions, such as Ai-Δ5/6 and Ai-Δ4/5/6.  Helios lacking a portion of exon 3  
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Figure 5-7. Most T-ALL samples express low levels of Ikaros and Aiolos protein.  Cell 
lysates were separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-Ikaros, 
anti-Aiolos, or p38 MAPK.  A) Bands corresponding to full-length Ikaros and Aiolos along with 
major splice variants are shown. B) Densitometry was performed using the images shown in ‘A’ 
and the relative protein levels of full-length Ikaros and Aiolos protein was normalized to that of 














































































































































































































































































































































































































































































Figure 5-8. Ikaros mRNA undergoes extensive alternative splicing in normal thymocytes 
and in T-ALL.  A) A schematic of the exon structure of Ikaros, Aiolos, and Helios with the 
position of the nested PCR primers shown.  Nested PCR was performed using mRNA isolated 
from the indicated normal thymocyte populations and each T-ALL sample for Ikaros (B), Aiolos 
(C), and Helios (D).  E) mRNA obtained from cells from one sample shown in (B) was amplified 














































































































































































































































































































































































































































































































































































(Hel-Δ3b) was the most evident splice variant observed (Fig. 5-8D), but some samples expressed 
full-length Helios and Helios lacking the entire third exon (Hel-Δ3). 
Based on these data, we conclude that the mRNA and protein levels of Ikaros and Aiolos do 
not directly correlate, which is consistent with our previous observations in normal human 
thymocytes (354).  Further, many splice variants are not translated at detectable levels.  For most 




The multi-parameter phenotypic analysis of cells from pediatric T-ALL patients revealed 
great heterogeneity among patients.  Even when analyzing a limited number of markers, 
leukemic cells resembled normal human thymocyte populations in only nine of the 24 samples 
studied.  For the majority of the samples, the phenotype deviated significantly from that of 
known normal human thymocyte populations.  For example, cells from some T-ALL patients 
were CD8lo with little or no CD4 expression.  The CD3–CD4–CD8lo T-ALL cells are similar to 
the ISP population observed during murine T cell development and a population of human 
thymocytes found in a fraction of patients (Fig. 3-1) (376).  The CD3+CD8lo leukemia cells 
expressed lower levels of CD8 than mature SP CD8+ thymocytes and they did not express CD69 
or CD27, making it unlikely that these are mature thymocytes.  Among the T-ALL samples were 
those in which the cells expressed markers representing conflicting stages of development.  For 
example, some cells co-expressed CD3 and CD34; in normal thymocytes, CD34 expression is 
terminated prior to CD3 expression. 
Collectively, our data indicate that correlating T-ALL cells to normal developmental 
stages is rarely possible.  In addition, each T-ALL sample had a unique phenotype.  These two 
features make classifying T-ALL patients a challenging endeavor, as seen by the difficulty in 
using phenotype as a prognostic indicator (82, 83, 394). 
As an alternate method to classify T-ALL patients, we focused on the Ikaros family of 
transcription factors, which was previously implicated in leukemogenesis.  ChIP-seq data 
showed that the Ikaros family can bind 4,500-7,120 sites in the genome and regulate several 
hundred genes (27, 43, 54), making these transcription factors key regulators of cell fate 
decisions in developing lymphocytes.  The importance of the Ikaros family in leukemogenesis 
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has been most clearly demonstrated in mice, where expression of dominant negative isoforms of 
Ikaros or Helios resulted in T cell malignancies (47-49).  Disease onset in these mice was 
dependent on the reduced functionality of the entire Ikaros family, as deletion of individual 
family members did not cause disease (50-52).  This observation highlights the importance of 
studying the entire family.  In humans, correlative studies have suggested the presence of 
dominant negative isoforms of Ikaros in T-ALL patients, but the percentage of patients harboring 
these splice variants is controversial (8-10, 85, 90, 91, 100, 105).  Our data indicate that 
alternative mRNA splicing of Ikaros is common in normal thymocytes and T-ALL cells, but not 
all splice variants are translated into protein products (Figs. 5-7 and 5-8).   
The mRNA levels of each Ikaros family member varied widely across T-ALL samples, 
but the greatest disparity was in Aiolos and Helios expression (Fig. 5-5A).  The samples with the 
highest Aiolos and Helios mRNA levels were 780-fold and 120-fold greater, respectively, than 
the samples with the lowest mRNA levels.  This level of variability is in contrast to the 18-fold 
and 10-fold changes in Aiolos and Helios mRNA levels, respectively, that normally occur as 
thymocytes progress from the DN to the DP stages.  By contrast, samples with the highest 
mRNA levels of Ikaros, Eos, and Pegasus only contained 8.6- to 11-fold more than the samples 
with the lowest levels. 
Based on these data, we propose the classification of T-ALL patients using the strategy 
shown in Fig. 5-6 and Table 5-2.  For most patients, Ikaros and Helios mRNA were the primary 
Ikaros family member transcripts detected, so the ratio of Ikaros mRNA levels to Helios mRNA 
levels was used to divide the samples into three groups.  The largest group of patients had Ikaros 
to Helios ratios similar to those of normal thymocytes.  Within this group, the mRNA levels of 
Aiolos and Eos varied in a manner that provided a means to subdivide these patients. 
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The importance of Ikaros family mRNA levels in leukemogenesis may arise from the 
function of the Ikaros family proteins.  Because of the limited number of cells we could obtain 
from the patients, we were only able to analyze Ikaros and Aiolos protein levels.  For both 
proteins, the protein levels did not correlate with mRNA levels and the protein levels were lower 
than in normal thymocytes for most patients (Figs. 5-5 and 5-7).  The reduction of Ikaros family 
proteins may be linked to leukemogenesis, as it is in mice (47-51, 55, 395).   
In addition to a general reduction of Ikaros family expression, the ratio of Ikaros to 
Aiolos protein varied across the T-ALL samples, suggesting the dimer composition may vary 
among patients.  For example, patient PATCHB had high Aiolos levels and low Ikaros levels 
whereas patient PAQNDF had the opposite pattern.  Even small changes in the ratio among 
Ikaros family members can have profound biological effects, as seen by the development of 
lymphoma when Helios was expressed at low levels in murine B cells (55). 
While Ikaros family protein levels have direct implications in leukemogenesis, the 
mechanisms that control Ikaros family transcription might control other genes that regulate the 
development of T-ALL.  For example, c-myc, IRF4, Runx1, and TAL-1 can regulate Ikaros 
expression and are activated in some T-ALL patients (76, 352, 396-403).  In addition, there are 
Ikaros binding sites within the promoters of Ikaros, Aiolos, Eos, and Pegasus (75, 76) and the 
correlations in the expression of some Ikaros family members we observed (Fig. 5-5) supports a 
model in which Ikaros family members may regulate the transcription of themselves and other 
family members.  Further, the Ikaros binding site is shared by all family members and by the 
Notch-dependent transcription factor RBP-Jκ (44, 59, 60, 404).  Because half of pediatric T-
ALL patients have an activating mutation in Notch (405), it would be expected that Ikaros family 
mRNA levels would be altered in these patients. 
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In summary, we used multi-parameter flow cytometry to demonstrate the tremendous 
variability among pediatric T-ALL samples.  Further, we performed the first comprehensive 
analysis of the expression of the entire Ikaros family of transcription factors reported in pediatric 
T-ALL.  More research is needed to extend these observations and determine whether the 




Chapter 6. Conclusions 
These studies present the most comprehensive characterization of subpopulations of human 
thymocytes and Ikaros family expression during human T cell development.  In Chapter II, we 
quantified mRNA and protein expression of Ikaros family members in murine and human 
thymocytes.  These results highlighted differences in expression between the species, which has 
implications for the different developmental pathways seen between murine and human 
thymocytes.  In Chapters III-IV, we used multi-parameter flow cytometry to identify 
subpopulations of human thymocytes, focusing on those populations that were undergoing the 
key αβT cell selection steps of β-selection, positive selection, and CD4/CD8 lineage 
commitment.  Analysis of Ikaros, Helios, and Aiolos protein levels in these subpopulations 
showed that these family members have differential expression at the time of selection and in the 
ensuing populations.  Finally, in Chapter V we compared surface marker and Ikaros family 
expression in cases of pediatric T-ALL to normal thymic populations.  T-ALLs showed 
extensive diversity in protein expression that did not correspond to that seen in normal thymic 
populations.  However, we were able to identify groups of T-ALL patients by the ratio of Ikaros 
family mRNA levels within the leukemic cells.  Further studies are needed to determine how the 
changes in Ikaros family members during development affect gene expression, cell survival, 
proliferation, and potential development of T-ALL. 
 
Stages of Human T cell Development 
β-selection has been proposed to occur as early as the DN3 stage and as late as the DP stage 
of human T cell development (109, 115-117, 119).  Studies looking at TCRβ protein expression 
focused on analysis of a single stage of development, either TSP or DP, but not both stages 
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within the same thymus.  We showed that within a single thymus, β-selection occurs in ISP 
thymocytes but there is also a population of unselected DP1 thymocytes (Figs. 3-2 and 3-3).  
Further studies will be necessary to determine if these DP1 cells are still in the process of 
rearranging their TCRB loci and capable of successfully undergoing β-selection to differentiate to 
the DP2 stage.  It is intriguing to hypothesize that cells in the DP1 stage have undergone 
extensive rearrangements of both TCRB loci without successful TCRβ production, and are thus 
likely to die due to unsuccessful TCRβ production.  As TCRγδ cells differentiate into DP cells in 
the human thymus (151), these CD3– DP1 cells could also be TCRγδ precursor cells.  However, 
since complete TCRB rearrangements are rare in TCRγδ cells, and the expression of surface 
markers and Ikaros family members in DP1 cells are similar to ISP1 cells (Figs. 3-2 to 3-5), we 
propose that these cells are differentiating along the αβT cell lineage pathway. 
Through analysis of CD69, CD28, and CD27 expression, we showed that positive selection is 
initiated in DP9 cells, the last subpopulation of CD3lo DP thymocytes.  It has been established 
that after positive selection, murine thymocytes stop transcription of CD8 and transition through 
a TSP CD4+ population (312-315, 317-320), but a corresponding population of human 
thymocytes had not yet been described.  We show that in human thymocytes, DP9 cells have 
lower CD4 expression than earlier DP populations, and CD4 expression continues to decline as 
cells move to a CD3lo CD4lo/–CD8+ TSP population.  TSP CD8+ cells are the most mature CD3lo 
thymocytes, with 77±3.8% of TSP2 cells having completed positive selection as measured by 
CD69 expression (Fig. 3-3).  Further studies are needed to determine if TSP CD8+ have similar 
properties as murine TSP CD4+, such as termination of CD4 transcription and potential to 
differentiate into both MSP CD8+ and MSP CD4+ cells. 
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Differences in the kinetics of CD28 and CD27 expression after positive selection give new 
insights into the timing of CD4/CD8 lineage commitment in the human thymus.  We propose 
that CD27 expression is a marker of lineage commitment in human thymocytes. Vanhecke, et al. 
previously showed that CD27+ MSP CD4+ and MSP CD8+ cells are lineage committed, whereas 
CD27– MSP CD4+ cells retained some potential to differentiate into CD8+ cells in a human-
mouse fetal thymic organ culture system (386).  CD28 expression is induced by positive 
selection of human thymocytes, and is up-regulated after CD69 is expressed (Fig. 4-3B).  In DP9 
and TSP cells, CD28 and CD27 expression appear to be simultaneous (Fig. 4-3C).  In contrast, 
whereas all DP10, MSP1 CD4+ and MSP2 CD4+ cells express CD28, CD27 expression is 
minimal or absent on these cells (Fig. 4-4C).  These data suggest that while CD28 expression is a 
consequence of positive selection signaling, another signal is necessary for CD27 expression.  
According to the signal instruction model of lineage commitment, the down-regulation of 
CD4 in human DP9 and TSP cells would disrupt the TCR signal for MHC-II restricted cells, but 
allow for extended signaling in MHC-I restricted cells.  This would explain why some TSP CD8+ 
cells express CD28 and CD27 at the same time: they are MHC-I restricted cells undergoing 
lineage commitment immediately after positive selection.  In contrast, MHC-II restricted cells do 
not receive a lineage commitment signal until after CD4 has been re-expressed on the surface.  
Thus, DP10 and CD4+ MSP1 cells have up-regulated CD28 expression, but have not received 
proper lineage commitment signals for CD27 expression.  Our results suggest that CD8 lineage 
commitment occurs in the TSP population, prior to CD3 up-regulation, but CD4 lineage 





Expression of Ikaros Family Members During Key Selection Steps in Human αβT Cell 
Development 
Ikaros family expression remains constant at human γδT cell lineage commitment 
Sequencing of the β gene locus in human γδ T cells suggests that commitment to the γδ 
lineage happens before complete β gene rearrangement occurs in the ISP stage (109, 116, 162).  
Similarly, commitment to the γδ lineage is accomplished in murine thymocytes by the end of the 
DN3 stage, when complete β gene rearrangement occurs in this species (154, 406, 407).  Though 
γδ lineage commitment occurs with similar timing relative to β rearrangement in both species, 
Notch signaling has differential affects on the selection of the αβ versus γδ lineage between the 
two species.  Notch signaling is necessary for differentiation along the αβ lineage in murine 
thymocytes, whereas strong Notch signals induce human thymocytes to develop along the γδ 
lineage (112, 114, 130, 144, 164, 347, 408, 409).   
Differences in the response to Notch signaling between the species may be due to regulation 
of Notch target genes by Ikaros family members.  Ikaros, Aiolos, Helios, and Eos are all capable 
of competing with the Notch transcriptional regulator RBP-Jκ for binding at DNA with the 
shared consensus sequence GGGAA (14, 43, 44, 60, 77).  Though the Ikaros family members 
bind similar DNA sequences, their differential expression can affect what genes are targeted and 
the levels of transcription (1, 2, 5, 6, 14, 15, 27, 54, 55).  Thus differences in Ikaros family 
expression between murine and human thymocytes may result in altered targeting to and 
competitive binding to Notch target genes. 
Analysis of early human thymocytes revealed that expression of Ikaros, Helios, and Aiolos 
proteins does not change prior to β-selection in the ISP stage (Figs. 2-5 and 3-5).  However, 
Helios levels decrease in murine thymocytes at the early DN3 stage (Fig. 2-2).  Thus, there is a 
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smaller proportion of Helios containing dimers in murine thymocytes at the γδ lineage 
commitment stage than in earlier stages.  Overexpression of Helios in murine hematopoietic 
progenitor cells leads to a significant increase in the number of γδ T cells produced by these cells 
in reconstituted mice (48), suggesting that the decreased Helios levels in murine thymocytes are 
important for suppression of the γδ lineage fate.  These data suggest that the differential changes 
in Helios expression in early murine and human thymocytes are regulating the affects of Notch 
signaling on the γδ lineage decision.  Further studies are needed to determine the specific Notch 
target genes and Ikaros family dimers that are necessary for regulating γδ lineage commitment in 
murine and human thymocytes. 
 
Ikaros, Helios, and Aiolos levels increase after β-selection 
We identified changes in Ikaros, Helios, and Aiolos levels that correspond to β-selection.  
We used CD1a, CD28, and CD44 expression to identify β-selected thymocytes within the ISP 
and CD7++CD45RO– CD3– DP populations, showing that cellular proliferation increased with β-
selection of human thymocytes (Figs. 3-2 to 3-4).   Expression of all three Ikaros family 
members is higher in β-selected ISP2 and DP2 cells than in pre-β-selection ISP1 and DP1 cells 
(Fig. 3-5).  There is a larger increase in Helios protein expression after β-selection relative to that 
of Ikaros and Aiolos, suggesting that dimer formation in the cells will differ from pre-selection 
cells.   Further, in the most mature CD3– DP populations, Ikaros and Helios protein levels 
decline while Aiolos protein levels remain elevated.  These data suggest that the dimer make-up 
will change as thymocyte progress through β-selection, with more Helios containing dimers 
present in ISP2, DP2, and DP3 cells, and more Aiolos containing dimers present in the DP4 and 
DP5 cells.  Changes in dimer make-up within these populations will likely affect which target 
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sites are bound and the strength of transcriptional activation or repression (2, 5, 27, 55).  The 
overall increase in Ikaros family proteins levels may also affect whether dimers recruit the 
suppressive NuRD complex or the elongation-competent NuRD/P-TEFb complex (40). 
Interestingly, Aiolos and Helios protein levels also increase in DN4 murine thymocytes, after 
β-selection (Fig. 2-5).  Whereas Ikaros levels in murine DN4 cells were 1.6-fold higher than 
DN3 cells, Helios levels increased 5.3-fold and Aiolos levels increased 5.0-fold in DN4 
thymocytes.  The increase in Helios protein was transient, with levels declining in the ISP and 
DP stages, but Aiolos protein expression continued to increase through the DP stage. The 
sustained increase in Aiolos levels in post-β-selected murine and human thymocytes may 
regulate CD8 expression, and be responsible for the difference in co-receptor expression at the 
ISP stage in human and murine thymocytes.   
Murine DN thymocytes up-regulate CD8 to become ISP CD8+ cells, whereas human DN 
thymocytes express CD4 to become CD4+ ISP cells (110, 111).  In murine thymocytes, Ikaros is 
associated with both the CD4 and CD8α loci throughout T cell development (65, 66, 346), but 
the NuRD complex transitions from being associated with the CD8α locus in the DN stage to 
being associated with the CD4 locus in the DP stage (65, 66, 345).  Aiolos protein levels increase 
just prior to CD8 expression in both murine and human thymocytes (Figs. 2-2 and 3-5), and may 
be responsible for drawing NuRD away from the CD8 locus to allow transcription. In support of 
this, loss of Aiolos in Ikaros+/– murine thymocytes leads to an inability to properly up-regulate 
CD8 expression (346).  Further, Aiolos is capable of recruiting NuRD to the CD4 locus (27), and 
the high levels of Aiolos in murine ISP thymocytes may result in recruitment of the PTEF-
b/NuRD complex to the CD4 locus to promote transcriptional elongation.  Further studies are 
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needed to determine what NuRD and Ikaros family complexes are associated with the CD4 and 
CD8 loci in different stages of human thymic development.  
 
Ikaros is up-regulated after positive selection 
A role for the Ikaros family in regulating positive selection has been suggested by 
experiments in transgenic mice.  Both Ikaros null mice and mice expressing a dominant negative 
Ikaros isoform had an accumulation of TSP CD4+ cells, which underwent increased proliferation 
and apoptosis (380, 381).  Ikaros is the only family member whose protein levels increased in 
DP9 cells when CD69 is first expressed, and the levels slowly increased in subsequent stages 
where a higher percentage of cells had undergone positive selection (Fig. 4-6).   
The timing of the Ikaros peak in the TSP populations is intriguing, as it may have 
implications on the strength of signal necessary for productive CD8 lineage commitment.  Ikaros 
has been shown to regulate TCR signaling thresholds in murine thymocytes and splenocytes 
(367, 383).  The increased Ikaros protein levels in positively selected cells may serve to ensure 
that only stronger TCR signaling events induce lineage commitment at the TSP stage.  
 
Aiolos protein levels increase after CD8 and CD4 lineage commitment 
CD27 expression is associated with commitment to the CD8 and CD4 lineage in human 
thymocytes (386).  CD27 expression is up-regulated on a portion of TSP CD8+ thymocytes but 
not on DP10 and MSP1 CD4+ cells, suggesting that CD8 lineage commitment occurs at the TSP 
stage but commitment to the CD4 lineage does not occur until CD27 is expressed in MSP2 CD4+ 
thymocytes.  In contrast to Ikaros, Aiolos protein levels did not increase in CD3 expressing cells 
until CD8 lineage commitment occurs in the TSP population (Fig. 4-6).  Consistent with Aiolos 
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expression being associated with lineage commitment, protein levels were not elevated in DP10 
and MSP1 CD4+ cells, but increased in MSP2 CD4+ thymocytes.  Aiolos levels were highest in 
the phenotypically similar MSP3-4 CD4+ and MSP1-2 CD8+ populations.  These data suggest 
that Aiolos is up-regulated coincident with CD27 expression in response to lineage commitment 
signals in human thymocytes, and is supported by initial data from a single thymus (data not 
shown).  Further analysis of Aiolos protein levels in CD27– and CD27+ TSP and MSP2 CD4+ 
cells is necessary to confirm a correlation between Aiolos and CD27 expression.  Aiolos may 
play multiple roles during CD4/CD8 lineage commitment, including regulation of TCR signal 
strength, survival, and proliferation (26, 51, 384, 385).  Also, if increased Aiolos expression is 
required for CD8 expression as we propose, then increased Aiolos levels in lineage committed 
TSP cells could maintain CD8 expression and prevent diversion back to SP CD4+ cells (65, 66, 
346).   
 
Helios is up-regulated in cells potentially undergoing negative selection and Treg development 
Strongly reactive TCR transgenic CD4+ murine thymocytes up-regulate Helios expression in 
response to negatively selecting ligands (410).  Helios expression is also elevated in Treg cells, 
which are produced in the thymus when cells with strongly reactive TCRs are not negatively 
selected (74, 379).  In contrast, positively selecting ligands induce down-regulation of Helios 
protein expression from the DP to the SP stage of murine development (410). Identifying human 
thymocytes with strongly reactive TCRs is complicated by the fact that Helios expression can be 
induced by TCR signaling, as seen in activation of peripheral T cells (411) and thymic β-
selection (Fig. 3-5).  
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Within human thymocyte populations, Helios levels show a general decline after β-selection, 
as seen in the positively selected murine thymocytes (Fig. 4-6) (410).  However, there is a 
transient increase in Helios expression in the TSP populations.  Whereas it appears that all of the 
TSP cells have some increase in Helios expression, a population of Helioshi cells also develops 
and is particularly notable in the TSP2 and the MSP1 CD8+ populations (Fig. 4-6A and B).  
These Helioshi cells may be strongly reactive thymocytes that are in the process of negative 
selection, as they express the highest Helios levels of any thymocytes.   
A population of cells with increased Helios expression also develops in the MSP3 CD4+ 
stage of human development (Fig. 4-6B).  These cells have slightly lower Helios levels than the 
Helioshi TSP cells, and almost half of the population also expresses FoxP3, suggesting they are 
thymic derived Treg cells (Fig. 4-6D).  The presence of Helios+FoxP3– cells in this population has 
two implications.  These cells could be precursors to the Helios+FoxP3+ Treg cells, suggesting 
that Helios levels increase prior to FoxP3 levels in the process of Treg development.  
Alternatively, the Helios+FoxP3– cells could be strongly reactive CD4+ SP cells that have not 
received signals necessary for Treg development and are undergoing negative selection. 
 
Pediatric T-ALL Cells Can Be Grouped by the Ratio of Ikaros Family Members  
The ineffectiveness of current treatments for a portion of patients suggests that not all T-ALL 
cells are the same, and phenotypic markers are needed to categorize T-ALL patients for proper 
treatment strategies.  T-ALL patients are most commonly categorized according to their 
expression of CD4, CD8, and components of the TCR complex (78, 80).  Through multi-
parameter flow cytometry we looked at expression of the surface markers we used for identifying 
subpopulations of human thymocytes (Figs. 5-1 to 5-4).  Our original intent was to use 
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expression of surface markers on T-ALL cells to identify the corresponding thymic 
subpopulation from which they were derived, but analysis revealed extensive heterogeneity 
among T-ALL samples that precluded our ability to accomplish this. 
Surprisingly, there was also a great deal of heterogeneity in the expression of Ikaros family 
members in the T-ALL samples compared to one another and normal thymic populations.  Each 
T-ALL sample had mRNA levels of at least one Ikaros family member that fell outside the 95% 
confidence interval for those of normal thymic populations (Fig. 5-5).  Changes in Ikaros family 
dimer make-up can lead to altered DNA binding, recruitment of repressive or activating 
chromatin remodeling complexes, and gene activation (2, 5, 27, 55).  During normal human 
thymocyte development, Ikaros is the predominant mRNA species of the family, being expressed 
at 3.9-fold or higher levels than the other family members (Fig. 2-1).  However, we found that in 
one third of the T-ALL patients, either Helios, Aiolos, or Eos mRNA levels were at least fifty 
percent of Ikaros levels, and in three of these cases Helios mRNA levels were higher than those 
of Ikaros (Fig. 5-5).  Through analysis of the ratio of the mRNA levels of Ikaros family members 
to one another, we were able to identify groups of T-ALL patients. (Table 5-1 and Fig. 5-6).  
These groupings could have implications for direct involvement of Ikaros family members, as 
well as for altered function of other proteins that regulate transcription of Ikaros family 
members.  In particular, c-myc, IRF4, Runx1, and TAL-1 can be activated in some T-ALL 
patients and also regulate expression of some Ikaros family members (76, 352, 396-403).  
Unfortunately, outcomes data were not available for the T-ALL samples analyzed, so 
correlations between our groupings and disease progression could not be made. 
Although mRNA levels of at least one Ikaros family member were often elevated in the 
analyzed T-ALL samples, Ikaros and Aiolos protein levels were lower than normal thymic 
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populations (Fig. 5-7).  Though we did not identify dominant negative isoforms of Ikaros or 
Aiolos proteins in the T-ALL patients, the low levels of both Ikaros and Aiolos may sufficiently 
alter Ikaros family function to contribute to the development of T-ALL.  Alternatively, if Helios 
protein levels mirror mRNA levels in T-ALL cells, then there will be a large pool of Helios 
homodimers that can have profound impact on activation or repression of Ikaros family target 
genes.  Unfortunately, insufficient sample size precluded analysis of Helios protein levels in the 
T-ALL patients, so these need to be determined in future studies. 
Our analysis of mRNA and protein levels in murine and human DP thymocytes suggests that 
different mechanisms control Ikaros and Aiolos protein levels in the two species, and this may 
explain the low protein levels in T-ALL cells.  As was expected, protein expression of Ikaros 
family members mirrored increases in mRNA levels in murine DP thymocytes (Figs. 2-1 and 2-
2).   However, despite a 4.4-fold increase in Ikaros mRNA levels and a 18-fold increase in 
Aiolos mRNA levels, no increase in protein was seen in total human DP thymocytes by Western 
blot analysis (Figs. 2-4 and 2-5).  There was no increase in Ikaros protein and only a 1.9-fold 
increase in Aiolos in total DP thymocytes as measured by flow cytometry (Fig. 2-5).  In contrast, 
Helios protein levels increased 4.9-fold in total DP thymocytes, corresponding to a 10-fold 
increase in mRNA (Figs. 2-4 and 2-5).    
The low protein levels relative to mRNA found in both DP thymocytes and T-ALL cells 
could be due to increased degradation of Ikaros and Aiolos proteins or decreased translation of 
Ikaros and Aiolos mRNA.  Proteasomal degradation of both Ikaros and Aiolos, but not Helios, is 
induced by the thalidomide derivatives lenalidomide and pomalidomide (348-351), suggesting 
that a mechanism to regulate degradation of Ikaros and Aiolos, separate from Helios, may occur.  
Another possibility is that mRNA, particularly that of Aiolos, is being sequestered by miRNAs 
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or subcellular localization for rapid protein translation upon stimulation.  Analysis of Aiolos 
protein levels in CD3+ SP cells revealed that Aiolos protein expression increased in TSP and 
MSP populations (Fig. 4-6).  Thus, Aiolos mRNA may be amassed for rapid translation after 
stimulation, but further studies are needed to determine the mechanism of the sequestration and 
the exact signal received by positively selected thymocytes that induces translation.  
Identification of how Ikaros and Aiolos protein levels are being regulated in human DP cells and 
T-ALL may provide for new therapeutic targets. 
 
Using Surface Marker Expression to Understand T Cell Development 
Our identification of subpopulations of human thymocytes relied on the assumption that the 
expression levels of surface markers changes gradually as cells develop from one stage to the 
next.  Thus, each population only differs from the one before or after it by subtle changes in one 
or two surface markers.  However, not all surface markers change sequentially, resulting in 
parallel pathways within our proposed model of development in which populations have subtle 
changes in one surface marker as they move horizontally, and another marker as they move 
vertically (Figs. 3-6 and 4-7).  Of note is that changes in expression of some of these markers 
appear to be independent of pre-TCR or TCR signaling. For instance, DP3, DP4, and DP5 
thymocytes are CD3– but have similar expression of CD7, CD38, CD44, and CD45RO as the 
CD3lo DP6, DP7, and DP8 thymocytes, respectively (Fig. 4-1).  Changes in these surface 
markers may then be a result of different signals received by cytokine and chemokine signaling 
or cell-cell interactions as cells move through the thymus.  Further studies are needed to 
determine the functional significance of the changes in expression of CD7, CD38, CD44, and 
CD45RO during development. 
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Of particular note in our phenotyping of human thymocytes was the fluctuation of CD44 
expression (Fig. 4-1D).  Early thymocytes express high levels of CD44, which participates in 
homing of progenitor cells to the thymus (412).  CD44 surface expression decreases in the DN2 
stage, and remains low until a transient increase after β selection (Figs. 3-2 and 3-3).  CD44 
expression then increases again with positive selection, returning to high levels in the most 
mature thymocytes (Figs. 6-1,-2,-4, and -5).   
CD44 is able to bind both hyaluronan and fibronectin, and expression of these proteins is 
limited to the capsule, septae, vessels, and Hassall’s corpuscles in the post-natal human thymus 
(413, 414).  CD44 ligation is capable of inducing motility, proliferation, apoptosis, or protection 
from apoptosis in T cells depending on the splice variant of CD44 being expressed and the 
amount of CD3 co-stimulation (412, 415-422).  As CD3– thymocytes reside in the cortex (423), 
the CD44+CD3– cells would encounter ligand at the subcortical and intralobular septael areas.  
The subcortical area is populated by actively dividing thymocytes that have just completed β 
selection (423), and, in the case of human thymocytes, have just up-regulated CD44 expression 
(Figs. 3-2 and 3-3).  Activation of murine DN3, DN4, and DP thymocytes with sub-threshold 
levels of anti-CD3 antibody and anti-CD44 antibody promoted proliferation and survival (412).  
Thus, it is possible that CD44 engagement on human ISP2, DP2, and DP3 thymocytes near the 
subcortical and septael areas of the cortex may help promote the proliferation and survival seen 
after β selection.  To support this theory, CD44 expression decreases as the rate of proliferation 
decreases in DP4 and DP5 thymocytes (Figs. 3-2 to 3-4).  As CD44 expression decreases on 
these cells, it would also decrease the adherency of the cells, allowing for movement away from 
the subcortical region and towards the medulla for continued differentiation (424). 
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The increased CD44 expression after positive selection may play a role in negative selection.  
Cross-linking of CD44 and CD3 induces increased apoptosis of DP and SP murine thymocytes 
(412, 419).  CD44 is associated with the protein tyrosine kinase Lck in T cells, and cross-linking 
of CD44 and CD3 results in higher levels of Lck phosphorylation than CD3 cross-linking alone 
(412, 419, 424, 425).  Thus, binding of CD44 on CD3hi thymocytes to ligands on Hassall’s 
corpuscles in the medulla may result in augmented signals that affect negative selection.   
 
Conclusions and Implications 
These studies were conducted to determine if altered expression of Ikaros family members 
contributes to the development of T-ALL through an analysis of normal thymic development.  In 
Chapter 2, we identified differences in Ikaros family mRNA and protein expression between 
murine and human thymocyte development.  In Chapters 3 and 4, we used multi-parameter flow 
cytometry to identify 27 subpopulations of human thymic development.  Further, we showed that 
Ikaros, Aiolos, and Helios protein levels are differentially regulated after β-selection, positive 
selection, and lineage commitment of human thymocytes.  Finally, in Chapter 5 we addressed 
Ikaros family expression in cases of pediatric T-ALL, finding that T-ALL samples could be 
grouped according to the ratios of Ikaros family mRNA expression, but that Ikaros and Aiolos 
protein levels were low in T-ALL compared to normal thymocytes.   
Our data suggest that changes in the ratio of Ikaros family members, and thus dimer make-
up, are important for human thymocyte development and leukemogenesis.  Further analysis of 
the subpopulations we identified is needed to determine their functional significance and confirm 
the timing of selection steps as we have proposed them.  These data can then be used to identify 
Ikaros family targets at key stages of human thymic development, identify the Ikaros family 
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members associated with these targets, and determine if Ikaros family dimer formation and target 
binding are altered in T-ALL.  Further, determination of the mechanisms regulating protein 
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